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Abstract  
Rationale & Hypothesis: Pneumonia is a leading cause of infection-related death and 
Streptococcus pneumoniae, the commonest cause, accounts for approximately one million 
deaths in children each year. Macrophages are key effectors of innate immune responses but 
the precise microbicidal mechanisms used to control S. pneumoniae are incompletely 
characterised. West et al. reported that TLR1/2/4 agonists augment intracellular bacterial 
killing through inducing mitochondrial reactive oxygen species (mROS). Recently, the 
Dockrell group has demonstrated that in addition macrophages use mROS as a component 
of the microbicidal response and mROS are important effectors of microbicidal responses in 
an apoptotic programme that contributes to intracellular bacteria killing when other canonical 
mechanisms are exhausted. I hypothesized that mitochondrial homeostasis would be altered 
in response to intracellular bacteria as an important element of the microbicidal response to 
S. pneumoniae.  
Methodology: Mouse bone marrow cells and human monocytes were differentiated into 
macrophages. Macrophages metabolic profiles, mROS generation, bacterial killing and 
mitochondrial fission/mitophagy were evaluated by XF24 flux analyser, flow-cytometry, 
gentamicin protection assay and Confocal/Electron microscopy/Immunoblotting, 
respectively. 
Findings: Measures of respiration during bacterial infection have been less studied than the 
use of microbial components such as LPS. Methods were optimised to study metabolic 
profiles in macrophages challenged with S. pneumoniae. The macrophage’s bioenergetic 
profile demonstrated that S. pneumoniae significantly decreased mitochondrial respiration 
capacity and ATP-linked respiration but increased proton leakage, glycolytic respiration and 
mROS production. The HIV protein gp120 reduced ATP-linked oxygen consumption rate 
(OCR) and proton leakage while chronic obstructive pulmonary disease (COPD) reduced 
maximum respiration capacity, respiration reserve and ATP-linked OCR but increased 
proton leak. mROS were produced in close proximity to bacteria and to phagolysosomes as 
well as to nitric oxide production. Mitochondrial maximum respiration capacity was reduced 
following bacterial infection but this reduction was reversed by inhibiting mROS production. 
S. pneumoniae significantly increased mitochondrial fission resulting in reduced 
mitochondrial network complexity 12 hours after bacterial-challenge, before apoptosis 
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induction. Fission was induced via a Drp1-independent non-canonical pathway. Fragmented 
mitochondria were co-localised or adjacent to an E3 ubiquitin ligase Parkin, phagolysosomes 
and intracellular bacteria but LC3B was not recruited and electron microscopy failed to 
identify evidence of mitophagy. mROS co-localized with mitochondria that had undergone 
fission. Fission was reversed by the PI-3 kinase inhibitor 3-methyladenine (3MA) but was 
not altered by the Drp1 inhibitor Mdivi-1. Inhibiting mitochondrial fission with 3MA 
decreased mROS production, apoptosis and intracellular bacterial killing. 
Conclusions: Mitochondrial fission occurs prior to apoptosis induction and enhances mROS 
production.  Targeting mitochondrial homeostasis and fission represents potential cellular 
targets with which to modulate host innate immune responses against intracellular pathogens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 12 
 
Publications from this thesis 
1. HIV gp120 in lungs of ART-treated individuals impairs alveolar macrophage responses 
to pneumococci. Collini PJ, Bewley MA, Mohasin M, Marriott HM, Miller RF, Geretti 
AM, Beloukas A, Papadimitropoulos A, Read RC, Noursadeghi M, Dockrell DH. Am J 
Respir Crit Care Med. 2018 Jan 24. doi: 10.1164/rccm.201708-1755OC. [Epub ahead of 
print] 
 
2. Impaired mitochondrial microbicidal responses in Chronic Obstructive Pulmonary 
Disease macrophages. Bewley MA, Preston JA, Mohasin M, Marriott HM, Budd RC, 
Swales J, Collini P, Greaves DR, Craig RW, Brightling CE, Donnelly LE, Barnes PJ, 
Singh D, Shapiro SD, Whyte MKB, Dockrell DH. Am J Respir Crit Care Med. 2017 Oct 
1;196 (7):845-855. doi: 10.1164/rccm.201608-1714OC. 
 
3. Alveolar macrophages utilize apoptosis-associated killing to clear bacteria when initial 
macrophage killing mechanisms are exhausted. Preston JA, Bewley MA, Houghton AM, 
Marriott HM, Mohasin M, Jubrail J, Morris L, Stephenson YL, Cross S, Greaves DR, 
Craig RW, Rooijen NV, Bingle CD, Read RC, Mitchell TJ, Whyte MKB, Shapiro SD and 
Dockrell DH. Revision in the Am J Respir Crit Care Med. 
 
4. Macrophages utilize mitochondrial fission to enhance mROS production during responses 
to S. pneumoniae. Mohasin M, Marriott HM, Dockrell DH. Expected publication. 
 
Published abstracts 
1. Mitochondrial fission is associated with mROS-dependent microbicidal responses to S. 
pneumoniae in macrophages. Mohasin M, Marriott HM, Dockrell DH. British Society for 
Immunology annual congress, 4-7th December, 2017, Brighton, UK. (Oral presentation). 
 
2.  Alteration in mitochondrial homeostasis during responses to Streptococcus pneumoniae 
in macrophages. Mohasin M, Bewley MA, Collini PJ, Marriott HM, Dockrell DH. 
Symposium on Drugs Don’t Work, September 19-20, 2017, Florey Institute, University 
of Sheffield, UK. (Poster presentation).   
 
Page | 13 
 
 
3. Alteration in mitochondrial homeostasis during responses to Streptococcus pneumoniae 
in macrophages. Mohasin M, Bewley MA, Collini PJ, Marriott HM, Dockrell DH. 13th 
Annual School Research Meeting, June 15-16, 2017. Medical School, University of 
Sheffield, UK. (Poster presentation). 
4. Alteration in mitochondrial function influencing antimicrobial responses to Streptococcus 
pneumoniae in macrophages during COPD. Mohasin M, Bewley MA, Collini PJ, 
Marriott HM, Dockrell DH. British Society for Immunology annual congress, 6-9th 
December, 2016 ACC Liverpool, UK. (Poster presentation). 
 
5. Alteration in mitochondrial function influencing antimicrobial responses to Streptococcus 
pneumoniae in macrophages during COPD. Mohasin M, Bewley MA, Marriott HM, 
Dockrell DH. 12th Annual School Research Meeting, June 15-16, 2016. Medical School, 
University of Sheffield, UK. (Poster presentation). 
 
 
6. Pneumococcal infection exacerbates chronic obstructive pulmonary disease through 
changing metabolic status and phenotype of macrophages. Mohasin M, Bewley MA, 
Marriott HM, Dockrell DH. 11th Annual School Research Meeting, June 15-16, 2016. 
Medical School, University of Sheffield, UK. (Poster presentation). 
 
 
 
 
 
 
 
 
 
 
 
Page | 14 
 
Contents 
Abstract .................................................................................................................................10 
Chapter 1. Introduction .........................................................................................................23 
1.1. General Introduction...................................................................................................24 
1.2. Pneumococcal disease prevalence and treatment .......................................................25 
1.3. Pneumococcal virulence factors and their role in pathogenicity ................................26 
1.3.1. Polysaccharide capsule ........................................................................................26 
1.3.2. Pneumolysin ........................................................................................................27 
1.4. Host response to Streptococcus pneumoniae .............................................................28 
1.4.1. Innate immunity against pneumonia ....................................................................28 
1.4.2. Macrophages ........................................................................................................29 
1.4.3. Macrophages in host defence...............................................................................31 
1.4.4. Macrophage recognition of Streptococcus pneumoniae ......................................32 
1.4.5. Macrophages Phagocytosis ..................................................................................35 
1.4.6. Microbicidal mechanisms of macrophages .........................................................36 
1.4.7. Apoptosis mediated microbial killing ..................................................................37 
1.5. Macrophages role in COPD .......................................................................................39 
1.5.1. Reactive oxygen/nitrogen species in COPD ........................................................40 
1.6. Macrophages response to S. pneumoniae in HIV/AIDS compromised individuals...43 
1.7. Metabolic status and phenotype of Macrophages ......................................................44 
1.7.1. Metabolic profiles of M1 versus M2 macrophages .............................................44 
1.8. Mitochondrial Biology ...............................................................................................48 
1.8.1. Mitochondrial structure and its physiological importance ..................................48 
1.8.2. Mitochondrial genome .........................................................................................50 
1.8.3. Mitochondrial metabolism ...................................................................................51 
1.8.4. Physiological importance of proton and electron leak ........................................54 
1.9. Mitochondrial homeostasis and its role after bacterial infection ...............................54 
1.9.1. Mitochondrial complexity and its role in cellular homeostasis ...........................54 
1.9.2. Mitochondrial roles in innate immunity ..............................................................55 
1.9.3. Mechanism of mitochondrial fission/fusion ........................................................56 
1.9.4. Mitochondrial fission’s role in mitophagy ..........................................................58 
1.9.5. Relationship between mitochondrial dynamics and apoptosis ............................59 
Page | 15 
 
1.10. Hypothesis and aims ................................................................................................ 60 
Chapter 2. Methods and materials ........................................................................................ 62 
2.1. Study site and ethical issue ........................................................................................ 63 
2.2. Mouse Bone-Marrow cells culture ............................................................................ 63 
2.3. Human PBMCs culture and differentiated into monocyte-derived macrophages ..... 64 
2.4. Culture and stock of Streptococcus pneumoniae....................................................... 64 
2.4.1. Opsonisation and heat inactivation of S. pneumoniae ........................................ 65 
2.5. Optimisation of Seahorse extracellular flux assay conditions with BMDM ............. 65 
2.5.1. Schematic work flow for the Seahorse Extracellular flux assay ........................ 66 
2.6. Normalisation of Seahorse data ................................................................................. 69 
2.6.1. Normalisation using total cell count ................................................................... 69 
2.6.2. Normalisation using total cell protein ................................................................. 71 
2.7. Optimisation of Seahorse glycolytic and mitochondrial stress tests inhibitors ......... 71 
2.7.1. Titration of oligomycin A ................................................................................... 71 
2.7.2. Titration of FCCP ............................................................................................... 72 
2.7.3. Titration of 2-deoxy-D-glucose .......................................................................... 72 
2.7.4. Titration of rotenone ........................................................................................... 72 
2.7.5. Titration of antimycin A ..................................................................................... 73 
2.8. Measuring extracellular fluxes of BMDM in the presence of heat killed S. 
pneumoniae. ..................................................................................................................... 73 
2.9. Measuring glycolytic responses of mouse BMDM after stimulation with live S. 
pneumoniae, LPS, IFNγ and IL-4..................................................................................... 73 
2.10. Measurement of mitochondrial OXPHOS after challenge with pneumococci in wild 
type and Mcl-1 transgenic mouse BMDM ....................................................................... 74 
2.11. Measurement of mitochondrial OXPHOS in human MDM after challenge with S. 
pneumoniae ...................................................................................................................... 75 
2.12. Measurement of mitochondrial OXPHOS in human MDM after stimulation with 
HIV-1 glycoprotein gp120 and S. pneumoniae ................................................................ 75 
2.13. Measurement of mitochondrial OXPHOS in COPD MDM in the presence of S. 
pneumoniae ...................................................................................................................... 76 
2.14. Measurement of mitochondrial OXPHOS in MitoTempo pre-treated mouse BMDM
 .......................................................................................................................................... 76 
2.15. Flow cytometry ........................................................................................................ 76 
Page | 16 
 
2.15.1. Evaluation of mitochondrial inner transmembrane potential (ΔΨm) in COPD 
MDM .............................................................................................................................76 
2.15.2. Evaluation of mitochondrial ΔΨm in 3-methyladenine pre-treated mouse 
BMDM in the presence of pneumococci .......................................................................77 
2.15.3. Measurement of mROS in mouse BMDM after challenge with pneumococci .77 
2.15.4. Measurement of mROS in 3-methyladenine pre-treated mouse BMDM in the 
presence of pneumococci ...............................................................................................78 
2.16. Immunofluorescence ................................................................................................78 
2.16.1. Co-staining of mROS and mitochondrial outer membrane protein Tom20 ......78 
2.16.2. Labelling of S. pneumoniae with Alexa Fluor 647-conjugated succinimidyl 
ester ................................................................................................................................79 
2.16.3. Co-staining of Alexa Fluor-647 S. pneumoniae and mROS in macrophages ...79 
2.16.4. Co-staining of mROS and lysosome/phagolysosome in macrophages .............80 
2.16.5. Co-staining of mROS, nitric oxide and lysosome/phagolysosomes in 
macrophages ..................................................................................................................81 
2.16.6. Co-staining of mROS, NO and Alexa-Fluor 647-labelled S. pneumoniae in 
macrophages ..................................................................................................................81 
2.17. Evaluation of Mitochondrial morphological features ..............................................82 
2.17.1a. Staining of mitochondrial outer membrane protein TOM20 ...........................82 
2.17.1b. Quantification of mitochondrial network complexity by ImageJ ....................83 
2.17.2. Co-staining of mitochondrial Tom20 and phosphorylated-Drp1 (serine 616) ..85 
2.17.3. Co-staining of mitochondrial Tom20 and E3 ubiquitin ligase Parkin ...............86 
2.17.4. Co-staining of mitochondrial Tom20 and autophagy marker LC3B .................87 
2.17.5. Co-staining mitochondrial Tom20 and phagolysosomal LAMP1 .....................87 
2.17.6. Mitochondrial fission/fragmentation in pneumolysin deficient and heat 
inactivated pneumococci exposed macrophages ...........................................................88 
2.18. Western blotting with subcellular fractions ..............................................................89 
2.18.1. Isolation of cytosolic and mitochondrial fractions ............................................89 
2.18.2. Protein quantification assay ...............................................................................89 
2.18.3. Sodium dodecyl sulphate-Polyacrylamide gel electrophoresis (SDS-PAGE) ...89 
2.18.4. Semi-dry electro transfer and protein detection by chemiluminescence ...........90 
2.18.5. Densitometry ......................................................................................................91 
2.19. Transmission electron microscopy (TEM) ...............................................................91 
2.20. Evaluation of apoptotic macrophages after challenged with S. pneumoniae ...........92 
Page | 17 
 
2.21. Intracellular bacterial killing assay .......................................................................... 92 
2.22. Statistical analysis ................................................................................................... 93 
Chapter 3. Optimisation of extracellular flux assay with mouse BMDM and human MDM
 .............................................................................................................................................. 94 
3.1. Introduction ............................................................................................................... 95 
3.2. Optimisation of BMDM cell density and other conditions for the Seahorse 
Extracellular Flux Assay .................................................................................................. 97 
3.2.1. Cell density optimisation .................................................................................... 97 
3.3.2. Oxygen tension and pH optimisation.................................................................. 99 
3.3. Titration of oligomycin A, FCCP, 2-deoxy-D-glucose, Rotenone and Antimycin A 
for the Seahorse extracellular flux assay ........................................................................ 101 
3.3.1. Oligomycin A titration ...................................................................................... 101 
3.3.2. FCCP titration ................................................................................................... 103 
3.3.3. 2-deoxy-D-glucose titration .............................................................................. 104 
3.3.4. Rotenone and Antimycin A titration ................................................................. 105 
3.4. Optimising the Extracellular flux assay with human monocyte-derived macrophages 
(MDM) ........................................................................................................................... 107 
3.4.1. MDM glycolytic and mitochondrial stress test inhibitor optimisation ............. 108 
3.5. Characterisation of Streptococcus pneumoniae for macrophages challenge .......... 108 
3.6. Optimisation of extracellular flux assay with macrophages challenged with S. 
pneumoniae .................................................................................................................... 110 
3.6.1. Heat-inactivated S. pneumoniae’s effect on macrophage metabolism ............. 110 
3.6.1. Metabolically active S. pneumoniae’s effect on glycolytic metabolism in 
macrophages ............................................................................................................... 112 
3.7. Macrophages over expressing Mcl-1 show enhanced rates of mitochondrial oxidative 
phosphorylation .............................................................................................................. 114 
3.8. Human Mcl-1 transgenic mouse BMDM and non-transgenic BMDM show 
comparable baseline and bacterial induced glycolysis ................................................... 116 
3.9. Discussion ............................................................................................................... 116 
Chapter 4. Evaluation of macrophages metabolic phenotype and their metabolites mROS or 
NO interactions with S. pneumoniae in the phagolysosomes ............................................ 120 
4.1. Introduction ............................................................................................................. 121 
4.2. S. pneumoniae decreased mitochondrial OXPHOS of human monocyte-derived 
macrophages ................................................................................................................... 123 
Page | 18 
 
4.3. HIV-1 envelop glycoprotein gp120 and S. pneumoniae alter mitochondrial 
metabolism in human monocyte-derived macrophages ..................................................125 
4.4. S. pneumoniae diminishes mitochondrial respiration capacity in COPD macrophages
 .........................................................................................................................................128 
4.5. Streptococcus pneumoniae induces mitochondrial reactive oxygen species ...........131 
4.6. S. pneumoniae upregulates mitochondrial ROS, which are co-localised with 
intracellular bacteria ........................................................................................................133 
4.7. S. pneumoniae induces nitric oxide and mROS that co-localise with bacteria in the 
phagolysosomal compartment .........................................................................................140 
4.8. Inhibiting mitochondrial ROS restores mitochondrial respiration capacity .............144 
4.9. Discussion ................................................................................................................147 
Chapter 5. Mitochondrial fission triggers antimicrobial response in macrophages ............153 
5.1. Introduction ..............................................................................................................154 
5.2. S. pneumoniae upregulated Drp1-independent mitochondrial fission in macrophages
 .........................................................................................................................................155 
5.3. Activated Drp1 is not recruited on fragmented mitochondria after pneumococcal 
challenge ..........................................................................................................................158 
5.4. Pneumolysin is not essential for mitochondrial fission but metabolically active S. 
pneumoniae is ..................................................................................................................160 
5.5. S. pneumoniae exposure upregulates E3 ligase Parkin expression on fragmented 
mitochondria in macrophages .........................................................................................162 
5.6. Fragmented mitochondria during S. pneumoniae challenge do not associate with the 
autophagy marker LC3B .................................................................................................165 
5.7. Fragmented mitochondria stay proximal to the lysosome/phagolysosome ..............168 
5.8. Inhibiting mitochondrial fission by 3-methyladenine decreases mROS production 170 
5.9. Inhibition of PI-3K by 3MA restores mitochondrial inner transmembrane potential 
and decreases caspase activation .....................................................................................172 
9.10. The PI-3K inhibitor, 3-methyladenine decreases intracellular bacterial killing ....174 
5.11. Discussion ..............................................................................................................176 
Chapter 6. General Discussion ............................................................................................181 
6.1. Background discussion .............................................................................................182 
6.2. Key findings in the study..........................................................................................182 
6.3. Macrophages metabolic phenotype and its role in controlling internalised bacteria
 .........................................................................................................................................186 
Page | 19 
 
6.4. Importance of mitochondrial dynamics in innate responses against ingested 
extracellular bacteria ...................................................................................................... 186 
6.5. Limitations ............................................................................................................... 187 
6.6. Hypothetical model ................................................................................................. 188 
6.7. Future work directions ............................................................................................. 190 
6.8. Conclusions ............................................................................................................. 190 
Chapter 7: Appendices ....................................................................................................... 192 
7.1 XF assay medium for Glycol-stress test (200 mL) ................................................... 193 
7.2 XF assay medium for Mito-stress test (200 mL) ...................................................... 193 
7.3 Brain hear infusion broth (BHI broth) preparation (200 mL) .................................. 193 
7.4 Quenching solution for Immunofluorescence assay (500 mL) ................................ 193 
7.5 Blocking/PGAT solution for Immunofluorescence assay ........................................ 193 
7.6 Reagents used in Western blotting ........................................................................... 194 
i. Lysis buffer for cytosolic and mitochondrial fractions (10 mL) ............................. 194 
ii. 2x Sample buffer (for 25 mL)................................................................................. 194 
iii. Stacking gel preparation (5% for 2 gels) ............................................................... 194 
iv. Resolving gel preparation (12% for 2 gels) ........................................................... 194 
v. 10x Running buffer ................................................................................................. 195 
vi. 1x Running buffer .................................................................................................. 195 
vii. 1x Transfer buffer ................................................................................................. 195 
viii. 10x TBS ............................................................................................................... 195 
iX. 10x TBS-Tween .................................................................................................... 196 
X. Blocking solution (5% skimmed milk) (40 mL) .................................................... 196 
7.7 Araldite resin preparation (20 mL) (for TEM assay) ............................................... 196 
7.8 Growth of S. pneumoniae in cell culture media with mitochondrial fission inhibitors
 ........................................................................................................................................ 196 
Chapter 8: References ........................................................................................................ 198 
 
List of figures 
Figure 1.1. Macrophage polarisation 
Figure 1.2. Macrophage pattern recognition receptors sense S. pneumoniae 
Figure 1.3. Oxidative stresses in alveolar macrophages during COPD 
Page | 20 
 
Figure 1.4. Metabolic profile of M1 and M2 macrophages 
Figure 1.5. Tomographic view of mouse heart mitochondrion 
Figure 1.6. Mitochondrial metabolism is interlinked 
Figure 1.7. Mechanisms of mitochondrial fission and fusion. 
Figure 2.1. Schematic diagram for the extracellular flux assay with the XF 24 flux analyser 
Figure 2.2. Schematic diagram for cell counting through the Incell Analyser2000 
Figure 2.3. Schematic diagram for mitochondrial image processing by ImageJ 
Figure 2.4. Mitochondrial network complexity in a typical macrophage 
Figure 3.1. Mouse BMDM cell density titration with Seahorse XF24 flux plate 
Figure 3.2. Cell density titration and measurement of the rate of extracellular acidification 
Figure 3.3. Oxygen pressure optimisation through modification of the Seahorse execution 
protocol 
Figure 3.4. Oligomycin A titration for the extracellular flux assay using mouse BMDM 
Figure 3.5. FCCP titration for use in the extracellular flux assay using mouse BMDM 
Figure 3.6. 2-deoxy-D-glucose titration using mouse BMDM in the extracellular flux assay 
Figure 3.7. Rotenone and Antimycin A titration using mouse BMDM in the extracellular 
flux assay 
Figure 3.8. Human MDM cell density, oxygen tension optimisation for the EX24 flux assay 
Figure 3.9. Streptococcus pneumoniae D39 growth curve and microbiological 
characteristics 
Figure 3.10. Effect of different inocula of heat inactivated S. pneumoniae on mouse 
BMDM’s metabolism 
Figure 3.11. Metabolically active S. penumoniae upregulated macrophage glycolytic 
respiration 
Figure 3.12. Mitochondrial oxidative phosphorylation in macrophages is modified by a 
Mcl-1 transgene 
Figure 3.13. Comparable glycolytic respiration is observed in wild type and human Mcl-1 
transgenic mouse bone marrow-derived macrophages 
Figure 4.1. S. pneumoniae decreased mitochondrial respiration capacity and increased 
mitochondrial inner membrane proton leak in human MDM 
Figure 4.2. Human Immunodeficiency virus (HIV-1) envelop glycoprotein gp120 and S. 
pneumoniae effects on human MDM’s metabolism after 4 hours 
Page | 21 
 
Figure 4.3. Human Immunodeficiency virus (HIV-1) envelop glycoprotein gp120 and 
pneumococcal effects on mitochondrial respiration after 16 hours 
Figure 4.4. Mitochondrial metabolic phenotype of COPD and healthy MDM 
Figure 4.5. Glycolytic metabolism of COPD and healthy monocyte derived macrophages 
Figure 4.6. Mitochondrial inner membrane potential of COPD and healthy MDM 
Figure 4.7. S. pneumoniae triggers mitochondrial ROS in macrophages 
Figure 4.8. Mitochondrial ROS are co-localised with mitochondria 
Figure 4.9. S. pneumoniae labelled with Alexa Fluor tagged succinimidyl ester 
Figure 4.10. S. pneumoniae and mitochondrial ROS are co-localised in macrophages 
Figure 4.11. Lysosome/phagolysosome are co-localised with mitochondrial ROS in 
macrophages 
Figure 4.12.  Lysosomes and endoplasmic reticulum are not co-localised 
Figure 4.13. Mitochondrial ROS and internalised S. pneumoniae are co-localised with 
phagolysosome in macrophages 
Figure 4.14.  Mitochondrial ROS are co-localised with S. pneumoniae in macrophages 
Figure 4.15. Lysosome/phagolysosome specific cresyl violet staining does not influence 
mROS or endoplasmic reticulum detection 
Figure 4.16. Mitochondrial ROS and nitric oxide are co-localised with S. pneumoniae in 
macrophages 
Figure 4.17. Mitochondrial ROS and NO are co-localised with phagolysosomes 
Figure 4.18. Mitochondrial ROS signal does not influence NO or lysosome/phagolysosome 
detection in macrophages 
Figure 4.19. Inhibiting mROS partially restores mitochondrial maximal respiration capacity 
after pneumococcal challenge 
Figure 4.20. MitoTempo does not alter S. pneumoniae induces glycolytic metabolism and 
non-mitochondrial oxygen consumption 
Figure 5.1. S. pneumoniae induces mitochondrial fission in a Drp1 independent manner 
Figure 5.2. S. pneumoniae induces p-Drp-1 independent mitochondrial fission 
Figure 5.3. Pore-forming toxin pneumolysin is not essential to trigger mitochondrial fission 
Figure 5.4. Macrophage exposure to S. pneumoniae induces mitochondrial E3 ligase parkin 
expression in association with fragmentation 
Figure 5.5. Macrophages exposure to S. pneumoniae induces E3 ligase Parkin expression 
which translocate to mitochondria 
Page | 22 
 
Figure 5.6. S. pneumoniae does not modulate the autophagy marker LC3B 
Figure 5.7. Fragmented mitochondria following S. pneumoniae challenge do not engage 
with mitophagy 
Figure 5.8. Fragmented-mitochondria in response to pneumococci are associated with 
lysosomes/phagolysosomes 
Figure 5.9. The PI-3K inhibitor 3-methyladenine inhibits mitochondrial fission and mROS 
production in macrophages 
Figure 5.10.  The PI-3K inhibitor 3-methyladenine restores mitochondrial inner 
transmembrane potential and decreases macrophage apoptosis 
Figure 5.11. Bafilomycin A1 and PI-3K inhibitor 3-methyladenine decreases intracellular 
bacterial killing 
Figure 6.1. Schematic diagram of my hypothetical model 
Figure 7.1. S. pneumoniae culture in DMEM cell media 
 
 
List of Table 
Table 3.1. Microbiological characteristics of Streptococcus pneumoniae 
Table 6.1. Summary of key findings of all models 
 
 
 
 
 
 
 
  
  
 
 
 
 
Page | 23 
 
Chapter 1. Introduction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 24 
 
 
1.1. General Introduction 
Streptococcus pneumoniae (the pneumococcus) is a Gram-positive bacterium, and was 
formerly known as Diplococcus pneumoniae. The pneumococcus mostly lives 
asymptomatically in the nasopharynx of humans (i.e. upper respiratory tract), as part of 
the commensal flora. It can, however, cause infection and disease (e.g. pneumonia) when 
it spreads from the nasopharynx to small airways, or to the sinuses or middle ears (e.g. 
middle ear infection/otitis media). Moreover, pneumococcus may also penetrate through 
the respiratory epithelium into the blood circulation, resulting in local infection or 
bacteraemia and in some cases it may also cross the blood-brain barrier to the meninges, 
resulting the bacterial meningitis (Garcia-Suarez et al., 2007, Calbo and Garau, 2010). 
Pneumococcal invasion at sterile sites, such as blood, cerebrospinal fluid, or pleural 
space, is collectively defined as invasive pneumococcal disease (IPD) (Dockrell et al., 
2012a). 
 Recent epidemiological studies also suggested that pneumococci causes a high rate of 
mortality and morbidity globally (Song et al., 2013). For example, pneumococci is 
responsible for approximately 1.6 million deaths annually (Lynch and Zhanel, 2009). In 
addition to causing pneumonia in older people, pneumococcus also cause IPD such as 
sepsis and meningitis in young children, causing more than half a million deaths in this 
younger population annually (Ingels, 2015). 
 Moreover, pneumococcus is the most common bacterial pathogen for community-
acquired pneumonia (CAP), in both developed and developing countries (Song et al., 
2011, Welte et al., 2012). Immunocompromised individuals (e.g. patients with HIV-1 
infection) have increased incidence of severe pneumococcal infections (reviewed in 
(Kadioglu et al., 2008). In addition, pneumococcus is also responsible for infective 
exacerbations of chronic pulmonary diseases. For example, S. pneumoniae-associated 
bronchitis is responsible for 25% of infective exacerbations in chronic obstructive 
pulmonary disease (COPD) (Garcha et al., 2012). However, currently available vaccines 
(e.g. conjugate or polysaccharide vaccines) do not give complete protection against 
specific serotypes and only cover a limited number of serotypes. Moreover, antibiotic 
resistance to pneumococci raises further concerns and justifies further attention towards 
the pathogenicity of pneumococcal disease. Therefore, the host-defence mechanisms used 
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against pneumococci require better characterisation. Macrophages are an essential 
component in the first line of immune defense. Alveolar macrophages are particularly 
critical for responses against pneumococci in the lung and kill ingested bacteria using 
their large phagolysosomal capacity (Aberdein et al., 2013). My host group and other 
recent studies have demonstrated that macrophages mitochondria are a critical organelle 
involved in eradication of intracellular bacteria (Bewley et al., 2017, West et al., 2011a, 
Aberdein et al., 2013).  
 
1.2. Pneumococcal disease prevalence and treatment 
Streptococcus pneumoniae was first discovered and isolated by Griffith Sternberg in the 
United States (Watson et al., 1993, Sternberg, 1881) and by Pasteur in France, in 1881 
(Pasteur, 1881). It is the most common bacterial pathogen causing CAP and results in 
more than 20% mortality in patients with concurrent bacteraemia, in the United Kingdom 
(Balakrishnan et al., 2000, Lim et al., 2001). It mostly colonises in the upper respiratory 
tract and more frequently colonise in early childhood. The pneumococcus has around 91 
different serotypes, which are classified based on their cell surface polysaccharide 
capsule, which is structurally different and shows distinct antigenicity (reviewed in 
(Kadioglu et al., 2008)). The 23-valent polysaccharide vaccine (PPV23) replaced the 
earlier 14-valent polysaccharide pneumococcal vaccine, and contains 23 as opposed to 
the 14 purified capsular polysaccharide antigens of S. pneumoniae contained in the older 
vaccine. 
 However, this PPV23 polysaccharide vaccine shows moderate immune T-cell 
independent responses, does not induce memory T-cell responses or induce mucosal 
immunity and is not prescribed to those under two years old as it lacks efficacy in this 
group (reviewed in (Jedrzejas, 2001)). This has led to replacement of PPV23 with protein 
conjugate vaccines (PCV), initially containing 7 serotypes but now extended to 13 
serotypes (Prevnar). This vaccine has replaced PPV23 in the childhood vaccine schedules 
and induces T-cell and mucosal immunity resulting in reduction in not only IPD but also 
reduction in pneumonia. The introduction of PCV has not only reduced pneumococcal 
infection in vaccinated children but also in older age groups through reduced transmission 
of bacteria (Simonsen et al., 2011). Pneumococcal vaccination with PCV has resulted in 
some replacement of vaccine serotypes with non-vaccine serotypes in the community but 
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this has not offset the overall reduction in IPD associated with PCV programmes. 
Moreover, some pneumococcal strains also show antibiotic resistance towards penicillin 
(Baquero et al., 1991, Spika et al., 1991). For example, 35% of pneumococcal strains are 
resistance to penicillin, as isolated from developed and developing countries, although 
penicillin resistance remains low in the United Kingdom (Arnold et al., 1996, Duchin et 
al., 1995, Hofmann et al., 1995). Therefore, it is essential to identify pneumococcal 
virulence factors, to identify new vaccine candidates and to better understand 
pathogenicity and host-pathogen interaction at the cellular level. 
 
1.3. Pneumococcal virulence factors and their role in pathogenicity  
Like other Gram-positive bacteria, pneumococcus displays a range of proteins and enzymes 
on the surface which significantly contribute to pathogenesis. Although the polysaccharide 
capsule is considered as the primary virulence factor, certain pneumococcal proteins such as 
pneumococcal surface protein A, hyaluronate lyase, pneumolysin, autolysin, pneumococcal 
surface antigen A, choline binding protein A, and neuraminidase (NanA/B), also have 
significant roles in the pneumococcal pathogenesis. Fortunately, some of them are 
immunogenic and display antigenicity (reviewed in (Jedrzejas, 2001). In this review of the 
literature, I have mainly focused on the polysaccharide capsule and the pneumolysin toxin. 
 
1.3.1. Polysaccharide capsule 
The polysaccharide capsule is the outermost layer of pneumococci and its thickness is 
approximately 200-400 nm (Sorensen et al., 1988). This capsular polysaccharide (CPS) is 
covalently attached to peptidoglycan – one of the major cell-wall components of Gram-
positive bacteria, and pneumococci are known as encapsulated bacteria  (Sørensen et al., 
1990).  So far, 91 types of distinctive CPS have been identified in pneumococci, which show 
distinct serological and morphological phenotypes (Henrichsen, 1995, Kadioglu et al., 2008).  
The CPS is a critical virulence factor of pneumococci and it plays a substantial role in their 
pathogenicity (Austrian, 1981). For example, the CPS diminishes the phagocytosis of non-
immunised individuals. As a result, low numbers of colony forming units (cfu) of 
encapsulated pneumococci can establish lethal pneumococcal infection, whereas inocula of 
106-108cfu of non-encapsulated pneumococci are required to establish the same level of 
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infection in mice (Austrian, 1981). Mechanistically the CPS forms an inert shield that seems 
to hinder bacteria opsonisation through blocking either the interactions between the Fc region 
of immunoglobulin G (IgG) with the Fcγ receptors of the phagocytic cells  or inhibiting 
complement component iC3b deposition required for recognition by complement receptors 
(Winkelstein, 1981, Musher, 1992). Moreover, the pneumococcal capsule can also decrease 
the total amount of complement which is deposited on the bacterial surface (Abeyta et al., 
2003). The pneumococcal capsule also helps pneumococci to evade mucus-associated 
entrapment in the respiratory tract, which allows them to colonise the epithelial surface 
(Nelson et al., 2007).  
Collectively, it appears that the pneumococcal virulence factor CPS, prevents both clearance 
by the respiratory tract’s mucociliary escalator but also limits the phagocytosis by immune 
cells and attack by complement. However, CPS also has immunogenicity and although the 
polyvalent purified CPS vaccine (PPV23) was effective against approximately 90% of 
pneumococcal disease-causing serotypes. The vaccine was poorly immunogenic, as 
discussed above, because CPS contained in PPV23 are T-cell independent antigens and do 
not stimulate immunological memory – which is essential for longer protection. Thus, the 
CPS-protein conjugate vaccine (PCV13, Prevnar) which also triggers T-cell dependent 
immune responses, has replaced PPV23 in childhood vaccine schedules. But the PCV13 only 
raises immune responses to specific serotypes of pneumococci (reviewed in (Kadioglu et al., 
2008)) 
  
1.3.2. Pneumolysin 
Pneumolysin is a potent, soluble protein virulence factor of S. pneumoniae. It is a family 
member of cholesterol-dependent cytolysins (CDCs). Pneumolysin is not secreted during 
pneumococcal growth due to the lack of a protein secretion-signal sequence. However, it is 
released from the bacterial cytoplasm through coupling with the pneumococcal enzyme, 
autolysin (LytA). Autolysin degrades the bacterial cell wall and permits pneumolysin 
secretion during the stationary phase of pneumococcal growth or treatment with antibiotics 
(Rubins and Janoff, 1998). Pneumolysin is usually produced as a 52 kDa protein, which 
triggers pore-formation, approximately 260 angstrom in diameter, in the target cells after 
oligomerisation in the plasma membrane. This creates a transmembrane pore with a 
spectacular conformational change in pneumolysin structure (Tilley et al., 2005). 
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Pneumolysin makes pores, causing plasma membrane lysis of target cells, unlike listeriolysin 
O (LLO), the CDC of Listeria monocytogenes. The latter can only lyse phagosomal 
membranes with its optimum pH 5.5 (Geoffroy et al., 1987).  
Moreover, pneumolysin oligomers show toxicity, as observed by the effects seen with  sub-
lytic concentrations (Hirst et al., 2004). Apart from its membrane damaging effect, 
pneumolysin also inhibits ciliary beating and diminishes the respiratory bursts of phagocytes. 
While it also inhibits complement activation. In addition, it has been reported that 
pneumolysin interacts with TLR4 and induces cytokine production (Malley et al., 2003) and 
apoptosis (Srivastva et al., 2005) in peritoneal macrophages. In contrast, pneumolysin 
activates p38 MAPK in epithelial cells (Ratner et al., 2006) and nuclear factor of activated T 
cells (Koga et al., 2008) in a TLR4-independent manner. Besides, it has been demonstrated 
that pneumolysin induces humoral and cellular immunogenic mediators after recognition via 
nucleotide oligomerisation domain like receptor P3 (NLRP3) and related NLR (McNeela et 
al., 2010). For example, endotoxin free pneumolysin interacts with NLRP3 and induces 
proinflammatory cytokines in a TLR4-independent manner (McNeela et al., 2010).  
  
1.4. Host response to Streptococcus pneumoniae 
 1.4.1. Innate immunity against pneumococcus 
 
Innate immunity provides the first of line of defense. It involves a diverse array of protective 
components, including complement and mucociliary beating, as well as phagocytes (e.g. 
neutrophils and macrophages) which mediate humoral and cellular components of the innate 
immune response. The complement system performs three key functions; (i) opsonisation of 
bacterial surface to enhance bacterial phagocytosis by neutrophils or macrophages, (ii) 
chemotaxis of neutrophils to the site of infection and (iii) the direct killing of microbes by 
forming the ‘membrane attack complex’ on bacterial surfaces (Paterson and Orihuela, 2010). 
There are more than 30 serum and membrane proteins in the total complement system. C3 is 
the central complement component of the classical activation pathway. The genetic 
deficiency (Paterson and Orihuela, 2010) or loss of C3 complement causes recurrent 
pneumococcal infections, septicaemia and impaired macrophage activation (Jeremy et al., 
2002).  Whereas, mucociliary beating and clearance of bacteria prevents inhaled noxious 
particles coming in direct contact with epithelial cells and reaching the alveolar airspaces. 
Page | 29 
 
However, pneumococci and other airway pathogens either tightly adhere to epithelial 
surfaces and slow down mucociliary beating, or increase the viscosity of mucous through 
formation of  biofilms and evade ciliary clearance (Marks et al., 2012). 
On the other hand, phagocytic cells particularly neutrophils and macrophages, are essential 
cell-mediated host defence components against pneumococci. For example, alveolar 
macrophages (AMs) are the resident phagocytes that internalise and clear pneumococci from 
the small airway (Dockrell et al., 2003). However, this bacterial clearance capacity is 
diminished during other medical co-morbidities such as COPD (Taylor et al., 2010) or viral 
co-infection particularly with human immunodeficiency virus (HIV) (Collini et al., 2010). 
Thus, the finite AMs capacity to clear bacteria can be further compromised. 
1.4.2. Macrophages 
Macrophages originate from either bone marrow progenitors that mature to peripheral blood 
monocytes or from tissue macrophage intermediates that may replicate and mature in tissues 
(van Furth and Cohn, 1968, van Furth et al., 1972). Macrophages role is to engulf and digest 
cellular debris, foreign particles, microbes, and cancer cells in a process called phagocytosis. 
In addition, they are highly versatile cells and play major roles in embryonic development, 
homeostasis and wound healing in different tissues. Monocytes are attracted to a damaged 
site through chemotaxis, triggered by a range of stimuli, including damaged cells, pathogens 
and cytokines such as GM-CSF or G-CSF, released by resident macrophages and epithelial 
cells. The diverse characteristics of different resident macrophages are the result of additional 
micro-environment imprinting, as displayed in various tissues such as Langerhans cells in 
the epidermis, Kupffer cells in the liver, osteoclasts in the bone, microglia in the brain and 
alveolar macrophages in the lung.  
Phenotypic differences in macrophages are further induced by transient changes in local 
stimuli, a phenomenon described as macrophage polarisation. Macrophages which are 
classically activated by Th1 cytokines such as IFN-γ encourage tissue inflammation and are 
called M1 macrophages. The M1 macrophages have microbicidal, tumoricidal and antigen 
presenting capacity (Edwards et al., 2006), whereas macrophages which are alternatively 
activated by Th2 cytokines, such as IL-4/IL-13, show anti-inflammatory effects and 
participate in tissue repair and are called M2 macrophages. The latter macrophages not only 
maintain tissue homeostasis through wound healing but also resolve inflammation with 
clearance of apoptotic cells and debris (Zizzo et al., 2012, Uderhardt et al., 2012, Sindrilaru 
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et al., 2011) (Figure 1.1). This is however a gross simplification and in practice many 
variations in these polarisation extremes exist and many unique stimuli provide mixed 
phenotypes with a combination of M1 and M2 associated gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Macrophage polarisation. Monocytes are differentiated into either highly microbicidal 
and pro-inflammatory M1 macrophages or immunosuppressive and anti-inflammatory M2 
macrophages, upon encountering distinct cytokines. Classically activated M1 macrophages secrete 
tumour necrosis factor-α (TNFα) and interleukin-1β (IL-1β). Whereas, alternatively activated M2 
macrophages release IL-10 and transforming growth factor-β (TGF-β), the immune-regulatory 
cytokines. Figure is adapted from (Arango Duque and Descoteaux, 2014). 
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1.4.3. Macrophages in host defence  
Macrophages play essential roles in host defence against microbial infection. They are 
ubiquitous in all tissues where they act as sentinels responding to pathogens. In addition, 
microbial infiltration of tissues triggers the release of a variety of chemotactic agents that 
alert the macrophages to the infection. Subsequently, macrophages bind with pathogens via 
phagocytic receptors that initiate the cytoskeleton rearrangements and membrane re-
arrangements, which initiate the phagocytosis-mediated internalisation of pathogens. The 
internalised microbes should remain in a phagosome, which fuses with lysosomes and is 
converted into a phagolysosome where the pathogen is killed by a wide variety of 
microbicidal mechanisms such as oxidative or nitrosative stress involving reactive 
oxygen/nitrogen species and by proteases and cytotoxic peptides (Aderem and Underhill, 
1999, Underhill and Ozinsky, 2002, Greenberg and Grinstein, 2002). Microbial peptides 
released from dead pathogens are processed by the action of hydrolases in the 
phagolysosomes. Subsequently, the microbial peptides are processed and expressed as 
immunogenic epitopes in association with the major histocompatibility complex (MHC)-II, 
thereby facilitating the activation of an adaptive immune response, involving T cell 
responses. 
However, the capacity of macrophages to clear bacteria is limited and they may no longer be 
able to control bacteria in the airway if there is a high inoculum of, as suggested from studies 
of mice infection (Dockrell et al., 2003, Knapp et al., 2003). At this stage, macrophages play 
pivotal roles in regulating the inflammatory response in the lung. They produce inflammatory 
cytokines, such as IL-1β, which induce CXCL-8, also called interleukin 8 (IL-8), expression 
from epithelial cells. The chemokine, CXCL-8 attracts neutrophils which play a critical role 
in bacterial clearance (Knapp et al., 2003, Marriott et al., 2012). Moreover, macrophages not 
only induce apoptosis of inflammatory cells (such as neutrophils) but also remove apoptotic 
cells -by a process called efferocytosis, resulting in the down-regulation of pro-inflammatory 
cytokines and resolution of lung inflammation (Dockrell et al., 2001, Marriott et al., 2006).  
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1.4.4. Macrophage recognition of Streptococcus pneumoniae 
The pattern recognition receptors (PRRs) are the pathogen sensors of the immune system. 
They are classified broadly based on their cellular location. These groups include the 
transmembrane Toll-like receptors (TLRs), cytosolic nucleotide-binding oligomerisation 
domain (NOD)-like receptors (NLRs), retinoic acid-inducible gene (RIG)-1-like receptors 
(RLRs), which detect double stranded RNA, and cytosolic DNA sensors. They can recognise 
or interact with invading pathogens through conserved microbial molecules - also called 
pathogen-associated molecular patterns (PAMPs) - as well as endogenous molecules (e.g. 
danger-associated molecular patterns (DAMPs)), produced during tissue damage (Medzhitov 
and Janeway, 2000, Vance et al., 2009, Rock et al., 2010). For example, Gram-negative 
bacterial lipopolysaccharide (LPS) interacts with TLR4 in innate immune cells  (Hoshino et 
al., 1999). S. pneumoniae lack LPS, but TLR4 was suggested to interact with the 
pneumococcal virulence factor pneumolysin - a cholesterol-dependent cytolysin, however 
this interaction has been controversial and many authorities now believe pneumolysin is 
recognised by NLRs (see below), rather than by TLR4 (McNeela et al., 2010). Malley and 
colleagues who proposed the TLR4 pneumolysin interaction, suggest it harnesses 
macrophage immune responses which subsequently confer resistance to pneumococcal 
infection in mice (Malley et al., 2003). 
In addition, pneumococcal lipoteichoic acid (LTA) is recognised by TLR2 and an in vivo 
study with TLR2-/- mice has shown a reduced clearance of pneumococci from their 
nasopharynx (Van Rossum et al., 2005). However, the mortality rate and the bacterial 
susceptibility of TLR2-/- mice is increased after challenge with pneumolysin-deficient 
pneumococci, but it shows comparable mortality after challenge with wild-type pneumococci 
(Dessing et al., 2008), suggesting that pneumolysin-PRR signalling could compensate for 
loss of the LTA/TLR2-mediated immune responses. Moreover, the unmethylated cytosine-
phosphate-guanosine (CpG) motif of bacterial DNA interacts with the endosomal TLR9 
receptor, which also harnesses the innate immune responses against bacteria (Ishii and Akira, 
2006, Krieg, 2000). For example, TLR9 knockout mice show greater susceptibility to 
pneumococcal infection compared to either TLR2 or TLR4 deficient mice (Lee et al., 2007).  
The TLRs engage with myeloid differentiation factor 88 (MyD88) – a key signalling adaptor 
protein, which activates NF-κB mediated inflammatory cytokines and chemokines, in the 
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presence of pneumococcal infection (e.g. TNFα, IL-6, IL-1β and CXCL1) (Figure 1.2) 
(Koppe et al., 2012).  MyD88-deficient mice also show enhanced susceptibility to 
pneumococcal infection and more severe infection phenotypes were observed compared to 
the milder phenotypes, observed in single TLR2-, TLR4- and TLR9-knockout mice (Koedel 
et al., 2004). From these findings, Koppe and colleagues have speculated that during 
pneumococcal infection, TLRs may show functional redundancy or MyD88 itself may 
engage with other upstream signalling receptors (e.g. IL-1R or IL-8R) (Koppe et al., 2012). 
Moreover, internalised pneumococcal peptidoglycan fragments interact with NOD2 in the 
cytosol, which also activates NF-κB signal transduction (Opitz et al., 2004). In addition, 
internalised pneumococcal DNA in macrophages activates the adaptor molecule STING, 
which upregulates the transcription factor interferon regulatory factor (IRF) 3, a positive 
regulator of type I interferons (i.e. IFNα/β) (Nakamura et al., 2011). 
In addition, other host cell PRRs, such as inflammasome-forming proteins NLRP3 and AIM2 
(absent in melanoma-2), also recognise pneumococci which trigger host innate immune 
responses  (reviewed by (Koppe et al., 2012). For example, pneumococcal pneumolysin 
stimulates IL-1β production in macrophages and dendritic cells through interaction with the 
NLRP3 inflammasome complex and in a TLR4-independent manner (McNeela et al., 2010, 
Witzenrath et al., 2011). However, NLRP3-/- cells or mice challenge with pneumococci also 
produce IL-1β (Witzenrath et al., 2011). Fang and colleagues have also demonstrated that 
NLRP3-deficient macrophages produce IL-1β through interaction of AIM2 - another 
inflammasome complex which interacts with pneumococcal DNA (Fang et al., 2011). 
Interestingly, both NLRP3 and AIM2 inflammasomes interact with the ASC [apoptosis-
associated speck-like protein containing a CARD (caspase recruitment domain)] adapter 
molecule, and mice lacking ASC are more susceptible to pneumococcal pneumonia 
compared to wild-type or NLRP3-/- mice (Fang et al., 2011). Collectively, NOD2, NLRP3 
and AIM2 are essential host cell PRRs, which stimulate innate immune responses and play 
critical roles against S. pneumoniae. 
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Figure 1.2. Macrophage pattern recognition receptors sense S. pneumoniae. Pneumococcal 
lipopeptides or lipoteichoic acid (LTA) stimulate Toll-like receptor 2 (TLR2) and pneumolysin may 
stimulate macrophage cell surface receptor TLR4, although this is controversial. Whereas endosomal 
(e.g. phagosome/phagolysosome associated) TLR9 recognises unmethylated CpG of bacterial DNA 
(Sabroe et al., 2003). These TLRs engage MyD88, which upregulates inflammatory cytokine (e.g. 
TNFα, IL-6 and pro-IL-1β) and chemokine (e.g. CXCL1) expression, through turning on NF-κB 
mediated inflammatory gene transcription. Subsequently, the pro-interleukin-1β is converted into 
mature IL-1β by caspase-1-associated proteolytic cleavage. This cleavage is positively regulated by 
the NLRP3 inflammasome complex and AIM2 which are stimulated by pneumolysin (NLRP3 and 
AIM2) and pneumococcal DNA (AIM2). Moreover, internalised pneumococci are degraded in the 
phagosome, resulting in the release of bacterial peptidoglycan (PDG) and nucleic acid to the 
cytoplasm. Pneumococcal peptidoglycans are detected by the NOD2 within the cytosol, which 
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stimulates NF-κB dependent inflammatory cytokines. Whereas bacterial DNA interacts with a DNA 
receptor that turns on type I interferons (IFNs) expression, through inducing the STING/IRF3 signal 
transduction pathway.  (TLR –toll-like receptor, MyD88 –myeloid differentiation factor 88, NF-κB 
–nuclear factor-kappa B, NLRP3 –the NOD-like receptor (NLR) family, pyrin domain-containing 
3, NOD2 –nucleotide-binding oligomerisation domain containing protein 2, PDG-peptidoglycan, 
PLY-pneumolysin, STING –stimulator interferon genes, IRF3 –interferon regulatory factor 3). The 
figure is adapted from (Koppe et al., 2012). 
1.4.5. Macrophages Phagocytosis 
Phagocytosis is considered as an ancient adaptation process. While primitive organisms use 
phagocytosis as a strategy for the acquisition of nutrients, some specialised immune cells 
(macrophages and neutrophils etc.) in higher organisms use this process to bolster host 
defence while macrophages use it as a strategy to control inflammation through the removal 
of senescent cells which are produced either by programmed cell death or pathogen induced 
apoptosis (Cardelli, 2001). Dendritic cells also use phagocytosis to ingest particles, including 
micro-organism, as a source of antigens for presentation to T-cells. In addition, It is essential 
for embryonic development and tissue remodelling (Aderem and Underhill, 1999, Underhill 
and Ozinsky, 2002). Phagocytosis is a complex process which is initiated by the interaction 
of specific receptors on the surface of macrophages with ligands on the surface of microbes 
or other particles (Pommier et al., 1983). It leads to the polymerisation of actin at the site of 
ingestion which triggers internalisation of microbes, cells or other particles via an actin-based 
mechanism. 
 Subsequently, the actin surrounding the endosome containing the internalised particle is 
shed from the phagosome which matures by a series of fusion and fission events. This process 
involves the endocytic pathway and culminates in the formation of a mature phagolysosome 
(Aderem and Underhill, 1999), which enhances killing of microbes by different mechanisms.  
 
Phagocytic cells can engulf either non-opsonic microbes through engaging related PRRs with 
microbial surface antigens, or they initiate opsonic-phagocytosis  through deposition of 
proteins (e.g. antibodies or complement) on microbes, which are recognised by cell surface 
receptors of phagocytes (e.g. macrophages)  (Underhill and Ozinsky, 2002). For example, 
lipoteichoic acid (LTA) of non-opsonised pneumococci is recognised by scavenger receptors 
SR-AI/II or MARCO (macrophage receptor with collagenous structure) of macrophages. 
Mice deficient in scavenger receptors SR-AI/II or MARCO show reduced bacterial clearance 
capacity and increased mortality because they increase cytokine responses and inflammation 
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in the lung following pneumococcal infection (Arredouani et al., 2006, Arredouani et al., 
2004). On the other hand, anti-pneumococcal immunoglobulin G (IgG) mediates 
opsonisation and potentially enhances the Fc-gamma receptor (FcγR)-associated 
internalisation of pneumococci in macrophages (Ali et al., 2003). Interestingly, serum 
complement proteins also opsonise microbes (e.g. pneumococci) or particles in an antibody 
dependent or independent manner. For example, complement protein iC3b mediates the 
interaction of opsonised-pneumococci with CR3 (complement receptor 3), which increases 
pneumococcal phagocytosis by macrophages (Ali et al., 2003).  
 
1.4.6. Microbicidal mechanisms of macrophages 
Depending on the bacterial species, different phagocytic cells use different strategies for 
microbial killing. For example, ROS generated by nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase in phagocytic cells contributes to the killing of many bacteria. 
In addition, neutrophils express serine proteases such as cathepsin G and elastase for bacterial 
killing, which are not expressed in macrophages. Some species of bacteria, for example S. 
pneumoniae, evade oxidative stress with a variety of adaptive strategies.  
For example, S. pneumoniae genes encode several enzymes, such as superoxide dismutase 
(SodA), which removes superoxide by encoding a manganese superoxide dismutase 
(MnSOD), a NADH oxidase (encoded by Nox), that converts O2 to H2O rather than 
superoxide, SpxB, a pyruvate oxidase that repletes cellular ATP during oxidative stress 
through conversion of acetyl phosphate to ATP, pneumococcal surface antigen (Psa) A and 
PsaD that encode a manganese permease and a putative glutathione reductase respectively, 
which together limit hydrogen peroxide generation by pyruvate oxidase (SpxB) and PsaD 
mitigates oxidative stress through glutathione reductase (Yesilkaya et al., 2000, Yu et al., 
2001, Pericone et al., 2003, McAllister et al., 2004, Tseng et al., 2002, Potter et al., 2010). In 
this situation, macrophages need to change their antimicrobial strategies, for example, nitric 
oxide (NO) is generated via nitric oxide synthase (NOS) 2 and subsequently nitric oxide can 
react and form S-nitrosothiols such as S-nitrosoglutathione (GSNO) or react with ROS and 
generate peroxynitrite (one of reactive nitrogen species (RNS)), both of these make a 
significant contribution to early phagolysosomal killing of S. pneumoniae (Macmicking et 
al., 1997). 
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 In addition, some virulence factors (pneumolysin or pneumococcal cell wall) of S. 
pneumoniae upregulate NO generation and stimulate NO-mediated bacterial killing (Orman 
et al., 1998, Braun et al., 1999, Marriott et al., 2004b).  Other studies have also showed that 
NOS2 is indispensable for S. pneumoniae clearance from the lung of mice (Marriott et al., 
2007, Dockrell et al., 2012b).  Nevertheless, some bacterial genes help to evade and adapt to 
nitrosative stress (the effect of NO or RNS). For example, pneumococcal surface protein C 
(PspC) inhibits NOS2 mediated NO production, alcohol dehydrogenase C detoxifies S-
nitrosoglutathione and caseinolytic peptidase P (ClpP) mitigates the effect of RNS 
(Peppoloni et al., 2006, Stroeher et al., 2007, Park et al., 2010). Therefore, it is clear that 
macrophages need to apply additional antimicrobial strategies with combinations of ROS and 
RNS, or with alternative strategies to mediate phagolysosomal killing to control lung 
infection with S. pneumoniae.   
1.4.7. Apoptosis mediated microbial killing 
Bacterial infection may induce pathogen-mediated apoptosis to allow the bacteria escape 
from the immune system (Zychlinsky and Sansonetti, 1997). Alternatively the host may 
activate macrophage apoptosis to maximise bacterial clearance and control detrimental 
inflammation (Bewley et al., 2014). Apoptosis-associated bacterial killing occurs after the 
exhaustion of initial macrophage microbicidal activity (in phagolysosomes). 
The induction of apoptosis typically occur after 16-20 hours of bacterial ingestion in vitro 
(Marriott et al., 2004b). However, both in vitro and in vivo studies have demonstrated that 
macrophage apoptosis is involved with the clearance of S. pneumoniae (Dockrell et al., 2003, 
Dockrell et al., 2001). In addition, induction of apoptosis is positively correlated with the 
intracellular burden of bacteria in the case of pneumococci. The internalisation of 
pneumococci is increased by opsonisation (Ali et al., 2003).  
 
Moreover, the pneumococcal capsule, which impedes bacterial internalisation or a caspase 
inhibitor  down-regulates monocyte-derived macrophage (MDM) apoptosis (Ali et al., 2003), 
suggesting that intracellular bacteria  induce caspase mediated macrophage apoptosis. A 
previous study also demonstrated that NO induces mitochondrial outer membrane 
permeabilisation and apoptosis mediated bacterial killing, whereas inhibition of NOS2 
induces cell necrosis with decreased bacterial killing, suggesting the initial microbicidal 
response sensitised the macrophage for apoptosis (Marriott et al., 2004b). Recently Bewley 
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et al. demonstrated that the pneumococcal virulence protein pneumolysin activates both 
phagocytosis independent lysosomal membrane permeabilisation (LMP) and phagocytosis-
dependent conversion of this signal to the later stages of apoptosis after bacterial 
internalisation.  
 
 
 
Thus, the host response to this toxin promotes macrophage apoptosis rather than necrosis. 
The authors of this  study also showed that cathepsin D plays a critical role in apoptosis 
induction which helps to downregulate the pro-inflammatory effects of  LMP-mediated 
inflammasome activation through reduced pro-inflammatory cytokine generation (Bewley et 
al., 2014). In contrast, inhibition of the apoptotic response not only reduces bacterial killing 
but also increases pathogen-driven death by necrosis (Marriott et al., 2005, Bewley et al., 
2011, Marriott et al., 2004b).  Therefore, apoptotic macrophages down-regulate pro-
inflammatory cytokine expression as well as the recruitment of other inflammatory cells and 
therefore they help control lung inflammation (Marriott et al., 2007, Marriott et al., 2006). 
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1.5. Macrophages role in COPD  
The pulmonary macrophages help to maintain different anatomical compartments, 
including the alveolar spaces, airways and the interstitial lung space. Over 90% of 
pulmonary macrophages are AM in the alveolar spaces (van oud Alblas and van Furth, 
1979), which were previously thought to originate from bone marrow progenitor cells or 
by local replication from interstitial lung macrophages. However, it now appears from the 
fate mapping experiments they are derived from foetal monocytes derived from 
haematopoietic stem cells (possibly from the foetal liver) that differentiate in an 
environment that contains GM-CSF, and that these cells maintain the resident population 
unless there is overwhelming depletion in which case adult monocytes can contribute to 
re-population (Epelman et al., 2014, Guilliams et al., 2013, Jakubzick et al., 2013).   They 
are one of the most adept professional phagocytic cells and efficiently participate in 
limiting lung inflammation, with the clearance of lung irritants and pathogens in healthy 
subjects; whereas in COPD, AMs show phagocytic impairment with increased bacterial 
colonisation of the airway and subsequently patients suffer from persistent inflammation 
and declining lung function (Vlahos and Bozinovski, 2014). 
 
Moreover, in COPD, recruited inflammatory macrophages are attracted to the lungs by 
alveolar epithelial cells (AECs) and resident macrophages through secretion of 
chemoattractants such as MCP-1 (Shapiro, 1999) in the presence of different noxious 
particles, complementing total numbers of macrophages in the alveolar space. Previous 
studies have also demonstrated that the upregulation of MCP-1 in sputum and BAL, 
which attracts a high number of macrophages (that originate from monocytes) into the 
alveoli and small airways of patients with COPD (Traves et al., 2002, Capelli et al., 1999, 
de Boer et al., 2000). These recruited inflammatory macrophages may be less able to 
regulate inflammatory responses in the lung.  
Besides, a morphometric analysis showed a 25% increase of macrophage numbers in 
different respiratory compartments of emphysematous patients compared with smokers 
with normal lung function (Retamales et al., 2001). This indicates that AM numbers are 
positively associated with the severity of COPD. This assumption is strongly supported 
by an experimental model of COPD which demonstrated that depletion of pulmonary 
macrophages not only reduced smoke-induced airway remodelling and emphysema but 
also conferred protection against alteration of lung function (Beckett et al., 2013). 
However, either depletion of alveolar macrophages or impairment of their function causes 
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opportunistic infection and increases the susceptibility to Streptococcus pneumoniae 
colonisation and systemic invasion (Ghoneim et al., 2013). 
  
In addition, AMs play indispensable role in the resolution of inflammation by scavenging 
exhausted neutrophils and cell debris (i.e. efferocytosis). Thus, it seems that the resident 
AMs play important protective roles in the lung, while a subset of recruited inflammatory 
macrophages in the airspace may contribute to disease pathogenesis. Although, at least in 
theory, it is possible that altered pro-inflammatory activation states in resident AM might 
also contribute to phenotype. From these enigmatic roles of AMs in the lungs, it is 
apparent that it is important to elucidate the role of macrophages organelles in their 
specific function, especially that of mitochondria.  
Moreover, previous studies have shown that the upregulation of AMs mitochondrial ROS 
and the depletion of intracellular antioxidants (e.g. GSH) impair bacterial phagocytosis 
(Martí-Lliteras et al., 2009) and decrease efferocytosis (Hodge et al., 2007). The 
underlying mechanism of these phagocytosis impairments may be cigarette smoke -
mediated oxidant-dependant RhoA activation (Richens et al., 2009) and Rac1 inhibition 
(Minematsu et al., 2011), which impedes actin polymerisation mediated efferocytosis. 
Interestingly, in the pulmonary milieu, both altered pro-inflammatory and anti-
inflammatory functions of AMs could contribute to the overall phenotype of disease 
(Vlahos and Bozinovski, 2014),  with  an increase altered M1 AMs participating in the 
inflammatory role and an reduced M2 function limiting the resolution of inflammation 
(wound healing), as explained earlier.  
 
1.5.1. Reactive oxygen/nitrogen species in COPD  
Macrophages, along with other inflammatory cells (neutrophils, eosinophils) and 
structural cells (epithelial cells) are activated in the airways of COPD patients and 
produce ROS (MacNee, 2001), which  contribute to the increased oxidative stress in the 
airways (Paredi et al., 2000, Montuschi et al., 2000, Rahman et al., 2002). Cigarette smoke 
extract and other stimuli cause activation and assembly of a multicomponent NADPH 
oxidase in the macrophage cell membrane which generates superoxide anion (O2.
-). Then 
another enzyme, superoxide dismutase (SOD) converts the superoxide anion into 
hydrogen peroxide (H2O2) which is either detoxified to water by catalase or may form the 
highly reactive hydroxyl radical (.OH) by interacting with O2.
- in the presence of iron (Iles 
et al., 2002). 
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In addition, superoxide anion (O2.
-) also combines strongly with NO to form 
peroxynitrite, causing an increase in 3-nitrotyrosine immunoreactivity in AMs of COPD 
patients (Ichinose et al., 2000). Peroxynitrite also generates the hydroxyl free radical 
(Beckman and Koppenol, 1996). NO is generated by NOS2 that is upregulated in AMs 
and lung parenchyma of patients with COPD (Ichinose et al., 2000, van Straaten et al., 
1998, Maestrelli et al., 2003). Although the reactive oxygen/nitrogen species that are 
endogenously generated by the above mechanisms act as microbicidal molecules against 
pathogens, they also play an important role in cell signalling. For example, ROS also 
activate mitogen-activated protein (MAP) kinase signal transduction pathways and 
signalling pathways involving the GTPases Ras/Rac, c-Jun-NH2-terminal kinase (JNK), 
p38 mitogen-activated MAPK, protein tyrosine kinase, as well as the transcription factors, 
such as  NF-қB and activator protein (AP)-1 in COPD (Di Stefano et al., 2002) (Figure 
1.3). These activated signalling pathways and transcription factors induce transcription 
of multiple inflammatory genes, including TNF-α, IL-8, GRO-α, MCP-1, GM-CSF, 
NOS2, proteases such as metalloproteinase (MMP)-9 and adhesion molecules (e.g. 
intercellular adhesion molecule (ICAM)-1).  
 
In addition, oxidative stress also activates histone acetyltransferase (HAT) which 
subsequently modifies chromatin, allowing relaxation of chromatin structure, which 
enables the switching on of transcription of multiple inflammatory genes (Rahman, 2003, 
Tomita et al., 2003). Concomitantly, there is downregulation of histone deacetylase 2 
(HDAC2) activity in COPD (Ito et al., 2005), suggesting the underlining cause of 
resistance to corticosteroid-mediated anti-inflammatory activity (steroid resistance) may 
involve epigenetic mechanisms involving oxidative stress (Meja et al., 2008, Ito et al., 
2004). Indeed, oxidative stress activates phosphoinositide-3-kinase (PI-3K)–δ, which 
downregulates HDAC2 gene expression and decreases deacetylation activity (To et al., 
2010). The expression and activity of nuclear factor erythroid 2-related factor2 (Nrf2), is 
also regulated by acetylation, but in this case a posttranslational acetylation of the protein, 
in contrast to acetylation of a gene, result in protein downregulation (Mercado et al., 
2011). Nrf2 is an important transcription factor which controls expression of more than 
200 cellular antioxidant and detoxifying enzymes through its interaction with antioxidant 
response elements within the promoters of these antioxidant and cytoprotective genes 
(Mercado et al., 2011). This indicates that ROS may undermine the endogenous anti-
oxidant mediated cellular defences.  
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Figure 1.3. Oxidative stresses in alveolar macrophages during COPD. Cigarette smoke (CS) 
induces reactive oxygen/nitrogen species (ROS/RNS). CS also diminishes the antioxidant activity 
of cells. Subsequently ROS/RNS activates inflammatory genes and proteases. These reactive 
oxygen species also induce apoptosis of lung epithelial cells and trigger vasoconstriction. They 
deactivate nuclear factor erythroid 2-related factor 2 (Nrf2) and down-regulate histone 
deacetylase 2 (HDAC2), which inhibits anti-oxidants and corticosteroid activity, respectively. 
SOD-superoxide dismutase, NOS2- nitric oxide synthase 2, MAPK- mitogen activated protein 
kinase, AP-1- activator protein 1, NF-κB-nuclear factor kappa B, HAT-histone acetyl transferase.     
 
 
Like ROS, peroxynitrite activates the MAP kinase pathway in airway epithelial cells and 
induces extracellular signal regulated kinase (ERK) signalling, which mediates epithelial 
cells apoptosis, adding to lung injury (Nabeyrat et al., 2003). In addition, peroxynitrite is 
also responsible for pulmonary vasoconstriction in normoxic rat lung but not in the 
hypoxic setting, suggesting a loss of normal physiological function (Nossaman et al., 
2004). Furthermore, the lung is not only exposed to the above mentioned oxidative stress 
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but also other exogenous oxidants contained in cigarette smoke, itself an oxidant, and air 
pollutants, including ozone, nitrogen dioxide and diesel particulates, which may also 
increase the oxidative burden. These oxidative stresses are positively correlated with 
inflammatory gene expression, corticosteroid insensitivity, the prevalence of lung 
inflammation and COPD exacerbation (Sunyer, 2001). 
 
1.6. Macrophages response to S. pneumoniae in HIV/AIDS 
compromised individuals  
Pneumococcal pneumonia or invasive pneumococcal disease (IPD) is one of the leading 
causes of morbidity for human immunodeficiency virus (HIV) infected individuals 
(Gordin et al., 2008). Although the CD4+ T-cell is main cellular  reservoir for HIV-1, 
macrophages also provide an important site for cellular replication and cell-to-cell 
transmission to CD4-- cells (e.g. epithelial/endothelial cells), which contributes to 
acquired immunodeficiency disease syndrome (AIDS) pathogenesis (Muratori et al., 
2007). Moreover, the HIV-1 envelope glycoprotein (e.g. gp120) diminishes macrophage 
apoptosis by inducing the pro-survival cytokine macrophage colony stimulating factor 
(M-CSF), which upregulates the anti-apoptotic proteins Bfl-1 and Mcl-1 (Simon et al., 
2007, Lum and Badley, 2003).  
In addition, unlike most CD4+ T cells,  antiretroviral therapy (e.g. highly active anti-
retroviral therapy (HAART)) does not penetrate into macrophages as effectively, hence 
HIV-1 can persist in macrophages and macrophages may form a cellular reservoir, in 
addition to that observed in CD4+ memory T cells (Crowe and Sonza, 2000). Besides,  
HIV-1 infected monocyte-derived macrophages (MDM) are relatively resistant to the 
cytopathic effects of viral infection, and MDM can harbour the viral virions for prolonged 
periods in their cytosolic compartment (Cassol et al., 2006).  
Furthermore, AMs from HIV-infected subjects exhibit a normal phagocytic index with 
opsonised S. pneumoniae (Gordon et al., 2001). However, AMs from HIV patients, who 
develop Pneumocystis jirovecii show decreased phagocytic capacity of Staphylococcus 
aureus (Musher et al., 1990). HIV-1 infection in bronchoalveolar lavage (BAL) also 
modulates mROS production, apoptosis and pneumococcal killing in AM (Collini et al., 
2018), which might be one of the potential reasons for the increased susceptibility to IPD 
in people living with HIV. The HIV-1 envelope glycoprotein gp120 impinges 
macrophages function and inhibits  apoptosis induction (Cummins et al., 2010, Cicala et 
al., 2002). Recently, it has been demonstrated that gp120 not only diminishes 
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mitochondrial respiration capacity but also remodels mitochondrial morphology, with 
increased mitochondrial size and length, as well as its dynamics in neurons (Avdoshina 
et al., 2016). A further study shows gp120 promotes mitochondrial fusion and 
downregulates the fission protein dynamin 1-like (DNM1L) in neurones (Fields et al., 
2016). However, how gp120 in combination with S. pneumoniae effects macrophage 
function, particularly mitochondrial metabolism and dynamics needs to be elucidated. 
 
 1.7. Metabolic status and phenotype of Macrophages 
The general purpose of catabolic metabolism is to generate units of energy in the form of 
adenosine triphosphate (ATP) from the breakdown of organic matter and this process is 
essential for sustaining life. A recent study demonstrated upregulation of metabolic 
processes such as oxidative phosphorylation, aerobic glycolysis and immune responses 
to infection by activated memory CD8 T cell as compared with naive (resting) CD8 T 
cells, illustrating that metabolic capacity is linked to immune functional capacity (Van 
Der Windt et al., 2013). Metabolic status is also considered a key aspect of macrophage 
polarisation. Macrophage activation by either classic or alternative pathways brings 
enormous changes in their metabolic profiles (Rodríguez-Prados et al., 2010). Metabolic 
impairments of macrophages are implicated in functional impairment. For instance, 
inhibition of the glycolytic enzymes PFK1 (phospho-fructo kinase 1) and PFK2 by 
glucocorticoids in macrophages, not only blocks glycolysis but also impedes cytokine 
production (Bustos and Sobrino, 1992).  
In addition, macrophage’s metabolic profile can depend on the type of activation, which 
influences metabolism of key molecules such as L-arginine, influencing macrophage 
function. For example, classical activation by LPS or INFγ (M1 phenotype) results in 
catabolism of arginine into microbicidal metabolites such as nitric oxide and generation 
of citrulline due to the upregulation of nitric oxide synthase (NOS2). In contrast, alternate 
activation by IL-4/13 (M2 phenotype) induces agrinase-1 (Arg1), which converts arginine 
into urea, polyamines and ornithine and facilitates wound healing (Corraliza et al., 1995, 
Munder et al., 1998). These findings emphasise the potential therapeutic target of 
immunometabolic reprogramming of macrophages in disease settings. 
 
1.7.1. Metabolic profiles of M1 versus M2 macrophages 
Cellular respiration involves a set of metabolic reactions which generate ATP for cellular 
activity. Recent studies have demonstrated that metabolic reactions in macrophages not 
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only maintain cellular homeostasis through the supply of energy (ATP) but also regulate 
function through generation of pro-inflammatory (M1) or anti-inflammatory (M2) 
macrophages (Corraliza et al., 1995, Munder et al., 1998). To achieve this there are 
distinct differences between M1 and M2 macrophage’s cellular respiration. For instance, 
Gram negative bacterial LPS mediates classical macrophage activation (M1) and 
increases the extracellular acidification rate (ECAR) and decreases the oxygen 
consumption rate (OCR) (Haschemi et al., 2012), suggesting an increase in aerobic 
glycolysis, likely due to a modified ‘Warburg’ type effect. IFNγ/LPS also induces 
glutamine (Gln) uptake which is converted into succinate. The latter not only replenishes 
the Krebs cycle intermediate but also upregulates hypoxia inducible factor-1α (HIF-1α), 
a transcription factor which induces glycolytic flux through upregulation of genes 
involved in glycolytic metabolism (Tannahill et al., 2013). Others however have shown 
increases in glycolytic rate with enhanced cellular glucose uptake and conversion of 
pyruvate to lactate can also occur in a HIF-1α independent fashion, which is associated 
with downregulation of the rate of oxidative phosphorylation (Rodríguez-Prados et al., 
2010).  M1 macrophages also produce NADPH through the pentose phosphate pathway 
(PPP). Subsequently, NADPH plays an important role in the generation of cytosolic ROS 
and nitric oxide through NADPH oxidase and NOS2, respectively (Aktan, 2004).  
 
On the other hand, IL-4 stimulated macrophages demonstrate only delayed and marginal 
upregulation of ECAR and no alteration in OCR (Haschemi et al., 2012), suggesting that 
the basal state in culture has a metabolic profile more similar to the M2 macrophage and 
it is classical activation that produces a transcriptional response to reprogramme 
macrophage metabolism towards a glycolytic pattern. M2 macrophages turn on fatty acid 
oxidation through β-oxidation and use respiration through oxidative phosphorylation with 
high expression of electron transport chain (ETC) components. In addition, M2 
macrophages also stimulate the Krebs cycle through replenishment of its intermediates 
via pyruvate. The Krebs cycle produces both energy (ATP, GTP) and reducing 
equivalents (NADH, FADH2) which also generate ATP through the ETC and OXPHOS.  
Moreover, previous studies demonstrated that oxidative metabolism is essential for the 
M2 phenotype because blocking metabolism through oxidative phosphorylation induces 
M1 characteristics in M2 macrophages. Similarly, inducing oxidative phosphorylation in 
M1 macrophages gives them a M2 phenotype (Rodríguez-Prados et al., 2010, Vats et al., 
2006).  
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The different metabolic profiles are clearly distinguishable but the molecular mechanism 
by which different patterns of metabolic flux regulate macrophage polarisation is largely 
unknown. However, classically activated macrophages increase glycolytic flux through 
the transcriptional upregulation of the ubiquitous 6-phosphofructose-2-kinase/fructose-
2,6-bisphosphatase (u-PFK2), a more active isoenzyme of PFK2 as compared to the liver-
isoenzyme (L-PFK2) (Rodríguez-Prados et al., 2010).  A recent study demonstrated that 
LPS upregulates the first and rate-limiting enzyme (glucose-6-phospate dehydrogenase) 
of the PPP pathway (Reales-Calderón et al., 2014). In addition, LPS mediated classical 
activation also downregulates the carbohydrate kinase like protein (CARKL) which 
enhances flow of glucose through the glycolytic and PPP pathway and limits the 
restriction of these pathways exerted by the CARKL product  sedoheptulose-7-phosphate 
(S7P), which has the net effect of enhancing NADPH levels and thus ROS but also 
antioxidants such as glutathione (Haschemi et al., 2012).  
High levels of CARKL in cells not only attenuates LPS-stimulated superoxide production 
but also downregulates pro-inflammatory cytokine (IL-6 and IL-1β) production, 
suggesting that CARKL over-expression may reverse a M1 phenotype and favour a M2 
phenotype in macrophages (Haschemi et al., 2012). In contrast, alternatively activated 
macrophages, stimulated with IL-4, upregulate L-PFK2 and down-regulate fructose-2,6-
bisphosphate (a positive modulator of phosphofructo-kinase1), thus they decrease the 
glycolytic flux, but this is compensated through oxidative metabolism, involving fatty 
acid oxidation and oxidative phosphorylation. IL-4 activates STAT6,  a  transcription 
factor which subsequently turns on the co-activator protein peroxisome proliferator-
activated receptor (PPAR)γ-coactivator-1β (PGC-1β) and this upregulates mitochondrial 
respiration and biogenesis (St-pierre et al., 2003, Shao et al., 2010) (Figure 1.4). 
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Figure 1.4. Metabolic profile of M1 and M2 macrophages. Lipopolysaccharide (LPS) and 
interferon-γ (IFNγ) mediate classical activated M1 macrophages, inducing glycolysis as well as 
the pentose phosphate pathway (PPP). M1 macrophages also upregulate inflammatory cytokines 
through stimulation of the NF-κB signal transduction pathway. In addition, LPS/TLR-4 also 
induce the glycolytic flux through stabilising hypoxia-inducible factor-1α (HIF-1α). HIF-1α is 
also stabilised by the Krebs cycle intermediate succinate. In the mitochondrial matrix, the level 
of succinate is increased through glutaminolysis of glutamine. The uptake of glutamine is also 
increased in M1 macrophages. On the other hand, IL-4 or IL-13 activates macrophages into an 
M2 phenotype (also called alternatively activated macrophages). In M2 macrophages, IL-4/IL-
4R activates STAT6/PGC-1α signal transduction pathways which induce mitochondrial 
OXPHOS, fatty acid β-oxidation and mitochondrial biogenesis. Moreover, M2 macrophages also 
upregulate anti-parasitic and anti-inflammatory cytokines. STAT6 –Signal transducer and 
activator of transcription 6, PGC-1β –Peroxisome proliferator-activated receptor gamma 
coactivator-1β, PPP –pentose phosphate pathway, NOS2 –nitric oxide synthase 2, ROS –reactive 
oxygen species, Arg2 –arginase2, Glu –glutamate, GLUT –glucose transporter. Figure is adapted 
from (Galvan-Pena and O'Neill, 2014). 
 
 
There is evidence that knock-out of the transcription factor PGC-1β alters the metabolic 
status and function of M2 macrophages since it is a key transcription factor for several 
genes encoding factors required for oxidative phosphorylation (Vats et al., 2006). Thus, 
PGC-1β plays a pivotal role in metabolic reprogramming of M2 macrophages. Apart from 
 Wound repair 
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this, a recent study demonstrated that the TNF-α induced protein 8-like 2 (TIPE2) can 
change M1 macrophages to a M2 phenotype by inducing arginase1 mediated arginine 
metabolism (Lou et al., 2014). Recent reviews have highlighted the positive correlation 
between the severity of COPD and mitochondrial ROS production with decreased 
expression of antioxidants and impaired metabolism by oxidative phosphorylation 
(Kirkham and Barnes, 2013, Meyer et al., 2013). Since the focus has been on muscle cells, 
epithelial cells and recruited inflammatory cells as sources of ROS it is unclear how 
macrophages contribute to this. Although elevated macrophage production of ROS might 
suggest the contribution of an M1 macrophage, this does not fit with evidence for an M2 
bias amongst alveolar macrophages during COPD (Shaykhiev et al., 2009b).  Modulating 
the mitochondrial bioenergetic flux and M1 and M2 phenotype of macrophages could be 
a therapeutic approach for the management of chronic inflammatory diseases such as 
COPD. 
 
1.8. Mitochondrial Biology 
1.8.1. Mitochondrial structure and its physiological importance 
The mitochondrion (plural mitochondria) is a double-membrane containing organelle, 
which is ubiquitous in all eukaryotic organisms. It is called the metabolic hub and is 
considered as a power-house of the cell, because it links and regulates almost all 
metabolic pathways in the cell and produces most of the cellular energy as ATP. 
Mitochondria also occupy up to 25% of the volume of the cytoplasm, in amounts that 
vary by cell type. Structurally they are separated from the cytoplasm by the outer and 
inner membranes. However, these two-layer lipid membranes are separated by a ~20nm 
gap, called the intermembrane space, which is equivalent to the bacterial periplasm. An 
α-proteobacterium – a Gram-negative bacterium - seems to be the ancestor of 
mitochondria (Gray et al., 1999). Although conventional electron microscopy (EM) 
images with ultrathin plastic sections suggests that some sites have direct contact between 
outer and inner membranes (Schleyer and Neupert, 1985, Perkins et al., 1997), modern 
cryo-electron microscopy (cryo-EM) images of unfixed, unstained organelles 
demonstrate that proteins such as the translocases of outer membrane (TOM) and 
translocases of inner membrane (TIM) form a super-complex which spans the 
intermembrane space and are held together by the polypeptide chain in the transit (~20 
nm in length) (Gold et al., 2014). The latter observation suggests that conventional 
electron tomography with fixed, dehydrated and heavy-metal stained cells could induce 
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the artefact contact sites between outer and inner membrane (reviewed in (Kuhlbrandt, 
2015)).  
In addition, the mitochondrial outer and inner membrane show a distinctive structural and 
functional phenotype. For example, the outer membrane is a permeable membrane which 
allows ions and small, uncharged molecules to move through porins - the pore-forming 
membrane proteins.  For example, the voltage-dependent anion channel (VDAC) allows 
free movement of ions and small molecules, however larger molecules (e.g. proteins) are 
imported by special translocases (Bayrhuber et al., 2008). Hence there is no membrane 
potential resulting from movement of free ions across the outer membrane.   
 
On the other hand, the inner mitochondrial membrane (IMM) has a tight diffusion barrier 
which does not allow free movement of ions or molecules without aid of specific 
transporters. For example, the mitochondrial electron transport chain’s (ETC) complex I, 
III and IV pump out protons (H+) to the intermembrane space, from the mitochondrial 
innermost compartment - known as the mitochondrial matrix - to create an 
electrochemical gradient. This gradient is coupled with mitochondrial oxidative 
phosphorylation, which produces ATP by ATP synthase (complex V), and couples this 
to flux of protons from the intermembrane space to the matrix. Evolutionarily conserved 
mitochondrial matrix is similar to the bacterial cytoplasm, but its pH is quite high 7.9 to 
8.0, much like chloroplast stroma (Llopis et al., 1998). Moreover, the IMM also builds 
up an electrochemical membrane potential (~ -180 mV) as a result of its ion selectivity. 
The high pH and electrochemical potential allow cationic marker probes (attached with a 
triphenyl phosphonium cationic group) such as Mitotracker (green or red), MitoSox red 
and JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl benzimidazolyl carbocyanine iodide) to 
stain mitochondria, mROS and the inner mitochondrial transmembrane potential (ΔΨm), 
respectively. 
In addition, the IMM also forms a special folded structure called a crista (plural-cristae), 
which protrudes throughout the matrix. The crista lumen is also defined as the third 
compartment of mitochondria, which mostly holds the fully assembled electron transport 
complexes (i.e. complex I to V of mitochondrial ETC and OXPHOS) (Vogel et al., 2006). 
This lumen also contains large amounts of cytochrome c - a soluble electron carrier 
protein, which carries electrons from complex III (cytochrome oxidoreductase/reductase) 
to complex IV (cytochrome oxidase) of the ETC (Berg JM, 2002). Moreover, cristae play 
a pivotal role in cellular physiology. For example, in tissues which have a high energy 
demand (e.g. skeletal or heart muscle cells), the cristae form a highly stacked disk-like 
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lamellae which occupy most of the mitochondrial inner volume (Figure 1.5 is taken from 
(Kuhlbrandt, 2015)). Whereas in tissues with lower energy demands (e.g. liver, kidney), 
the cristae leave more room for the matrix and form a less compact structure. Moreover, 
it is postulated that cristae folding or invaginations prevent protons from escaping the 
mitochondrial intermembrane space, into the cytosol, which enhances ATP production by 
ATP synthase (reviewed in (Kuhlbrandt, 2015)).  
 
 
 
Figure 1.5. Tomographic view of mouse heart mitochondrion. Figure A shows the three 
dimensional volume of a mitochondrion, which is determined by modern Cryo-Electron 
microscopy (cryo-EM). It shows the outermost membrane (grey) surrounded by the inner 
membrane (light blue). Figure B shows the tomographic slice of a mitochondrion. Figure is 
copied from (Kuhlbrandt, 2015).  
 
 
1.8.2. Mitochondrial genome  
The mitochondrial genome is the only extra-chromosomal DNA within most eukaryotic 
cells (except for chloroplasts in plant cells). Its genome size is only 16.6kb in humans, 
which consists of a multicopy, circular double-strand DNA, similar to a bacterial genome. 
Its genome encodes 13 polypeptides within mitochondrial organelles, and these 
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polypeptides are indispensable for mitochondrial OXPHOS and RNA machineries 
(reviewed in (Taylor and Turnbull, 2005)). However, mitochondrial physiology is 
regulated by both nuclear and mitochondrial DNA. For example, the fully functional 
mitochondrial ETC (e.g. the OXPHOS) is comprised by nuclear-encoded genes and the 
above mentioned 13 mitochondrial polypeptides. 
 
1.8.3. Mitochondrial metabolism 
Eukaryotic cells maintain physiological functions in different anatomical compartments. 
However, the major metabolic pathways in different compartments are interlinked. The 
mitochondrion is the central point of cellular metabolism. For example, the end product 
of glycolysis, pyruvate, is converted into acetyl-CoA by pyruvate dehydrogenase in the 
mitochondrial matrix. Moreover, mitochondrial fatty acid metabolism, also called β-
oxidation, produces acetyl-CoA (David and Michael, 2008). This acetyl-CoA combines 
with oxaloacetate to yield citrate and initiate the tricarboxylic acid cycle (TCA cycle, also 
called the Krebs cycle) which is the central pathway of cellular oxidative metabolism 
(Geoffrey, 2000). During each cycle, two carbon atoms of citrate are completely oxidised 
into two molecules of carbon-dioxide, producing one molecule of GTP, three molecules 
of NADH and one molecule of FADH2.  
In the mitochondrial matrix, NADH is oxidised and releases electrons to complex I (i.e. 
NADH dehydrogenase), whilst FADH2 also releases electrons to complex II (i.e. 
succinate dehydrogenase) in the mitochondrial respiration chain. Electrons from these 
complexes (I and II) are transferred to complex III (i.e. cytochrome reductase) by the 
soluble electron carrier protein ubiquinone (Q). Then cytochrome c accepts electrons 
from complex III and transfers these to complex IV (i.e. cytochrome oxidase), where it is 
reduces molecular oxygen to water (David and Michael, 2008). During this electron 
passage, protons are pumped out (by complex I, III and IV) from the matrix to the 
intermembrane space and generate an electrochemical gradient, also known as the proton-
motive force (Δp) (reviewed in  (Jastroch et al., 2010)). This force drives protons back 
into the matrix through the nano-machine ATP synthase (complex V), and the resulting 
free energy is coupled with ATP production from ADP and inorganic phosphate 
(Mitchell, 1961). However, like a hydroelectric engine, this coupling is not one hundred 
percent efficient, because protons can return to the matrix without ATP synthase. This 
proton by-passing process is called proton leak. The rate of proton leak can be measured 
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indirectly, in the presence of oligomycin - an inhibitor of ATP synthase (Jastroch et al., 
2010).  
 
Besides, mitochondrial reactive oxygen species (mROS) are produced as a by-product of 
mitochondrial OXPHOS (Balaban et al., 2005). Superoxide is produced as a result of 
single electron leak from the ETC and transfer to dioxygen (O2), instead of an electron 
pair mediating the reduction of oxygen to H2O, at complex IV of the mitochondrial 
respiration chain (Murphy, 2009).  Evidence suggests that electron leak (or slippage) 
happens at complex I, which produces superoxide only at the matrix, and at complex III, 
which produces superoxide both sides of the inner mitochondrial membrane (Raha and 
Robinson, 2000). 
In addition, during different cellular physiological conditions, mitochondrial TCA cycle 
intermediates are removed to serve as biosynthesis precursors, or they are replenished by 
other metabolites. For example, one of the TCA cycle intermediates, α-ketoglutarate, is 
produced from glutamate, which is replenished from glutamine through glutaminolysis 
(David and Michael, 2008) (Figure 1.6).  
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Figure 1.6. Mitochondrial metabolism is interlinked. In most eukaryotic cells glucose is 
oxidised to pyruvate by glycolysis or oxidised by the pentose phosphate pathway (PPP) to produce 
nucleic acids precursors. Pyruvate is converted to lactate under hypoxic or anaerobic conditions, 
resulting in extracellular acidification. Whereas, under aerobic conditions, pyruvate is converted 
into Acetyl-CoA by pyruvate dehydrogenase in the mitochondrial matrix. Acetyl-CoA and 
oxaloacetate produce citrate which enters into the Krebs cycle (i.e. TCA cycle). Acetyl-coA is 
also produced from β-oxidation of fatty acids which replenishes the TCA cycle intermediate 
citrate. Moreover, glutamine replenishes the TCA cycle intermediate, α-ketoglutarate (α-KG), 
which is converted into succinate. Both glycolysis and the TCA cycle produce reducing 
equivalents as NADH, which releases electrons to complex I of mitochondrial OXPHOS. The 
TCA cycle also produces FADH2 which donates electrons to complex II (succinate 
dehydrogenase). Electrons from complex I and II are carried to complex III by ubiquinone (Q). 
Then cytochrome c carries electrons from complex III to IV. At complex IV electrons reduce 
oxygen into water. The figure also shows that protons (H+) are pumped out from the matrix to the 
intermembrane space (IMS) through complex I, III and IV. Moreover, premature release of free 
electrons from the ETC, mainly via complex I and III, produce superoxide (mROS). The 
mitochondrial ETC is inhibited by the complex I inhibitor rotenone or the complex III inhibitor 
antimycin A or the complex V inhibitor oligomycin A. Like uncoupler proteins, FCCP (is a 
synthetic OXPHOS uncoupler) that carries proton from IMS to the matrix and diminishes ΔΨm. 
OMM-outer mitochondrial membrane. 
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1.8.4. Physiological importance of proton and electron leak 
The basal proton leak is quite variable from tissue to tissue, and it contributes significantly 
to the basal metabolic rate (BMR, also called the resting metabolic rate). This is the 
energy expenditure per unit time during the resting state. For example, approximately 20-
30% of BMR is utilised as proton leak in rat hepatocytes, whereas it is up to 50% of BMR 
in skeletal muscle (Brand et al., 1999). This basal proton leak is induced by fatty acids 
and reactive alkenals (e.g. 4-hydroxynonenal), which upregulate IMM anion carrier 
proteins ANT (adenine nucleotide translocase) and UCPs (uncoupling proteins) (Parker 
et al., 2008).  
Moreover, proton leak also implies the coupling efficiency of mitochondrial OXPHOS. 
Thus, more proton leak retrospectively produces less ATP, which is mostly observed 
during aging (Conley et al., 2007). However, proton leak is indispensable for heat 
production in brown adipose tissue, where high abundance UCP1 transports protons from 
intermembrane space to the matrix. Apparently, it seems that the futile proton cycle of 
proton pumping and leakage allows human infants, small rodents and hibernators to adapt 
in the winter season (Cannon and Nedergaard, 2004). In addition, UCP1 in brown 
adipocytes is also activated by catecholamine release from sympathetic nerves in the form 
of noradrenergic stimulation (Jastroch et al., 2010), which emphasises the importance of 
stimuli such as noradrenaline (norepinephrine) as a positive modulator of uncoupling and 
physiological thermal regulation.  
On the other hand, electron leak from the mitochondrial ETC/complexes results in 
superoxide production. At low concentrations, the resulting mROS may be associated 
with signal transduction, but at high concentrations cause detrimental effects to cellular 
molecules (Murphy, 2009). Moreover, recent studies demonstrated that mROS has a role 
in innate immunity (West et al., 2011b). For example, mROS significantly contributes to 
intracellular bacterial killing in the phagolysosomes of macrophages (West et al., 2011a, 
Bewley et al., 2017). 
 
1.9. Mitochondrial homeostasis and its role after bacterial infection 
 
1.9.1. Mitochondrial complexity and its role in cellular homeostasis 
The word ‘mitochondrion’ originates from the Greek words ‘mitos’ for thread and 
‘chondros’ for grain. They are highly dynamic organelles in eukaryotic cells. Moreover, 
they frequently fuse (a process termed ‘fusion’) and divide (‘fission’), which dictates the 
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average size and degree of connectivity in the mitochondrial network. A typical 
mitochondrial population is quite variable in size (<1 to ≥15µm) and they maintain a 
complex network with a tubule-like structure. In cells, mitochondria are heterogeneous in 
both functional and morphological aspects (Collins et al., 2002). They regulate a number 
of cellular processes such as metabolism, proliferation and apoptosis. Mitochondrial 
fission and fusion ensure the quality of mitochondria. For example, a damaged 
mitochondrion can combat its functional failure through integration (i.e. fusion) with a 
healthy mitochondrion, which allows exchange of mitochondrial DNA and proteins 
between them (Chan, 2006, Tomoko et al., 2001).  
In contrast, a severely damaged mitochondrion triggers fission or fragmentation to 
generate smaller mitochondria that also lose their inner mitochondrial transmembrane 
potential (m), which is critical since m is  indispensable for fusion (Legros et al., 
2002). However, mitochondrial fission events often generate two populations of progeny 
mitochondria. One population exhibits increased m, which shows a high probability of 
subsequent fusion with nearby healthy mitochondria. Whilst another group shows 
decreased membrane potential and a lessened probability of fusion or integration with 
healthy mitochondria. Rather the latter population is either removed by selective 
autophagy (i.e. mitophagy) (Twig et al., 2008) or triggers programmed cell death (i.e. 
apoptosis) (Richard and Mariusz, 2005) (Figure 1.7). 
 
1.9.2. Mitochondrial roles in innate immunity 
Mitochondria originate from a symbiotic relationship between an α-proteobacterium and 
eukaryotic cell more than two billion years ago (Gray et al., 1999). They maintain a 
distinct double-membrane compartment and have their own circular genome. Moreover, 
mitochondria are the central hub of cellular metabolism and they show cell- and tissue-
specific morphological phenotypes, and have dynamic behaviour with constant fission or 
fusion (Jonathan and Jodi, 2014). These mitochondrial dynamics are essential to maintain 
an interconnecting network and cellular homeostasis (Suen et al., 2008). Previous studies 
demonstrated that some specific TLR-agonists augment mROS production (West et al., 
2011a) and downregulation of mROS production reduces the bactericidal activity of 
macrophages (Hall et al., 2013).  
In addition, the metabolic rewiring of mitochondria, shifting metabolism from OXPHOS 
to glycolysis, disrupts the Krebs cycle and leads to the generation of pro-inflammatory 
cytokines. During this process, LPS-stimulated M1 macrophages accumulate succinate, 
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which acts as a signalling molecule to upregulate HIF-1α and induces IL-1β production 
(Tannahill et al., 2013). Moreover, the mitochondrial Krebs cycle intermediate citrate is 
converted into itaconic acid that limits the growth of intracellular bacteria, such as 
Salmonella enterica and Mycobacterium tuberculosis (Jha et al., 2015, Alessandro et al., 
2013). Furthermore, succinate induces mROS production, by reverse electron transfer to 
complex I, rather than to the downstream electron carrier ubiquinone in the mitochondrial 
ETC (Lambert and Brand, 2004, Liu et al., 2002, Hansford et al., 1997). Thus, the shifts 
in immunometabolism associated with classical activation allow the mitochondria to 
generate metabolites that play a role in microbicidal responses or stimulate pro-
inflammatory cytokines. 
 
1.9.3. Mechanism of mitochondrial fission/fusion  
Dynamic fission and fusion of mitochondria are indispensable for mitochondrial 
homeostasis and cellular viability (Chan DC, Cell, 2012).  For example,  interruption of 
mitochondrial fusion causes the loss of Δm, as well as hampering embryonic 
development (Chen et al., 2003). Whereas, defective mitochondrial fission is associated 
with increased inflammation in macrophages (Sangjun et al., 2015).  
In addition, mitochondrial fission is universally linked with programmed cell death (i.e. 
apoptosis) (Suen et al., 2008). Mitochondrial fission is promoted by the recruitment of a 
GTPase, called dynamin-related protein 1 (Drp1), to the outer membrane. Subsequently, 
Drp1 forms a ring-like structure through oligomerisation. The ring-shaped Drp1-
oligomers constrict both outer and inner membranes and produce smaller fragmented 
mitochondria (Scott and David, 2007). Drp1 is a cytosolic protein, which is translocated 
to the mitochondria during fission, and this recruitment is regulated by post-translational 
modifications. For example, cyclin-dependent kinase 1 (CDK1) or protein kinase c delta 
(PKCδ) mediates phosphorylation of Drp1 at serine 616 (S616 isoform 1 of Drp1 
corresponds to 579 of isoform 3 in H. sapiens) promoting mitochondrial fission (Ishihara 
et al., 2007) during mitosis or oxidative stress, whilst phosphorylation at serine 637 by 
cyclic AMP-dependent protein kinase A (PKA) impairs its recruitment to the 
mitochondria (Chang and Blackstone, 2007). Moreover, Drp1 also interacts with multiple 
putative receptors such as mitochondrial fission factor (Mff), mitochondrial fission 
protein 1 (Fis1), mitochondrial dynamics protein 49 (MiD49) and MiD51 in the 
mitochondrial outer membrane, to execute fission (Loson et al., 2013).  
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Figure 1.7. Mechanisms of mitochondrial fission and fusion. During fission (A-B), 
mitochondria recruit dynamin related protein 1 (Drp1) to their outer membrane from the cytosol. 
Then Drp1 assemble with Fis1 and form chain-like structures across the membrane through 
oligomerisation. This oligomer then constricts mitochondrial membranes, and mitochondrial 
fission divides one mitochondrion into two progeny mitochondria. The nascent mitochondria 
become like their parental mitochondrion by biogenesis (C). Mitochondria are mostly tethered 
with endoplasmic reticulum (ER) to mitofusin 2. Alternatively, mitochondrial fusion (D-E) is 
orchestrated by mitofusin 1 or 2 (Mfn1/2) in the outer membrane, and optic atrophy 1 (Opa1) in 
the inner membrane. Mfn1/2 works like glue, to merge the outer membrane of two neighbouring 
mitochondrion. Opa1 seals then the inner membrane and forms a fused mitochondrion. 
Physiological stress (e.g. oxidative stress) breaks the constitutive reversible fission/fusion cycle. 
Excessive fission either turns on mitophagy, through recruitment of Pink1/Parkin and the adapter 
molecule p62 and the cytoskeleton protein LC3B, or triggers apoptosis through release 
cytochrome c from fragmented mitochondria.  Figure is adapted from (Cai and Tammineni, 2016). 
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In addition, Endoplasmic reticulum (ER)-mitochondria tethering is indispensable for 
mitochondrial fission (Friedman et al., 2011). F-actin filaments are required to regulate 
mitochondrial network fragmentation in DRP-1 dependent models of fission (De Vos et 
al., 2005). On the other hand, mitochondrial fusion is indispensable for the oxidative 
phosphorylation (Chen and Chan, 2010). The molecular players for mammalian cell 
mitochondrial fusion are mitofusin 1/2 (Mfn1/2), which are GTPases that localise to the 
outer mitochondrial membrane. Moreover, Opa1 (optic atrophy type 1) - another GTPase 
located in the IMM - is also essential for fusion (Chen et al., 2003).  Mitochondrial fusion 
is initiated by the homotypic/heterotypic interactions of outer membrane proteins Mfn1/2 
in adjacent mitochondria, triggering outer membrane fusion (Chen et al., 2003). Whereas, 
Opa1, on the opposing mitochondrion’s inner membrane promotes their integration 
(Otera and Mihara, 2011) (Figure 1.7). 
 
1.9.4. Mitochondrial fission’s role in mitophagy  
Autophagy (derived from the Greek autophagos which means ‘eating of self’) is a self-
degradation or catabolic process which mostly acts as a survival mechanism for cells, 
during starvation and stress conditions. This process plays a housekeeping role through 
degradation of misfolded or aggregated intracellular proteins and damaged organelles, as 
well as intracellular pathogens, by forming a circular double membrane autophagosome 
(Glick et al., 2010). For example, when mitochondrial damage (e.g. through accumulation 
of misfolded polypeptides) is identified in a cell, mitochondrial quality surveillance 
pathways such as (i) protease-associated degradation and (ii) selective autophagy (also 
called mitophagy), perform the repair function based on the persistence of mitochondrial 
damage cues. For instance, if the mitochondrial damage is not sufficiently repaired, the 
damaged mitochondria show diminished respiration capacity and loss ofm, so 
mitochondrial quality monitoring systems recruit mitophagy to selectively remove the 
damaged mitochondria from the population (Lazarou, 2015). Frank et al. demonstrated 
that transient mild oxidative stress induces Drp1-dependent mitochondrial fission which 
recruits LC3 to the fragmented mitochondria and triggers mitophagy in mammalian cells. 
They also showed that a dominant-negative Drp1 (Drp1k38A) not only inhibits oxidative 
stress associated mitochondrial fission, but also prevents induction of mitophagy (Frank 
et al., 2012), suggesting that fission is an upstream process of mitophagy.  In the same 
year another group demonstrated that mitophagy reduces mROS production, whilst 
mitophagy-deficient (autophagy-related protein Atg32 or Atg11 knockout) yeast produce 
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excessive mROS. This mROS damages mitochondria, which produces more mROS and 
creates a vicious cycle (Kurihara et al., 2012).  
On the other hand, overexpression of Parkin (an E3 ubiquitin ligase) in an FCCP-treated 
depolarised mitochondria, triggers mitophagy (Narendra et al., 2008). Moreover, PINK1 
(a mitochondrial kinase) (Ziviani et al., 2010), p62 and NIX are essential for Parkin-
dependent oxidative stress mediated mitophagy (Ding et al., 2010). Interestingly, Parkin 
also has a positive role in innate immunity. For example, mutations in Parkin’s regulatory 
regions increase the susceptibility to infectious disease in humans (Ali et al., 2006, Mira 
et al., 2004). In addition, Parkin also interacts with the mitochondrial translocator protein 
and voltage-dependent anion channel 1 protein complex (TSPO-VDAC1) and both 
factors are required for immunity during bacterial infection in Drosophila (Cho et al., 
2015). However, Parkin’s precise role in mitochondrial responses during innate immunity 
remain to be determined.  
 
1.9.5. Relationship between mitochondrial dynamics and apoptosis  
Mitochondrial dynamics (fission and fusion) are maintained by the cellular cytoskeleton, 
which governs mitochondrial number, morphology and subcellular distribution inside 
living cells (Bereiterhahn and Voth, 1994). Perturbation of these mitochondrial processes 
have profound influences on cellular viability (Karbowski and Youle, 2003). For 
example, inhibition of mitochondrial fission inhibits programmed cell death. Moreover, 
mitochondria trigger fragmentation before the activation of caspases, the family of 
apoptosis executioner cysteine proteases (Richard and Mariusz, 2005). Inhibition of Fis1, 
which triggers fission after combining with Drp1, respectively show inhibits apoptosis 
while overexpression of Fis1stimulates the mammalian mitochondrial apoptosis pathway 
(Lee et al., 2004, James et al., 2003). Collectively, this suggests that mitochondrial fission 
is essential for caspase-associated intrinsic (mitochondrial) pathway of apoptosis. This 
pathway of programmed cell death involves activation of caspase 9,  by cytochrome c 
that is released from the mitochondrial intermembrane space after mitochondrial outer 
membrane permeabilisation (MOMP) and which forms an apoptosome with apoptotic 
protease activating factor (Apaf-1) to cleave caspase 9, which in turn activates the 
downstream executioner caspases such as caspase 3 (Xiong et al., 2014). However, 
excessive fission can occur without triggering apoptosis. For example, FCCP-induced 
mitochondrial fission does not alter cell viability (Richard and Mariusz, 2005). Rather 
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FCCP-mediated excessive mitochondrial fission activates the pro-survival process, 
autophagy (Narendra et al., 2008).  
Moreover, viral infection, for instance with cytomegalovirus (CMV), also induces 
mitochondrial fission/fragmentation which also does not induce apoptosis (Damien et al., 
2004, Poncet et al., 2004). Interestingly,  HIV-1 viral protein R (vpr) and hepatitis B virus 
protein HBx interact with mitochondrial outer membrane proteins voltage dependent 
anion channel VDAC and VDAC3, resulting in the opening of the mitochondrial 
permeability transition pore (MPTP), loss of ΔΨm, massive mitochondrial fragmentation, 
and subsequent apoptosis (Jacotot et al., 2000, Rahmani et al., 2000). My host group has 
previously demonstrated that Streptococcus pneumoniae reduces mitochondrial ΔΨm and 
induces intrinsic apoptosis in macrophages (Marriott et al., 2004b). Therefore, further 
investigation of mitochondrial dynamics was warranted, particularly to determine if there 
was a relationship between fission and macrophage apoptosis after challenge with 
pneumococci. 
 
1.10. Hypothesis and aims 
It is clear that macrophages are a critical cellular effector of innate immune responses 
against S. pneumoniae. Macrophages sense bacterial presence very rapidly by their cell 
membrane and cytoplasmic pattern recognition receptors, demonstrating plasticity in their 
morphology, functional phenotype and metabolism. Moreover, macrophages also need to 
adapt these responses to engage a range of antimicrobial strategies after phagocytosis of 
bacteria that include mitochondrial-mediated responses such as generation of mROS and 
apoptosis, to eradicate internalised bacteria.  
 
I hypothesised that;  
the macrophage response to S. pneumoniae involves changes in mitochondrial 
metabolism and dynamics, which optimises the microbicidal response to pneumococci by 
enhancing mROS generation and enhances the mitochondrial contribution to innate 
immunity in response to internalised bacteria.  
 
On the basis of my hypothesis, the aims of my doctoral work were: 
1. To investigate macrophage metabolic phenotypes during host-pathogen interactions 
between macrophages and S. pneumoniae 
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2. To observe any defects in the macrophages host response to S. pneumoniae 
mitochondrial respiration, during COPD or HIV-1 infection in macrophages, 
conditions associated with both altered mitochondrial dynamics and susceptibility to 
pneumococci. 
3. To evaluate mROS and nitric oxide levels, investigating their interaction with the 
pneumococcus and their localisation relative to mitochondria and phagolysosomes. 
4. To observe mitochondrial morphology and dynamics, after challenge with S. 
pneumoniae and 
5. To examine the role and relationship of mitochondrial dynamics to microbicidal 
responses generated by macrophages during innate immunity to pneumococci. 
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Chapter 2. Methods and materials 
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2.1. Study site and ethical issue 
The study was conducted in the Department of Infection, Immunity and Cardiovascular 
Disease, Medical School, University of Sheffield. Approval for mouse experiments was 
from the Sheffield Ethical Review Committee, University of Sheffield and were 
conducted in accordance with the Home Office Animals (Scientific Procedures) 1986 
under Project license 40/3251. Human blood was drawn from healthy volunteers from 
Sheffield teaching hospital (STH), University of Sheffield. Recruitment of COPD patients 
and age-matched healthy volunteers were approved by the National Research Ethics 
Service (NRES) committee Yorkshire and the Humber (Sheffield cohort, reference 
number: 10/H1016/25). Written consent from STH’s staff, students, COPD patients and 
age-matched healthy volunteers were obtained as a requirement of ethical guidelines.  
2.2. Mouse Bone-Marrow cells culture 
Bone-marrow progenitor cells (BMPC) were extracted from C57BL/6 mouse femurs and 
tibias and placed in Dulbecco’s Modified Eagle’s Media (BioWhittaker®DMEM, Lonza, 
BE12-604F). Cell clumps were removed by pipetting up and down gently with a 1mL 
pipette. BMPC were counted with a haemocytometer, centrifuged for 5 minutes at 200xg 
at 4C and resuspended in 10% dimethyl sulfoxide (DMSO, Sigma-Aldrich, C67-68-5) + 
90% heat inactivated fetal calf serum  at 7.5 x106 cells/mL and placed in vials at 1mL/vial. 
BMPC were frozen slowly to -80C and then transferred for storage in liquid nitrogen. 
Cell vials were thawed under a running tap water and diluted in 50mL warm DMEM 
media supplemented with 10% heat inactivated fetal calf serum, 10% L929 conditional 
medium (source of M-CSF), penicillin (100U/mL) and streptomycin (100μg/mL). After 
counting in a haemocytometer, the cell suspension was re-adjusted to 2.0 x105 cells/mL 
by adding DMEM culture medium.  Subsequently, 25 mL was added to a T-75 cell culture 
flask or 1mL/well to a 24-well culture plate (Corning Inc. NY) with or without coverslips 
(size:13x13mm), and incubated in an incubator at 37οC and 5% CO2. After 5 days, the 
medium was changed, non-adherent cells were removed, and media replaced with 
DMEM media supplemented with 10% heat inactivated fetal calf serum and 10% L929 
conditional medium without penicillin/streptomycin. The medium was then replaced 
every other day up to 14 days. These differentiated BMPC, also called bone-marrow 
derived macrophages (BMDM) were used for extracellular flux assays and other 
experiments. 
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2.3. Human PBMCs culture and differentiated into monocyte-derived 
macrophages 
Human peripheral blood mononuclear cells (PBMCs) were separated from whole blood 
by Ficoll-PaqueTM (GE Healthcare, Life Sciences) density centrifugation. Briefly, 25 mL 
of heparinised blood was gently added onto 12.5 mL of Ficoll-PaqueTM in a 50 mL 
centrifuge tube (Thermo-Fisher Scientific). Subsequently, blood was centrifuged at 1500 
rpm for 23 minutes. Then the mononuclear cell layer was transferred to a sterile 50 mL 
centrifuge tube and diluted to 50 mL with phosphate buffered saline (PBS, Oxoid). The 
tube was then centrifuged at 1000 rpm (rotation per minute) for 10 minutes. The pellet 
was resuspended with PBS and centrifuged again at 1000 rpm for 10 minutes. Finally, 
PBMCs were counted by a haemocytometer and the cell number readjusted to 2 x 106 
cells/mL with RPMI 1640 media (Lonza) supplemented with 10% fetal calf serum and 
2mM L-glutamine (Gibco BRL). These PBMCs were seeded at 1 mL/well in 24 well 
plates or 20 mL/flask in T-75 flasks and differentiated into monocytes-derived 
macrophages (MDM) after 14 days culture, as described previously (Dockrell et al., 
2001). 
2.4. Culture and stock of Streptococcus pneumoniae  
S. pneumoniae serotype 2 (wild type D39 strain, NCTC 7466) or pneumolysin deficient 
D39 [(STOP D39 or ΔD39, as described in (Bewley et al., 2014)] was plated onto 
Columbia blood agar (CBA) plates and incubated overnight in the incubator at 37οC and 
5% CO2. Pneumococcal colonies were confirmed by observing their microbiological 
characteristics such as Gram stain positivity, catalase reaction negativity and optochin 
sensitivity. Moreover, it was also observed that the colonies were haemolytic on blood 
agar and form diplococci. Subsequently, 9-10 colony forming units (cfu) were selected 
from each blood agar plate and inoculated in culture broth of brain heart infusion (BHI, a 
mixture of 12.5g/L brain infusion solids and 5.0g/L beef heart infusion solids 
supplemented with 10.0g/L proteose peptone, 2.0g/L glucose, 5.0g/L NaCl, 2.5g/L Di-
sodium phosphate (Oxoid, CM1135)). To make 250mL of BHI broth, 9.26g of BHI 
mixture powder was dissolved in 250mL distilled water and autoclaved at 121oC for 15 
minutes. 9-10 cfu were inoculated into 30mL BHI broth with 20% heat inactivated fetal 
calf serum (in a 50 mL centrifuge tube), then put on a shaker (at 250 rpm) in an incubator 
at 37οC and 5% CO2. Subsequently, optical density (OD at 610nm) was recorded at 
different time points. Simultaneously, serial dilutions of bacterial suspensions were added 
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onto blood agar plates to estimate the bacterial cfu at the comparable time points, a 
technique called the Miles-Misra surface viable count method (Miles et al., 1938). The 
growth curve from the recorded OD and Miles-Misra count was used to estimate the mid-
log phase. The bacterial suspension at mid-log phase was then stored at -80οC in an 
Eppendorf tube (1mL/vial).  
2.4.1. Opsonisation and heat inactivation of S. pneumoniae  
The stored aliquot of S. pneumoniae was thawed in running tap water and centrifuged at 
9000 rpm for 3 minutes and washed twice with PBS. Subsequently, the bacterial 
suspension (in serum free DMEM/RPMI 1640 media) was opsonised either with 10% 
mouse pooled immune serum collected from the Pneumovax (PPV23) immunised mouse 
whole blood or 10% human pooled immune serum collected from the PPV23 immunised 
adult humans whole blood, incubated for 30 minutes at 200 rpm at 37oC and 5% CO2. For 
heat inactivation, freshly thawed bacterial suspension was kept in a heat block at 60οC for 
40 minutes. This was then centrifuged at 9000 rpm for 3 minutes and washed with PBS 
twice before opsonisation with mouse immune serum. The opsonised heat inactive 
pneumococci were washed twice with PBS, and centrifuged at 9000 rpm for 3 minutes. 
The bacterial pellet was re-suspended in 1mL DMEM medium. Finally, bacterial viability 
was re-checked by the Miles-Misra method (Miles et al., 1938) to confirm heat 
inactivation, with confirmation of no bacterial growth. Opsonised live bacteria and heat 
inactivated D39 were exposed to mouse BMDM or human MDM in subsequent 
experiments.  
 
2.5. Optimisation of Seahorse extracellular flux assay conditions with 
BMDM  
After 14 days of culture the supernatant was discarded from adherent BMDM in T-75 cell 
culture flasks and the cells washed once with 5mL sterile Dulbecco’s PBS (Life 
Technologies). Cells were detached by incubating with 5mL/flask Accutase (Biolegend) 
for 15 minutes at 37οC and 5% CO2. After detachment, the cell suspension was 
centrifuged at 200xg for 10 minutes at 20οC. The cell pellet was resuspended in DMEM 
medium at a concentration of 2x106 BMDM/mL, after counting by haemocytometer. 
Subsequently, different concentrations of cell suspensions were prepared through diluting 
with DMEM medium, to get 1000,000 to 5000,000 cells/mL. 100μL/well of these cell 
suspensions were seeded in XF24 cell plates to get 1x105, 2x105, 3x105 and 5x105 
BMDM/well unless other cell densities are stated. 
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The plates were incubated for 2 hours at 37οC and 5% CO2. 150μL/well DMEM medium 
was added without disturbing the seeded cells and the plates left overnight at 37οC and 
5% CO2. The following day, the supernatant was removed, and wells washed once with 
XF assay medium (XFAM, Bioscience) supplemented with 25mM glucose (pH adjusted 
to 7.4) medium. Subsequently, 630μL/well XFAM with 25mM glucose was added and 
incubated at 37 οC for an hour in a warm room. Simultaneously, the XF24 sensor 
cartridges (Seahorse Bioscience) were hydrated for consistent results. Thus, 1mL/well 
XF calibrant pH 7.4 (Seahorse Bioscience) was added to the Seahorse XF24 flux plate 
and a sensor cartridge applied to the top of the plate so that the sensors were submerged 
in calibrant solution. Then the plate was hydrated at 37ºC without CO2 in a warm room 
for 16 hours. For titration of the cell number, 70μL of XFAM with 5.5mM (1 g/L) glucose 
medium was added in port A of the cartridge, and kept at 37ºC without CO2 in a warm 
room for an hour. The cartridge contained 24 probes (with H+ and O2 sensors) along with 
4 injection ports (A-D) attached to each probe. The injection ports inject pneumatically 
and deliver different substrates/inhibitors/stimulators simultaneously to all the wells of 
the Seahorse cell culture microplate. To start recordings from the experiment the Seahorse 
cartridge with flux plate was loaded into the Seahorse flux analyser. Then, a calibration 
step was performed for approximately 6 minutes, after this only the XF24 flux plate was 
removed and the cell plate loaded. Next, the equilibration was performed prior to 
initiation of the mixing, waiting and measuring cycle. The analyser measured both the 
extracellular acidification rate (ECAR) or proton production rate (PPR) by the H+ sensor, 
and also the oxygen consumption rate (OCR) by the O2 sensor, making measurements 
kinetically in real time in a non-invasive way. 
 
2.5.1. Schematic work flow for the Seahorse Extracellular flux assay 
As described in the section 2.5, XF24 cell plate was prepared through re-seeding either 
mouse BMDM or human MDM and the XF24 flux plate prepared simultaneously with 
the XF calibrant (1mL/well) and incubated overnight. Following day, cell plate was with 
mock-infected or challenged with opsonised S. pneumoniae and incubated for a specific 
time point (see below). Subsequently, the non-buffered XF assay medium (BD, 
Bioscience) with antibiotics (penicillin and streptomycin) and supplements was added 
onto the cell plate and incubated for 60 minutes at 37ºC without CO2. Parallelly, the XF 
flux plate was prepared through adding either Glyco-stress test (i.e.  measurement of 
glycolysis) inhibitors such as oligomycin A and 2-deoxy-D-glucose (2DG) in the 
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cartridge’s injection port A and B, respectively or Mito-stress test (i.e. measurement of 
mitochondrial OXPHOS) inhibitors such as oligomycin A, FCCP and rotenone plus 
antimycin A in the cartridge’s injection port A, B and C, respectively and incubated for 
60 minutes at 37ºC without CO2. Subsequently, the XF flux plate with the sensors (H
+ 
and O2 sensors) cartridge was loaded into the XF24 flux analyser for calibration. After 
calibration, the flux plate was unloaded without the cartridge. Next, the cell plate was 
loaded into the flux analyser. Subsequently, the analyser automatically added either 
Glyco-stress test inhibitors or Mito-stress test inhibitors consecutively according to the 
customised command programme. The H+ (proton) sensor measures the glycolytic 
metabolism as the rate of acidification or rate of the extracellular proton production 
(ECAR) and the O2 sensor measures mitochondrial OXPHOS as the rate of oxygen 
consumption (OCR) in a non-invasive and real time manner. From the Glycol-stress or 
Mito-stress test kinetic data, we can measure the different glycolysis or mitochondrial 
OXPHOS related parameters using the following formulae (also labelled in Fig 2.1):   
i. Basal glycolysis (ECAR) = Rate of baseline glycolysis –  Rate of glycolysis 
after 2DG treatment. 
ii. Maximum glycolytic capacity = Rate of glycolysis after oligomycin A 
treatment –  Rate of glycolysis after 2DG treatment. 
iii. Glycolytic reserve = Rate of glycolysis after oligomycin A treatment –  Rate 
of basal glycolysis. 
iv. Non-glycolytic acidification = Rate of glycolysis after 2DG treatment. 
 
 
v. Basal OXPHOS (OCR) = Baseline OCR – OCR after rotenone plus 
antimycin A treatment. 
vi. ATP-linked OCR = OCR after oligomycin treatment –  Basal OCR. 
vii. Maximum respiration capacity = OCR after FCCP treatment – OCR after 
rotenone plus antimycin A treatment. 
viii. Respiration reserve/spare = OCR after FCCP treatment – Basal OCR 
ix. Proton (H+) leak = OCR after oligomycin treatment - OCR after rotenone 
plus antimycin A treatment. 
x. Non-mitochondrial OCR = OCR after rotenone plus antimycin A treatment. 
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Figure 2.1. Schematic diagram for the extracellular flux assay with the XF 24 flux analyser.  Figure 
shows the major steps of extracellular flux assay, briefly the flux plate with the cartridge is loaded into the 
XF24 flux analyser to complete the assay calibration. Subsequently, the cell plate is loaded into the analyser. 
Next, the XF24 flux analyser measures (A) the extracellular acidification rate (ECAR) as mpH/minute using 
the proton (H+) sensor and (B) the oxygen consumption rate (OCR) as pmoles/minute using the oxygen 
(O2) sensor. The diagram also shows different sets of glycolytic and OXPHOS parameters which are 
labelled in the respective kinetic data. Oligo –Oligomycin, 2DG –2-deoxy-D-glucose, FCCP –Carbonyl 
cyanide-4-(trifluromethoxy) phenylhydrazone, Rot –Rotenone, AntA –Antimycin A. 
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2.6. Normalisation of Seahorse data  
 
2.6.1. Normalisation using total cell count  
At the end of the Seahorse experiment, CyQuant® NF dye (Invitrogen, C35007) was used 
to estimate cell numbers. A stock solution was made up by adding 2μL of Cyquant 
dye/mL of 1x Hank’s Balanced Salt Solution (HBSS) buffer and 200μL of this solution 
was added into each well of the Seahorse cell plate and the plate incubated for an hour at 
37ºC without CO2 in a warm room. Then, the plate was loaded in the InCell Analyser2000 
to capture (20x) images from the central area of each well, capturing a total of 9 fields for 
each well. After acquisition, automated image analysis was performed with the InCell 
Developer toolbox 1.9 software (GE Healthcare) using custom-developed analysis 
protocol. For cell segmentation and nuclei count readout, images were captured in the 
eGFP/FITC channel using 490nm excitation and 525nm emission wavelength filters with 
a 0.1 second exposure time. The custom protocol developed for nuclei count readout 
identifies nuclei based on object segmentation and data is reported as the sum of the nuclei 
count for the whole well (i.e. central 9 fields). 
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Figure 2.2. Schematic diagram for cell counting through the Incell Analyser2000. Figure 
shows BMDM cells counting and seeding density which also shows the consistency of the cell 
layer in the XF24 microplates, using InCell Analyser2000. 
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2.6.2. Normalisation using total cell protein  
As an alternative to cell count, the Seahorse data was normalised by total protein of each 
well. At the end of the Seahorse experiment, each well was washed twice with PBS. Then 
100 µL/well of lysis buffer (ProfoundTM lysis buffer, Thermo Scientific) with 1:25 
protease inhibitor (Roche, Ref no. 04693132001) was added for 10 minutes at room 
temperature. The lysates of each well was preserved at -20oC. Subsequently, for total 
protein estimation the Bio-Rad protein assay kit (Bio-Rad) was used.  25µL of reagent A’ 
(composed of 20µL Reagent S in 1mL Reagent A) was added into each well of 96 well 
plate. Then 5µL of each Seahorse well lysate was added into each well (duplicate well). 
In parallel, 5µL of bovine serum albumin (BSA) in a serial dilution (0-10mg/mL) was 
added to the plate for a standard curve. Then 200µL/well of Reagent B was added to each 
well and left for minimum 15 minutes to allow the colour development. The photometric 
assay protocol was used to measure the optical density of each well by a plate reader 
(VarioskanTM Flash multimode Reader with SkanltTM software) at a wavelength of 
630nm. A standard curve was created using the OD of BSA in GraphPad PrismTM v6.1 
(GraphPad Software Inc.) and the amount of total protein (in µg) for each well was 
estimated by interpolating the known standard curve.  
 
2.7. Optimisation of Seahorse glycolytic and mitochondrial stress tests 
inhibitors 
 
2.7.1. Titration of oligomycin A  
2mM stock solution of oligomycin A (Sigma-Aldrich) was prepared in DMSO. A range 
of different working concentrations initially 2.5-50μM then 5-25μM were obtained by 
diluting stock solution in XFAM + 25mM glucose medium and oligomycin A applied 
via the injecting port A (70μL/port) that attached to the cartridge. After injection of 
oligomycin A to the respective well of cell plate, it was diluted tenfold (630μL existing 
XFAM + glucose media + 70μL oligomycin A). Hence, the final oligomycin A 
concentrations in the wells were 0.25-5.0μM and 0.5-2.5μM. OCR and ECAR were 
measured three times before and after injecting oligomycin A by the Seahorse XF24 
flux analyser. Three separate optimisation experiments were performed with a range of 
oligomycin A concentrations. Comparing these experiments, 1.0µM oligomycin A was 
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found to be the optimum concentration which was applied via the injecting port A in 
FCCP and 2-Deoxy-D-glucose titration in subsequent experiments.  
2.7.2. Titration of FCCP 
A 10mM stock solution of FCCP (Sigma-Aldrich, C370-86-5) was prepared in DMSO. 
A range of different working concentrations initially 6-25μM then 10-30μM were 
obtained by diluting stock solution in XFAM + 25mM glucose medium) and FCCP 
applied via the injecting port B (77μL/port) attached to the cartridge. Injection of FCCP 
into the wells of the plate resulted in a tenfold dilution (700μL existing XFAM+ 25mM 
glucose media per well + 77μL FCCP from injecting port). Hence, the final FCCP 
concentrations in the wells were 0.6-2.5μM and 1.0-3.0μM. OCR and ECAR were 
measured three times before and after injecting FCCP by the Seahorse XF24 flux 
analyser. 
 
2.7.3. Titration of 2-deoxy-D-glucose  
Like FCCP, 2-DG (Sigma-Aldrich) titration experiments were performed with a range 
of concentrations from 10mM to 200mM. The Seahorse protocol was adapted so that 
after the basal ECAR and OCR measurements were performed over three cycles, 70 μL 
of oligomycin A (10µm) was injected from port A to all wells and responses were 
measured for 3 more cycles. Then, 0mM (only XFAM+ 25mM glucose medium), 
10mM, 25mM, 50mM, 100mM and 200mM 2-DG in XFAM + 25mM glucose medium 
(adjusted to pH 7.4 with 1.0M NaOH) was injected to the respective group of wells from 
port B and measurements performed over three more cycle. The 2-DG titration assay 
was also performed twice separately, with the same settings.  
 
2.7.4. Titration of rotenone 
First a range of different working concentrations of rotenone, initially 5-50μM then 5-
25μM and 5-15µM, were obtained by diluting stock solution in XFAM + 25mM glucose 
medium) and rotenone applied via the injecting port C (85μL/port) that attached to the 
cartridge. After injection of optimised oligomycin and FCCP, rotenone was injected into 
the respective wells of the cell plate becoming diluted tenfold (777μL existing XFAM+ 
25mM glucose media per well + 85μL rotenone from injecting port). Hence, the final 
rotenone concentrations in the wells were 0.5-5.0μM, 0.5-2.5μM and 0.5-1.5μM. OCR 
and ECAR were measured during basal conditions, oligomycin A and FCCP injections 
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and consecutively extracellular fluxes were measured three times after injecting 
rotenone.  
 
2.7.5. Titration of antimycin A 
Like rotenone, the concentration of antimycin A (Sigma-Aldrich) was optimised by 
testing a range of different concentrations of antimycin A, initially 10-200μM then 10-
50μM were obtained by diluting stock solution in XFAM + 25mM glucose medium) 
and antimycin A applied via the injecting port C (85μL/port). Antimycin A was injected 
to the respective wells of cell plate, becoming diluted tenfold (777μL existing XFAM + 
85μL antimycin A from injecting port). Hence, the final antimycin A concentrations in 
the wells were 1.0-20.0μM and 1.0-5.0μM. OCR and ECAR were measured during 
basal conditions, oligomycin A and FCCP injections and consecutively extracellular 
fluxes were measured three times after injecting antimycin A. 
 
2.8. Measuring extracellular fluxes of BMDM in the presence of heat 
killed S. pneumoniae. 
After 14 days of BMDM culture, 2x105 BMDM/well were re-seeded in Seahorse cell 
plates and the Seahorse flux plate (cartridge with flux plate) also prepared as per section 
2.5. On the day of the Seahorse experiment, the Seahorse cell plates were separated into 
3 groups for analysis without bacteria, analysis of plates with heat-inactivated (HI) 
bacteria (multiplicity of infection, MOI=10) and plates exposed to HI bacteria (MOI =20) 
during the experiment (i.e. HI bacteria added from the cartridge port A). The flux plate 
injection port A was prepared either with HI S. pneumoniae (HISpn) (MOI=10 or 20 in 
XFAM with 25mM glucose) or without bacteria (XF medium with 25mM glucose only). 
Then oligomycin A (77μL at 10μM) and 2-deoxy-D-glucose (85μL at 1.0M) were added 
to injection port B and C, respectively. Like previous Seahorse experiments, cell plates 
and flux plates were kept at 37ºC without CO2 for an hour before loading in the 
extracellular flux analyser.  
 
2.9. Measuring glycolytic responses of mouse BMDM after stimulation 
with live S. pneumoniae, LPS, IFNγ and IL-4  
Macrophage mediated real-time aerobic glycolytic respiration (e.g. Extracellular 
acidification) was measured by the XF24 extracellular flux analyser (Seahorse, 
Page | 74 
 
Bioscience). Briefly, after 14 days of culture of wild type mouse bone marrow cells into 
BMDM in the T-75 flask, cells were detached using Accutase solution (Biolegend) 
followed by re-seeding at 2x105 BMDM/well into the XF24 cell plate. After overnight 
incubation to allow adherence, BMDM were challenged either with mock infection or 
opsonised D39 (MOI=10) or heat inactivated D39 (MOI=10, heat inactivated at 700C for 
40 minutes) or stimulated with LPS (100ng/mL) and mouse IFNγ (20ng/mL) or mouse 
IL-4 (20ng/mL) for 4 hours at 37οC with 5% CO2. Subsequently, cells were washed twice 
by the XF medium (Seahorse, Bioscience) (supplemented with 4.5g/L D-glucose, 2mM 
L-glutamine and penicillin (100U/mL and streptomycin (100μg/mL), pH 7.4 adjusted 
with 1.0M NaOH, then the XF medium (630μL/well) was added and incubated for an 
hour at 37οC without CO2. Meanwhile, the XF24 utility plate containing cartridge with a 
sensors probe was submerged into the XF calibrant (Bioscience) and incubated overnight 
at 37οC, afterwards the optimised concentration of ATP synthase inhibitor oligomycin A 
(70μL at 10μM), the glucose analogue 2-deoxy-D-glucose (77μL at 1M) were added in 
the cartridge containing injection port A and B, respectively and incubated for an hour at 
37οC. Finally, after successful calibration by calibrant containing plates, the cell plate was 
loaded into the XF24 analyser and the rate of oxygen consumption (OCR) and 
extracellular acidification (ECAR) were measured kinetically before and after injecting 
oligomycin, 2-deoxy-D-glucose (Sigma-Aldrich), respectively. From the kinetic data, the 
basal OCR, maximum glycolytic capacity and glycolytic reserve were calculated 
following Pelletier M et al. calculation formula (Pelletier et al., 2014).  
2.10. Measurement of mitochondrial OXPHOS after challenge with 
pneumococci in wild type and Mcl-1 transgenic mouse BMDM 
After 14 days culture and differentiation of wild-type and human CD68 Mcl-1 transgenic 
mouse bone marrow cells into BMDM (described in (Bewley et al., 2017)) in T-75 flasks, 
cells were detached using Accutase (Biolegend) for 15 minutes at 37οC with 5% CO2 
followed by re-seeding at 2x105 BMDM/well in the XF24 cell plate. After adhering 
overnight, cells were either mock-infected or exposed to opsonised D39 (MOI=10, 
opsonised with 10% mouse immune serum) for 4 hours at 37οC with 5% CO2. 
Subsequently cells were washed twice in XF medium (Seahorse, Bioscience) 
(supplemented with 4.5g/L D-glucose, 2mM L-glutamine, 1.0mM sodium-pyruvate, 
penicillin (100U/mL) and streptomycin (100μg/mL) at pH 7.4 adjusted with 1.0M 
NaOH), before the XF medium (630μL/well ) was added and incubated for an hour at 
37οC without CO2. ECAR and OCR were then measured using extracellular flux analyser. 
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2.11. Measurement of mitochondrial OXPHOS in human MDM after 
challenge with S. pneumoniae 
Human MDM were culture in T-75 flask for 14 days. Cells were washed 3 times with 
PBS and treated with Accutase for 15 minutes at 37οC and 5% CO2. The detached cells 
were re-seeded in XF24 cell plate (at 150,000 MDM/well), then exposed to opsonised 
D39 (MOI =10) for 4 or 16 hours. Subsequently, cells were washed twice with XF 
medium (as in section 2.10) and the XF medium (630μL/well) was added and incubated 
for an hour at 37οC without CO2. At the same as the cell plate was being set up the XF24 
utility plate containing sensors probes were submerged into the XF calibrant and 
incubated overnight at 37οC. Then, 70µL oligomycin A (15µM), 77µL FCCP (20μM) and 
85µL rotenone (10µM) plus antimycin A (10µM) were added in the cartridge containing 
injection port A, B and C, respectively, and incubated for an hour at 37οC without CO2. 
Finally, the calibration plate was loaded into the XF24 flux analyser. After calibration 
completion, the cell plate was loaded into the XF24 analyser and the OCR and ECAR 
were measured kinetically before and after injecting oligomycin, FCCP and rotenone plus 
antimycin A, respectively. The rate data were normalised using total cell protein and the 
key parameters of mitochondrial OXPHOS and ECAR were calculated, described in 
(Pelletier et al., 2014).  
2.12. Measurement of mitochondrial OXPHOS in human MDM after 
stimulation with HIV-1 glycoprotein gp120 and S. pneumoniae  
Human PBMCs were differentiated into monocyte derived macrophages (MDM) in T-75 
flasks (Dockrell et al., 2001). MDM were detached using Accutase (Biolegend) for 15 
minutes at 37οC and 5% CO2. Cells were then gently scrapped with a cell scrapper 
followed by re-seeding at 1.5x105 cells/well into the XF24 cell plate and incubated 
overnight at 37οC and 5% CO2. Subsequently, cells were treated either with or without 
recombinant gp120 (100ng/mL in RPMI media) and incubated for 24 hours at 37οC and 
5% CO2. Cells were either challenged with mock infection or opsonised pneumococci 
(D39, MOI=10) with or without recombinant gp120 for 4 or 16 hours at 37οC and 5% 
CO2. After incubation, cells washed 2 times with XF medium. Then 630μL of XF medium 
with or without recombinant gp120 was added to each well and incubated for an hour at 
37οC without CO2. ECAR and OCR were then measured as in section 2.11. 
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2.13. Measurement of mitochondrial OXPHOS in COPD MDM in the 
presence of S. pneumoniae 
Both COPD patients and age-matched healthy volunteers PBMCs were differentiated into 
monocyte-derived macrophage (MDM) in the T-75 flasks. MDM were gently detached 
using Accutase and gentle scrapping followed by re-seeding at 1.5x105 MDM/well into 
the XF24 cell plate. After overnight incubation, cells were either mock-infected or 
exposed to opsonised pneumococci (MOI =10) for 4 hours at 37οC with 5% CO2. 
Subsequently cells were washed twice with XF medium, 630μL XF medium was added 
to each well of XF24 cell plate and incubated for an hour at 37οC without CO2. The OCR 
and ECAR was then measured as in section 2.11. 
2.14. Measurement of mitochondrial OXPHOS in MitoTempo pre-
treated mouse BMDM  
Mouse bone marrow cells were culture in T-75 flask and differentiated into BMDM (detail 
protocol in 2.2). Then cells were re-seeded at 200,000 cells/well in the XF24 Seahorse 
cell plate and incubated overnight at 37oC and 5% CO2. Cells were treated or untreated 
with MitoTempo (10µM) (Sigma-Aldrich) for an hour prior to pneumococcal (D39, 
MOI=10) exposure for 12 hours. Cells were then washed with XF medium (explained in 
2.4). Next, 630µL/well of XF medium with/without MitoTempo were added and 
incubated for an hour at 37oC without CO2. Subsequently oligomycin A, FCCP and the 
combination of rotenone and antimycin A were added to the inject ports of the flux plate, 
and incubated for an hour at 37οC without CO2. The OCR and ECAR were measured 
kinetically before and after the consecutive injection of oligomycin, FCCP and rotenone 
plus antimycin A, using the XF24 extracellular flux analyser. From the OCR and ECAR 
rate data, the key parameters of mitochondrial OXPHOS and glycolysis were calculated. 
Data were normalised using total cell protein. 
 
2.15. Flow cytometry 
2.15.1. Evaluation of mitochondrial inner transmembrane potential 
(ΔΨm) in COPD MDM  
Both COPD and age-matched healthy control volunteers MDM were exposed to S. 
pneumoniae (D39, MOI=10) or mock infected and left an hour on ice and incubated 3 
hours at 37οC with 5% CO2. They were then washed 3 times with pre-warmed HBSS 
followed by staining with 10µM of 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl 
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benzimidazolyl carbocyanine iodide (JC-1, diluted in phenol red free RPMI media 
supplemented with 2mM L-glutamine) (eBioscience, 65-0851-38) for 30 minutes at 37οC 
with 5% CO2 and washed 3 times with HBSS before being resuspended in 300µL/well 
PBS. The loss of mitochondrial inner transmembrane potential (ΔΨm) is equivalent to the 
loss of JC-1 aggregates (red fluorescence) from mitochondrial matrix, was measured by 
the FACSCalibur (Becton Dickinson) using FL-2H channel. The forward and side scatter 
were used to distinguish the cell population and a total of 10,000 events for each sample 
were recorded. The settings were saved and the same instrumental settings were used for 
subsequent sample acquisition and analyses. Data were analysed using the FlowJo 
software, version 8.8.4 (Tree Star Inc.).  
2.15.2. Evaluation of mitochondrial ΔΨm in 3-methyladenine pre-
treated mouse BMDM in the presence of pneumococci 
Mouse BMDM were pre-treated with/without 3-methyladenine (10mM) for an hour. 
Then, S. pneumoniae (D39, MOI=10) was exposed to BMDM for 16 hours at 37οC and 
5% CO2. Then macrophages washed 3 times with pre-warmed HBSS followed by staining 
with JC-1 (10µM) for 30 minutes at 37οC and 5% CO2. Subsequently cells were washed 
3 times with HBSS before being gently scrapped and resuspended in 300µL/well PBS. 
The loss of mitochondrial inner transmembrane potential (ΔΨm) or loss of JC-1 
aggregates (i.e. red intensity) from mitochondrial matrix was measured by the 
FACSCalibur (Becton Dickinson) using FL-2H channel (detail protocol in 2.15.1).  
 2.15.3. Measurement of mROS in mouse BMDM after challenge with 
pneumococci  
Mouse BMDM were challenged with S. pneumoniae (D39, MOI=10) or mock-infected 
and left for an hour on ice and 3 hours at 37οC and 5% CO2, washed three times with 
PBS, then incubated in fresh DMEM+10% heat inactivated fetal calf serum for 12 hours 
at 37οC and 5% CO2. As a positive control, BMDM were treated with rotenone (2.0µM) 
and antimycin A (10 µM) for 30 minutes at 37οC and 5% CO2 followed by washed 3 times 
with pre-warmed HBSS. Subsequently, MitoSox red (2.5µM) (Invitrogen, M36008) was 
diluted in pre-warmed phenol red free RPMI media supplemented with 2mM L-
glutamine, or Mito-tracker green FM (1:1000) (Invitrogen, cat. no. M7514) was added 
for 30 minutes at 37οC and 5% CO2. Cells were resuspended in PBS (300µL/well), after 
gentle scrapping and washed 3 times with HBSS. The oxidised Mitosox Red and Mito-
tracker green were measured by the FACSCalibur (Becton Dickinson) using FL-2H and 
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FL-1H channels, respectively. The forward and side scatter were used to distinguish cell 
populations and a total of 10,000 events were recorded. The instrumental settings were 
saved and used for subsequent sample acquisition and analyses. Data were analysed using 
FlowJo software, version 8.8.4 (Tree Star Inc.).  
 
2.15.4. Measurement of mROS in 3-methyladenine pre-treated mouse 
BMDM in the presence of pneumococci 
Mouse BMDM were treated with/without 3-methyladenine (10mM) for an hour at 37oC 
and 5% CO2. S. pneumoniae (D39, MOI=10) was exposed to BMDM for 12 or 14 or 16 
hours at 37oC and 5% CO2. Cells were washed 3 times with pre-warmed HBSS, before 
being treated with MitoSox red (2.5µM) for 30 minutes at 37oC and 5% CO2. Then, cells 
were washed 3 times with HBSS. Subsequently cells were resuspended in PBS 
(300µL/well) after gently detached with a cell scrapper. The oxidised MitoSox red was 
measured by the FACSCalibur (Becton Dickinson) using FL-2H channel. To measure 
MitoSox red fluorescence intensity, total 10,000 events per sample were recorded and 
data were analysed using FlowJo software, version 8.8.4 (Tree Star Inc.).  
 
2.16. Immunofluorescence 
2.16.1. Co-staining of mROS and mitochondrial outer membrane 
protein Tom20  
Mouse BMDM were challenged with S. pneumoniae (D39, MOI=10) or mock-infected 
and incubated for an hour on ice, followed by 3 hours at 37οC with 5% CO2. After washing 
three times with PBS, cells were incubated for 12 hours at 37οC with 5% CO2. Cells were 
washed 3 times with pre-warmed HBSS and mROS were labelled using the live cell 
mROS staining probe MitoSox red (2.5µM). Cells were fixed with 2% paraformaldehyde 
(in PBS) for 20 minutes at room temperature (RT). Cells were permeablised using 50mM 
NH4Cl with 0.1% Triton-X-100, and blocked with working solution PGAT (PGAT 
composition: 0.2% Gelatin with 0.02% Na-azide and 0.01% Triton X-100 in PBS) for 15 
minutes each. Subsequently, the blocking solution was replaced with 200µL/well rabbit 
anti-Tom20 (FL-145) (Santa Cruz, cat no. sc-11415) at a 1:500 dilution in PGAT solution 
and incubated overnight at 4oC. The following day, cells were washed 3 times with the 
PGAT solution, then, the secondary antibody Alexa Fluor 488-conjugated goat anti-rabbit 
IgG (Thermo-fisher scientific, cat. no. A32723) at a 1:500 dilution in PGAT solution was 
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added for an hour at RT. Cells were washed 3 times with the PGAT solution and 2 times 
with PBS. Finally, nuclei were stained with Draq5 (BioStatus LTD) with a 1:1000 
dilution in PBS for 12 minutes at RT. After washing 3 times with PBS and once with 
distilled H2O, cells were mounted with a glycerol free poly-(vinyl alcohol) (CITIFLUOR 
MOWIOL Tris-MWL 4-88) mounting agent in the microscopic slides. Images were 
acquired by the Zeiss LSM 510 inverted confocal fluorescence microscopy (ZEISS), 
using 63 X 1.4 NA oil objective (zoom 2) lens and 488nm, 568nm and 633nm excitations 
lasers and 500-530nm (for Alexa Fluor 488), 565-615nm (for MitoSox red) and 661-
704nm (for Draq5) emission spectrums, respectively. 
 2.16.2. Labelling of S. pneumoniae with Alexa Fluor 647-conjugated 
succinimidyl ester 
S. pneumoniae (D39) (3 x 108 cfu/mL) was thawed and washed twice with PBS, 
centrifuging at 9000 rpm for 3 minutes, then the bacterial pellet was resuspended in PBS 
to obtain a concentration of 108 cfu/mL. 18.8µL of Alexa Fluor 647-conjugated 
carboxylic acid succinimidyl ester (stock concentration was 0.5mg/mL in DMSO) (Life 
Technologies, A37573) (AF647-NHS-ester) was added to 500µL bacterial suspension 
and incubated for an hour at RT, with frequent mixing. This was then centrifuged at 
2000xg for 10 minutes, and the pellet washed twice with PBS. Subsequently the pellet 
was resuspended in phenol red and serum free RPMI 1640 media (Sigma-Aldrich, R7509-
500mL) and opsonised with 10% mouse or human pneumococcal immunised serum for 
30 minutes at 37oC and 5% CO2. The Alexa Fluor-647 NHS ester labelled bacterial 
suspensions were subsequently either air dried on a microscopic slide to confirm the 
labelling (by fluorescence microscope) or used to challenge macrophages. Labelled 
bacterial images were captured by the Zeiss LSM510 inverted confocal microscopy using 
63x1.4 oil (zoom 2) objective lens and 633nm excitation and 650-704nm emission 
spectrum.  
 
2.16.3. Co-staining of Alexa Fluor-647 S. pneumoniae and mROS in 
macrophages 
Mouse BMDM were pretreated with 10µM MitoTempo (Sigma-Aldrich, SML0737-
5MG) for an hour, then, cells were challenged with Alexa Fluor-647-NHS ester (or 
vehicle) labelled opsonised S. pneumoniae (D39, MOI=10) and incubated for 16 hours. 
mROS specific 2.0µM of MitoSox red and, as a negative control endoplasmic reticulum 
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(ER) specific 500nM ER-tracker red (BODIPY TR Glibenclamide) (Thermo-Fisher 
scientific, E34250), were added for 15-30 minutes at 37oC and 5% CO2. Cells were then 
washed 3 times with pre-warmed HBSS, and fixed with 4% paraformaldehyde for 20 
minutes at RT, before being mounted onto microscopic slides with poly-(vinyl alcohol) 
mounting agent. Cells were visualised with Z-stack images which were captured by Zeiss 
LSM510 inverted confocal microscopy, using 63x1.4 oil (zoom 2) objective lens. 633nm 
excitation and 650-704nm emission spectrum was used for AF-647-NHS ester labelled 
D39, 488nm excitation and 565-615nm emission spectrum was used for MitoSox red, and 
543nm excitation and 560nm emission was used for ER-tracker red. The Pearson’s 
correlation coefficient was measured by ImageJ (v1.48, NIH) using the Pearson co-
localisation test with the Costes threshold regression, described in (Bewley et al., 2017). 
In addition, the total corrected cellular fluorescence [TCCF = Integrated density – (area 
of selected cell x mean fluorescence of background readings)] was measured for MitoSox 
red from the maximum projected Z-stack images by ImageJ. 
 
2.16.4. Co-staining of mROS and lysosome/phagolysosome in 
macrophages  
Alexa Fluor 647-NHS ester-labelled opsonised S. pneumoniae (D39, MOI=10) was 
exposed to mouse BMDM for 16 hours. Cells were washed three times with HBSS, then, 
both mROS specific MitoSox red (2.0µM) and lysosome/phagolysosomes specific Cresyl 
violet (0.5µM) (Sigma-Aldrich, C10510540) were added for 30 minutes at 37oC and 5% 
CO2. For negative controls, both lysosome/phagolysosome specific Cresyl violet and 
endoplasmic reticulum (ER) specific ER-tracker red (500nM) (BODIPY TR 
Glibenclamide) were added for 30 minutes at 37oC and 5% CO2. All staining probes were 
diluted in phenol red and serum free RPMI media supplemented with 2mM L-glutamine. 
Cells were washed 3 times with HBSS, then cells were fixed with 4% paraformaldehyde 
for 20 minutes at RT, before being mounted onto microscopic slides with a drop of poly-
vinyl alcohol mounting agent. Then, Z-stack images were captured by the above 
mentioned confocal microscope. The MitoSox red and Cresyl violet labelled mROS and 
lysosome/phagolysosomes images were acquired using 488nm and 633nm excitation 
lasers, and 565-615nm and 650-704nm emission spectrums, respectively. ER and 
lysosome/phagolysosome labelled ER-tracker red and Cresyl violet stains were acquired 
with 543nm and 633nm excitation lasers and 560nm and 650-704nm emission spectrums, 
respectively. The Pearson’s correlation coefficient was measured by ImageJ using the 
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Pearson co-localisation test with Costes threshold regression, described in (Bewley et al., 
2017). 
 
2.16.5. Co-staining of mROS, nitric oxide and 
lysosome/phagolysosomes in macrophages 
Alexa Fluor 647-NHS ester-labelled opsonised S. pneumoniae (D39, MOI=10) was 
exposed to mouse BMDM for 16 hours. Cells were washed three times with HBSS, then 
nitric oxide (NO)-specific DAF-FM diacetate (4-Amino-5-Methylamino-2',7'-
Difluorofluorescein-Diacetate) (Thermo-Fisher Scientific, Cat. no. D23844) 
(10µM) was added for 30 minutes at 37oC and 5% CO2. Cells were washed three 
times with HBSS before being treated with mROS-specific MitoSox red (2.0µM) and 
lysosome/phagolysosome-specific Cresyl violet (0.5µM) for 30 minutes at 37oC and 5% 
CO2. For negative controls, either NO-specific DAF-FM diacetate and ER-specific ER-
tracker red (BODIPY TR Glibenclamide), or lysosome/phagolysosome-specific Cresyl 
violet and ER-tracker were used for 30 minutes, at 37oC and 5% CO2. All staining probes 
were diluted in phenol red and serum free RPMI media, supplemented with 2mM L-
glutamine. Cells were also separately stained with each of these specific probes (single 
staining) to compensate the overlapping excitation and emission spectrums. Subsequently 
cells were washed 3 times with pre-warmed HBSS. The MitoSox red, DAF-FM and 
Cresyl violet labelled mROS, NO and lysosome/phagolysosomes cells, respectively were 
visualised with 543nm, 488nm and 633nm excitation lasers, and 565-615nm (for MitoSox 
red), 500-530nm (for DAF-FM) and 650-704nm (for Cresyl violet) emission spectrums. 
ER tracker red and DAF-FM labelled ER and NO stained cells images were acquired with 
543nm and 488nm excitation lasers and 560nm and 500-530nm emission spectrums, 
respectively. From three independent experiments, the percentage of macrophages 
showing co-localisation signal for mROS (red), NO (green) and 
lysosome/phagolysosome (pink) was measured by ImageJ.    
 
2.16.6. Co-staining of mROS, NO and Alexa-Fluor 647-labelled S. 
pneumoniae in macrophages  
Alexa Fluor 647 NHS ester-labelled opsonised S. pneumoniae (D39, MOI=10) was 
exposed to mouse BMDM and incubated for 16 hours. Cells were washed three times 
with HBSS and NO-specific DAF-FM diacetate (10µM) was added for 30 minutes at 
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37oC and 5% CO2. Subsequently, cells were washed three times with HBSS before being 
treated with mROS-specific MitoSox red (2.0µM) for 30 minutes at 37oC and 5% CO2. 
For negative control, both mock-infected and Alexa Fluor 647-labelled pneumococci 
exposed BMDM were stained with NO-specific DAF-FM and ER-specific ER-tracker 
red together, or only ER-tracker for 30 minutes at 37oC and 5% CO2. All staining dyes 
were diluted in phenol red and serum free RPMI media, supplemented with 2mM L-
glutamine. Subsequently, macrophages were washed 3 times with HBSS before being 
fixed with 4% paraformaldehyde for 20 minutes at RT. Cells were washed with PBS, and 
mounted in microscopic slides with poly-vinyl alcohol mounting agent. Z-stack images 
were captured by Zeiss LSM510 inverted confocal microscopy using 63x1.4 oil (zoom 2) 
objective lens. The images of MitoSox red and DAF-FM stained macrophages with or 
without Alexa Fluor 647-labelled pneumococci were visualised with 543nm, 488nm and 
633nm excitation lasers, and 565-615nm or 500-530nm and 650-704nm emission 
spectrums, respectively. Whilst as a control, the ER-tracker red and DAF-FM labelled ER 
and NO stained images were captured with 543nm and 488nm excitation lasers and 
560nm and 500-530nm emission spectrums, respectively. From three independent 
experiments, the percentage of macrophages showing co-localisation signal for mROS 
(red), NO (green) and Alexa Fluor 647-labelled intracellular D39 (blue) was counted by 
ImageJ. The co-localisation of the negative comparator, ER with NO, was also observed 
in mock-infected and Alexa Fluor 647-labelled D39 exposed macrophages. In addition, 
single stained cells images were also visualised to compensate the overlapping excitation 
and emission spectrums 
 
2.17. Evaluation of Mitochondrial morphological features  
2.17.1a. Staining of mitochondrial outer membrane protein TOM20  
Mouse bone marrow cells on coverslips (13x13mm) in 24 well plate and differentiated 
into bone marrow-derived macrophages (BMDM). Cells were treated with Mdivi-1 
(25µM) (Sigma-Aldrich, M0199) or 3-methyladenine (10mM) (Sigma, M9281) for an 
hour prior to mock-infection or challenged with opsonised S. pneumoniae (D39, 
MOI=10), and then the plate left on ice for an hour and 3 hours at 37oC and 5% CO2. 
Cells were washed 3 times with PBS, and added fresh DMEM media with the respective 
inhibitors and incubated for 4, 8 and 10 hours at 37oC and 5% CO2. Subsequently, cells 
were washed 3 times with PBS, before being fixed with 4% paraformaldehyde for 20 
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minutes at RT. Next, they were washed once with quenching solution and 250µL/well 
quenching solution [50mM NH4CL (1.34g in 500mL PBS) in 0.1% Triton-x-100 (500µL 
in 500mL PBS)] added for 15 minutes at RT. Cells were washed once with blocking 
solution (PGAT solution) and 250µL/well blocking solution [PGAT solution:  0.2% 
Gelatin (sigma-aldrich) + 0.02% Na-Azide (Sigma-Aldrich) + 0.01% Triton-x-100 
(promega) in PBS] added for 15 minutes at RT. The blocking solution was replaced with 
200µL/well rabbit anti-Tom20 (FL-145) (Santa Cruz, cat no. sc-11415) at 1:500 dilution 
in PGAT solution and incubated overnight at 4oC. Cells were washed 3 times with PGAT 
solution with 1-2 minute intervals and Alexa Fluor 488-conjugated goat anti-rabbit IgG 
(H+L) (Life technologies, A11034) secondary antibody was added for an hour (in the 
dark) at RT. Next cells were washed 3 times with PGAT solution and 2 times with PBS. 
Finally, nuclei were stained with Draq5 (BioStatus LTD) with 1:1000 in PBS for 12 
minutes at RT. Cells were washed 3 times with PBS and once with distilled H2O followed 
by mounting on poly-vinyl alcohol mounting agent and left overnight at RT. Cells were 
visualised by the Zeiss LSM 510 inverted confocal fluorescence microscopy using 63 X 
1.4 oil objective (zoom 2) lens, and 488nm and 633nm excitations with 500-530nm and 
660-704nm emission spectrums for Tom20 and nuclei, respectively. 
2.17.1b. Quantification of mitochondrial network complexity by 
ImageJ 
To assess mitochondrial network complexity, the Z-stack images of mitochondrial outer 
membrane protein, Tom20 were acquired by LSM510 inverted confocal fluorescence 
microscopy (Zeiss). Z-stack images were converted into maximum projected images by 
ImageJ. Subsequently, individual cell was duplicated and adjusted its brightness and 
contrast. The resolution of mitochondrial population was fine-tuned with a 13 x 13 hat 
filter (matrix developed by Dr. De Vos Kurt), described in (De Vos et al., 2005). The total 
population of mitochondria were skeletonised after threshold level optimisation. 
Subsequently the binary connectivity were quantified by the Morphology plugins of 
ImageJ software, this procedure shows schematically in figure 2.2. As an output it returns 
0, 1, 2, 3, 4 and so on for the total number of background pixels, single pixels, end points, 
junctions with two neighbouring pixels, branch points (value is ≥4), respectively (Figure 
2.3). The network complexity of mitochondrial population of individual cell was 
measured as the ratio of total branch points and total end points.    
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Figure 2.3. Schematic diagram for mitochondrial image processing by ImageJ. It quantifies 
the network complexity of total mitochondrial population in a macrophage. Figure shows (1-6) 
how a single cell was skeletonised by ImageJ. Free hand selection and then duplication of each 
cell from the maximum projected Z-stack image. The background noise is minimised by adjusting 
brightness/contrast. The hat filter (13 x 13) was increased the resolution of signal pixels. Then the 
binary image was skeletonised after threshold level optimisation. Subsequently the voxels binary 
connectivity was quantified using morphology plugins. 
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Figure 2.4. Mitochondrial network complexity in a typical macrophage. The total population 
of mitochondria were skeletonised, then ran the connectivity morphology plugins by ImageJ. 
Figure A shows the visual explanation of skeletonised voxel’s connectivity. The blue quadrant 
represents the single pixel of binary skeletonised images. It also shows the end point which 
represents single pixel with one neighbouring pixel, junction pixel shows the length of 
skeletonised voxel. Whereas branch point shows single pixel’s with three or more than three 
neighbours. Table B shows an example of mitochondrial network complexity of a typical wild-
type (WT) mouse BMDM as a ratio of total branch points and end points, which was 0.69.  
 
2.17.2. Co-staining of mitochondrial Tom20 and phosphorylated-Drp1 
(serine 616)  
Human PBMCs were culture on coverslip in a 24-well plate and differentiated into MDM. 
S. pneumoniae (D39, MOI=10) were exposed to MDM and the plate left on ice for an 
hour and 3 hours at 37oC and 5% CO2. Cells were washed 3 times with PBS and added 
fresh RPMI media, and incubated for 12 hours at 37oC and 5% CO2. In the positive control 
wells, MDM were treated with the mitochondrial OXPHOS uncoupler FCCP (20µM) for 
8 hours.  Cells were then washed 3 times with PBS before being fixed with 4% 
paraformaldehyde for 20 minutes at RT. Next, cells were washed once with quenching 
solution and added 250µL/well quenching solution for 15 minutes at RT. Cells were 
washed once with PGAT solution and added 250µL/well PGAT solution for 15 minutes 
at RT. Subsequently the PGAT solution was replaced with primary antibodies, 
200µL/well mouse monoclonal anti-Tom20 (F-10) (Santa Cruz, cat no. sc-17764) at 
1:500 dilution to give a final concentration of0.4µg/mL in PGAT solution and rabbit anti-
A. 
B. 
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phospho-Drp1 (Ser616) (Cell signalling Tech, cat no. 3455) at 1:500 dilution (in PGAT 
solution) and incubated overnight at 4oC. Cells were washed 3 times with PGAT solution 
with 1-2 minutes intervals. Alexa Fluor 488 and 568-conjugated goat monoclonal anti-
mouse (Molecular probes, A11001) and goat anti-rabbit IgG (H+L) (Thermo-fisher 
scientific, A11011) secondary antibodies were added for an hour at RT. Subsequently 
cells were washed 3 times with PGAT solution and twice with PBS. Finally, cells nuclei 
were stained with Draq5 (BioStatus LTD) with 1:1000 in PBS for 12 minutes at RT, 
washed 3 times with PBS and once with dH2O followed by mounting in microscopic 
slides with a drop of glycerol-free poly-vinyl alcohol mounting agent. Cells were 
visualised by the Zeiss LSM 510 confocal fluorescence microscopy using 63 X 1.4 oil 
objective (zoom 2) and 488nm, 543nm and 633nm excitations with 500-530nm 565-
615nm and 660-704nm emission spectrums, respectively. 
2.17.3. Co-staining of mitochondrial Tom20 and E3 ubiquitin ligase 
Parkin  
Mouse BMDM were untreated or treated with Mdivi-1 (25µM) or 3-MA (10mM) for an 
hour, then exposed to S. pneumoniae (D39, MOI=10), and the plates left on ice for an 
hour and 3 hours at 37oC and 5% CO2. Cells were washed 3 times with PBS and fresh 
DMEM media added with respective inhibitors and incubated for 8 hours at 37oC and 5% 
CO2. Cells were fixed with 4% paraformaldehyde for 20 minutes at RT. After quenching 
and blocking, the primary antibodies, rabbit anti-Tom20 (200µL/well) at 1:500 dilution 
and mouse monoclonal anti-Parkin IgG2 (PARK8) (Santa-Cruz, cat no. SC-32282) at 
1:100 dilution in PGAT solution were added and incubated overnight at 4oC. Cells were 
washed 3 times with PGAT solution before being treated with secondary antibodies, 
Alexa Fluor 568-conjugated goat anti-rabbit IgG (H+L) and Alexa Fluor 488 goat anti-
mouse IgG for an hour at RT. Cells were washed and nuclei were stained with Draq5 
before being mounted in microscopic slides. Cells were visualised by the Zeiss LSM 510 
confocal fluorescence microscopy using 63 X 1.4 oil objective (zoom 2) lens. Images 
were acquired using 568nm, 488nm and 633nm excitation lasers, and respectively with 
565-615nmm, 500-530nm and 660-704nm emissions for Tom20, Parkin and nuclei 
stains. For quantification, Parkin’s fluorescence intensity for each condition, was 
measured as the corrected total cell fluorescence (CTCF) by ImageJ (NIH). Moreover, 
the Pearson’s correlation coefficient for mitochondrial outer membrane protein Tom20 
and Parkin in mock-infected and D39 exposed BMDM was quantified by ImageJ. 
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2.17.4. Co-staining of mitochondrial Tom20 and autophagy marker 
LC3B  
Human MDM were exposed to S. pneumoniae (D39, MOI=10) and the plates left on ice 
for an hour and 3 hours at 37oC and 5% CO2. Cells were washed 3 times with PBS and 
fresh RPMI media added for 12 hours at 37oC and 5% CO2. In the positive control wells, 
MDM were treated with FCCP (20µM) for 12 hours, then washed 3 times with PBS and 
fixed with 4% paraformaldehyde for 20 minutes at RT. After quenching and blocking, 
the blocking solution was replaced with the primary antibodies, mouse anti-Tom20 at 
1:500 dilution (Santa Cruz) and rabbit polyclonal anti-LC3B (Abcam, cat no. ab48394) 
at 1:500 dilution in PGAT and incubated overnight at 4oC. They were then washed 3 times 
with PGAT solution and treated with secondary antibodies, Alexa Fluor 488 conjugated 
goat anti-mouse IgG (H+L) and Alexa Fluor 568 goat anti-rabbit IgG for an hour at RT. 
Cells were washed 3 times with PGAT and twice with PBS followed by nuclei staining 
with Draq5. Images were acquired by the Zeiss LSM 510 confocal fluorescence 
microscopy using 63 X 1.4 oil objective (zoom 2) lens. To capture images, 568nm, 488nm 
and 633nm excitation lasers, respectively used with 565-615nmm, 500-530nm and 661-
704nm emission spectrums for Tom20, LC3B and nuclei stains.  
 
2.17.5. Co-staining mitochondrial Tom20 and phagolysosomal LAMP1  
Human MDM were exposed to S. pneumoniae (D39, MOI=10) and the plates left on ice 
for an hour and 3 hours at 37oC and 5% CO2. Then cells washed 3 times with PBS and 
fresh RPMI media added for 12 hours at 37oC and 5% CO2. After washing 3 times with 
PBS the cells were fixed with 4% paraformaldehyde for 20 minutes at RT. Cells were 
quenched and blocked followed by treated with the primary antibodies, rabbit polyclonal 
anti-Tom20 at 1:500 dilution (Santa Cruz) and mouse monoclonal anti-LAMP1 (H4A3) 
(Abcam, cat no. ab25630) at 1:100 dilution in PGAT solution and incubated overnight at 
4oC. After washing 3 times with PGAT solution, secondary antibodies Alexa Fluor 568-
conjugated goat anti-rabbit IgG and Alexa Fluor 488-conjugated goat anti-mouse IgG 
(H+L) were added for an hour at RT. Cells were washed 3 times with PGAT and twice 
with PBS followed by stained with Draq5 at RT. Cells were washed 3 times with PBS 
and once with distilled H2O followed by mounting in microscopic slides. Images were 
acquired by the Zeiss LSM 510 confocal fluorescence microscopy using 63 X 1.4 oil 
objective (zoom 2) lens, and 568nm, 488nm and 633nm excitations, and respectively with 
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565-615nmm, 500-530nm and 661-704nm emissions for Tom20, LAMP1 and nuclei 
stains. 
 
2.17.6. Mitochondrial fission/fragmentation in pneumolysin deficient 
and heat inactivated pneumococci exposed macrophages 
Metabolically active S. pneumoniae (D39, MOI=10), D39 was heat inactivated (at 60oc 
for 40 minutes) (MOI=10 to 40), pneumolysin deficient D39 [ΔPLY D39 or PLYSTOP 
D39, MOI=10 to 50)] (Bewley et al., 2014) or 0.5µg/mL-5µg/mL exogenous purified 
pneumolysin (source: E. coli, using a HIS tag, and purified by the HPLC) (Gift from 
Timothy J. Mitchell’s lab, University of Birmingham) were exposed to mouse BMDM 
and the plates were left on ice for an hour and 3 hours at 37oC and 5% CO2. Macrophages 
were washed 3 times with PBS and fresh DMEM media added with or without exogenous 
pneumolysin and incubated for 8 hours at 37oC and 5% CO2. Cells were washed 3 times 
with PBS before being fixed with 4% paraformaldehyde for 20 minutes at RT. As 
described in section 2.17.1a cells were treated with quenching and blocking solution. 
Blocking solution was replaced with primary antibody rabbit anti-Tom20 (200µL/well) 
at 1:500 dilution and incubated overnight at 4oC. Subsequently cells were washed 3 times 
with PGAT solution before being treated with secondary antibody, goat anti-rabbit IgG 
(H+L)-conjugated with Alexa Fluor-488 for an hour at RT. Cells were washed 3 times 
with PGAT and twice with PBS. Cell nuclei were stained with Draq5 with 1:1000 in PBS 
for 12 minutes at RT. Cells were then washed 3 times with PBS and once with distilled 
H2O followed by mounting in microscopic slides with glycerol-free poly-vinyl alcohol 
mounting agent. Images were acquired by the Zeiss LSM 510 inverted confocal 
fluorescence microscopy using 63 X 1.4 oil objective (zoom 2) lens. And 488nm and 
633nm excitations with 500-530nm and 660-704nm emission spectrums for Tom20 and 
nuclei stains, respectively. At least 300 macrophages with or without fission/fragmented 
mitochondria were counted (in each condition) from the acquired images and data were 
shown as the percentage of macrophages with fission/fragmented mitochondrial 
population.  
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2.18. Western blotting with subcellular fractions  
2.18.1. Isolation of cytosolic and mitochondrial fractions 
Mouse bone-marrow cells were culture in T-25 flasks (2 million cells/flask) for 14 days 
and differentiated into BMDM as described in section 2.2. BMDM were treated with or 
without 3MA (10mM, 3 mL/flask) for an hour followed by exposed to opsonised S. 
pneumoniae (D39, MOI=10) and left on ice for an hour and 3 hours at 37oC and 5% CO2. 
Cells were washed 3 times with PBS and fresh DMEM media with or without 3MA added 
and incubated for 8 hours at 37oC and 5% CO2. BMDM were washed 3 times with ice 
cold PBS followed by 100µL lysis buffer (lysis buffer compositions: 0.1M NaH2PO4, 
0.2M Na2HPO4 and 1.0M NaCl in PBS) containing complete protease inhibitor cocktail 
(Roche, reference no. 05892970001), and 9.38µg per million cells digitonin and kept on 
ice. Cells were scrapped into the lysis buffer, placed into a 1.5mL Eppendorf tube and 
vortexed for 30 seconds, then centrifuged at 13000 rpm for 60 seconds. The supernatant 
containing the cytosolic fraction was collected and put into a fresh tube and stored at -
80oC. The pellet was resuspended in 100µL lysis buffer containing complete protease 
inhibitor but without digitonin and centrifuged at 13000 rpm for 60 seconds. The 
supernatant was discarded and the pellet containing the mitochondrial fraction was 
resuspended in the lysis buffer without digitonin and stored at -80oC.  
  2.18.2. Protein quantification assay 
The protein concentration of the cytosolic and mitochondrial lysates were estimated using 
DC protein assay (Bio-Rad) described in section 2.6.2.  
2.18.3. Sodium dodecyl sulphate-Polyacrylamide gel electrophoresis 
(SDS-PAGE) 
12% resolving gels and 4% stacking gels were prepared (for recipe see Appendix 7.6 iii 
and iv) to give 1.5mm thick gels with ammonium persulphate (APS) and tetramethyl 
ethylene diamine (TEMED) being added immediately before the gels were poured. After 
the resolving gel was poured isopropanol was added to form a small layer on the top. 
After polymerisation the isopropanol was removed and the gel rinsed with distilled water. 
The sacking gel was poured on top of the resolving gel and immediately 10 well combs 
were inserted into the stacking gels and after setting they were placed into a tank with 
running buffer (Appendix 7.6 vi) and the combs carefully removed. To achieve equal 
loading of samples the same quantity of protein of each sample was loaded on the gel by 
adjusting all samples to the same concentration using 1.5M Tris base and then adding 
Page | 90 
 
20µL of each sample.  Equal volumes of reducing sample buffer (also called Laemmli 
buffer (Laemmli, 1970), Appendix 7.6 ii) were added to the samples (cytosolic or 
mitochondrial) and were denatured by heating at 95oC for 1-2 minutes. The denatured 
samples with a protein ladder (Geneflow Ltd, UK) were loaded into the wells. The electric 
current was applied at 80V for 15 minutes or until the samples was passed the stacking 
gel, then at 125V until the loading dye in the sample reached to the bottom of the resolving 
gel.  
 
2.18.4. Semi-dry electro transfer and protein detection by 
chemiluminescence 
To detect specific proteins, the proteins separated by SDS-PAGE were transfer to poly-
vinylidene difluoride (PVDF) membrane (Bio-Rad laboratories Ltd., UK) using semi-dry 
blotting. The PVDF membrane was activated by soaking in methanol for 1-2 minutes at 
RT. Three pieces of blotting paper (Whatman International, Maidstone, UK) were soaked 
in transfer buffer (25mM Tris-Base, 192mM glycine and 20% methanol, Appendix 7.6 
vii), on top of these pieces of filter papers were placed the membranes and the gels were 
placed on the top of the membranes. Then three more pre-soaked pieces of blotting papers 
were placed on top of each gel, like a sandwich, which was placed in a semi-dry transfer 
blotter (Trans-Blot SD transfer cell, Bio-Rad). Air bubbles within  the stack were removed 
by rolling a stripette over the top, and 15V constant voltage applied for 45 minutes 
(Towbin et al., 1992). Transfer of proteins to the PVDF membrane was checked by 
Ponceau S staining dye. After confirmed proteins transfer, the Ponceau S dye was cleaned 
with the Tris buffered saline (TBS)-tween for 5 minutes. The membrane was blocked 
with 5% skim milk in TBS-tween for an hour at RT on a plate shaker. The membrane was 
then put into a 50mL centrifuge tube with 5mL of mouse anti-Parkin IgG2 (PARK8) 
(Santa-Cruz, cat no. SC-32282) (1:200 dilution in 5% milk TBS-tween) antibody or rabbit 
polyclonal anti-actin (1:10000 dilution in 5% milk TBS-tween) (Sigma-Aldrich) or rabbit 
anti-VDAC (1:1000 dilution) (Cell Signaling Tech. lot-4) and incubated overnight at 4oC 
on a rolling platform. The membranes were washed 3 times for 10 minutes with TBS-
tween. Next, the membranes were put into 50ml tube with 5mL secondary antibodies, 
either horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Dako, P0447) with 
1:2500 dilution in 5% milk TBS-tween or goat anti-rabbit IgG (Dako, P0448) with 1:2500 
dilution and incubated for one hour on a rolling platform at RT. Then the membrane was 
washed three times with TBS-tween. Equal volumes of ECLs substrate (GE Healthcare) 
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were mixed together, added to the membrane for 5 minutes at RT and excess substrate 
removed from the membrane. Finally the specific proteins bands were detected by 
enhanced chemiluminescence. Chemiluminescence -high resolution images were 
acquired by the ChemidocTM XRS machine using Image lab software (Rio-Rad), using 
30 seconds first exposure, then images (total 20) were captured with 200 seconds 
exposure-interval. Colorimetric images were acquired to record the ladder. 
2.18.5. Densitometry 
Western blotting allows to measure the level of specific protein expression in a semi-
quantitative manner. The intensity of each band area was measured using the ImageJ (v1.8 
NIH) software. Then the intensity ratio of Parkin to cytosolic loading control actin, and 
Parkin to mitochondrial loading control VDAC were calculated from individual protein 
band intensity.   
2.19. Transmission electron microscopy (TEM) 
Mouse bone-marrow cells were culture in T-25 flasks (2 million cells/flask) for 14 days 
and differentiated into BMDM. Then BMDM were mock-infected or exposed to S. 
pneumoniae (D39, MOI=10) and flasks left on ice for an hour and 3 hours at 37oC and 
5% CO2. Cells were washed 3 times with PBS, fresh DMEM media added and cells 
incubated for 8 hours at 37oC and 5% CO2. BMDM were washed 3 times with HBSS and 
2.0mL/flask Accutase added for 15 minutes at 37oC and 5% CO2. The cell suspensions 
were centrifuged at 2000xg for 10 minutes, the pellets washed once with HBSS and 
centrifuged again at 2000xg for 10 minutes and the pellet fixed with 3% glutaraldehyde 
in 0.1M cacodylate buffer at 4oC overnight. Cells were washed twice with 0.1M 
cacodylate buffer in a 30 minutes incubation at 4oC. Secondary fixation was carried out 
with 3% aqueous osmium tetroxide for 2 hours at RT. The fixative was washed out twice 
with 0.1M cacodylate buffer in a 30 minutes incubation at 4oC. The cells were dehydrated 
twice using a graded series of ethanol; 75% for 15 minutes, 95% for 15 minutes, and 
100% for 15 minutes and 100% ethanol with anhydrous copper sulphate for 15 minutes 
at RT. Then the specimen pellets were placed in an intermediate solvent of propylene 
oxide for 15 minutes twice at RT. Each specimen was infiltrated by placing the specimen 
pellets in a 50/50 mixture of propylene oxide/araldite resin and incubated overnight at RT 
with a rota mix. The mixture was mostly discarded, then the specimen left in the full 
strength araldite resin for 6-8 hours at RT. Subsequently the specimen pellets were 
embedded in fresh araldite resin (in the hexagonal blocks) for 48-72 hours at 60oC. The 
resin blocks were cut and confirmed cells section by an ultra-microtome with a binocular 
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microscopy. The ultrathin (thickness was 90nm) tissue sections were cut on a Reichert 
Ultracut E ultramicrotome with a diamond knife. The sections were transferred to a 
copper wire girds (3.05µm diameter). These sections were respectively stained with 
Uranyl acetate for 30 minutes and Lead citrate for 10 minutes. After the sections were 
washed twice, electron micrographs were acquired by a transmission electron microscopy 
using a Gatan digital camera at an accelerating voltage of 80Kv.   
 
2.20. Evaluation of apoptotic macrophages after challenged with S. 
pneumoniae 
Mouse bone marrow cells were culture on coverslips (13x13mm) in 24 well plates and 
differentiated into BMDM. Cells were pre-treated with/without 3MA (10mM) for an hour 
at 37οC and 5% CO2. BMDM exposed to S. pneumoniae (MOI=10) for 12, 14 and 16 
hours at 37οC and 5% CO2. Cells were washed 3 times with pre-warmed HBSS and 
200µL/well NucViewTM 530 (1:500 dilution in phenol red and serum free RMPI media) 
(Biotium, cat no. 10406) was added for 30 minutes at 37οC and 5% CO2. Cells were fixed 
with 2% paraformaldehyde for 15 minutes at RT after being washed 3 times with HBSS. 
Then, the nuclei staining dye DAPI, 0.5µg/mL in PBS, was added for 12 minutes at RT. 
Subsequently cells were mounted on microscope slides with a drop of glycerol-free 
polyvinyl alcohol. NucViewTM 530 is comprised of a fluorogenic high-affinity DNA dye 
and a DEVD caspase substrate moiety. In the caspase 3/7 positive macrophages the 
fluorogenic DNA dye is cleaved from the DEVD substrate, and the fluorogenic 
intercalating DNA dye binds with nucleus and emits red fluorescence. The NucViewTM 
530 (red) positive and DAPI (blue) positive cell counted as an apoptotic cell. Whereas 
NucViewTM 530 (red) negative and DAPI positive cell counted as a non-apoptotic cell. 
At least 300 nuclei were counted for each condition using the Zeiss LSM510 inverted 
fluorescence microscope.      
 
2.21. Intracellular bacterial killing assay  
Mouse BMDM were pre-treated with/without 3MA (10mM) or Mdivi-1 (25µM) or 
bafilomycin A1 (100nM) (Sigma, 88899-55-2) for an hour at 37οC and 5% CO2. Cells 
were exposed to S. pneumoniae (D39, MOI=10) and the plates were left on ice for an 
hour followed by 3 hours at 37οC and 5% CO2. After washing 3 times with PBS cells 
were incubated for 4 hours at 37οC with 5% CO2. In one set of experiment (total 8 hours 
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post-bacterial challenge), cells were treated with gentamicin (20µg/mL) and penicillin G 
(40U/mL) (Sigma, PENNA-100MU) for half an hour at 37οC and 5% CO2, to kill the 
extracellular bacteria. Viable intracellular bacteria were measured by treating cells with 
250µL/well 0.02% saponin diluted in distilled water (Sigma, S4521) for 15 minutes at 
37οC and 5% CO2. 750µL PBS was then added to each well and macrophages lysed with 
vigorous pipetting and scrapping across the wells. Subsequently the lysates were 5-fold 
serial diluted and plated on blood agar plates, described in (Miles et al., 1938).  
In another set of experiment, after first 4 hours incubation, cells were incubated for 8 
hours more at 37οC and 5% CO2. Cells were washed 3 times with PBS followed by 
treatment with gentamicin (20µg/mL) and penicillin G (40U/mL) for half an hour at 37οC 
and 5% CO2. Subsequently cells were washed 3 times with PBS before being either 
treated with 0.02% saponin for viable count as above or incubated 4 hours more with 
vancomycin hydrochloride (0.75µg/mL) (Sigma, V2002) at 37οC and 5% CO2. Cells were 
washed 3 times with PBS followed by treatment with 0.02% saponin for 15 minutes and 
Miles-Mirsa as above. The intracellular survival bacterial colonies were counted after 16 
hours incubation at 37οC and 5% CO2 and data were calculated as cfu/mL.     
2.22. Statistical analysis 
Flow cytometry data were analysed using FlowJo software version 8.8.4 (Tree Star Inc.). 
Western blotting and immunofluorescence images were analysed using ImageJ (v1.8 
NIH) image processing software. Data were analysed by One-way ANOVA with 
Bonferroni post-hoc test for multiple comparison or pair t-test for pair-wise comparison, 
unless otherwise stated. All statistical tests were performed using GraphPad Prism 6.0 
(GraphPad Software Inc, San Diego, CA). Data were shown as mean ± standard error 
mean (SEM) and p<0.5 were considered to be statistical significance, with a 95% CI 
(confidence interval). 
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Chapter 3. Optimisation of extracellular flux assay with 
mouse BMDM and human MDM  
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3.1. Introduction 
Macrophage’s metabolism and functional phenotype are interconnected. Two decades 
ago Murphy and Newsholme demonstrated that BCG-activated macrophages in 
glutamine and L-arginine rich media increase to nitric oxide (NO) production (Murphy 
and Newsholme, 1997), and later on Gross and co-workers showed that NO induces 
phagocytosis and antimicrobial function in macrophages (Gross et al., 1998). Recent 
studies have observed that infectious stimuli alter the metabolic phenotype of 
macrophages or dendritic cell and a switch in metabolism to glycolysis from 
mitochondrial oxidative phosphorylation (OXPHOS), is essential for innate immunity 
(Tannahill et al., 2013, Pantel et al., 2014, Krawczyk et al., 2010). Distinct stimuli result 
in macrophage polarisation, for example, TLR-agonists (e.g. LPS) or IFN-γ mediate 
classical activation and IL-4 plus IL-13 mediate alternative activation of macrophages 
(Mantovani et al., 2004, Stein et al., 1992). These activated macrophages are often 
referred to as M1 and M2 macrophages, respectively. As part of these distinct phenotypes 
there are specific changes in molecules associated with metabolism. M1 macrophages 
upregulate hypoxia-inducible factor (HIF)-1α, glucose transporter channel-1 (GLUT1) 
and ubiquitous phosphofructokinase 2 (PFK2), a positive regulator of glycolysis, 
promoting glycolysis (Rodríguez-Prados et al., 2010).  
Moreover, M1 macrophages also induce expression of the mitochondrial citrate carrier, 
which is essential for NO, ROS and prostaglandin production (Jha et al., 2015, O’neill, 
2015, Infantino et al., 2011), along with IL-6, IL-12 and TNF-α (Mills et al., 2000), 
promoting their antimicrobial and inflammatory phenotype, respectively. M2 
macrophages, however, induce mitochondrial oxidative phosphorylation through 
upregulation of Peroxisome proliferator-activated receptor-γ co-activator 1β (PGC-Iβ) 
and components of the electron transport chain (St-pierre et al., 2003, Shao et al., 2010). 
These studies highlighted the metabolic and phenotypic differences between 
macrophages after classical activation with Th1 cytokines or TLR-agonists, as compared 
with alternative activation by Th2 cytokines. Despite this, detailed analysis of metabolic 
phenotypes and features of mitochondrial homeostasis in macrophages during host-
pathogen interactions with live bacteria are yet to be elucidated in detail. Presumably, 
since mitochondria are the metabolic hub of eukaryotic cells and the major source of 
energy production that is essential for immune cells functions such as migration and 
phagocytosis, mitochondrial metabolism and homeostasis must be carefully regulated and 
aligned to functional phenotype (Buttgereit et al., 2000). Mitochondria are also an 
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important effector of innate immune functions beyond their role as a source of ATP 
production. Recently, Bewley and colleagues demonstrated that COPD alveolar 
macrophages fail to upregulate mitochondrial reactive oxygen species (mROS) 
production and that inhibiting mROS, decreased intracellular S. pneumoniae killing in 
healthy but not COPD alveolar macrophages  (Bewley et al., 2017). Therefore, it is also 
essential to elucidate how macrophages metabolic phenotype and mitochondrial 
homeostasis influences microbicidal responses during host-pathogen interactions 
perspective. 
To investigate the overall cellular metabolic phenotype rather than specific metabolites 
by NMR spectroscopy or mass spectrometry, the Extracellular Flux Analyser (XF24, 
Seahorse Bioscience), has proven a useful method. This technique is the latest and 
simplest method of analysis but also represents a non-invasive way to measure the cellular 
bioenergetic status of living cells in a real time manner. Seahorse simultaneously 
measures the major metabolic fluxes, such as glycolysis and mitochondrial OXPHOS 
through extracellular proton production or acidification rate (i.e. extracellular 
acidification rate (ECAR)) and oxygen consumption rate (OCR), respectively.  
Moreover, the mitochondrial stress test reveals a range of mitochondrial metabolic 
parameters, such as ATP linked OXPHOS, proton leak, respiration reserve and maximal 
respiration capacity. These important parameters can be quantified through performing 
the mitochondrial-stress test with sequential addition of oligomycin A (as an ATP 
synthase inhibitor), trifluoro-carbonyl cyanide phenylhydrazone [(FCCP), as a 
mitochondrial OXPHOS uncoupler] and a mixture of rotenone (inhibitor of complex I) 
and antimycin A (inhibitor of complex III). On the other hand, the glycolytic stress test 
reveals baseline glycolysis, glycolytic respiration capacity or reserve through sequential 
addition of oligomycin A and 2-deoxy-D-glucose, which has the 2-hydroxyl group 
replaced by hydrogen, and which blocks conversion of glucose to glucose-6-phosphate, 
therefore enabling it to function as an effective inhibitor of glycolysis.  
The aims of this chapter were therefore to optimise the extracellular flux assay for use 
with mouse bone marrow-derived macrophages (BMDM) and human monocyte-derived 
macrophages (MDM). This would allow me to investigate the metabolic phenotype of 
activated mouse BMDM and then to analyse the metabolic and bioenergetic status of non-
transgenic and human Mcl-1 transgenic mouse BMDM after exposure to S. pneumoniae.  
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3.2. Optimisation of BMDM cell density and other conditions for the 
Seahorse Extracellular Flux Assay 
3.2.1. Cell density optimisation 
To perform the extracellular flux assay a consistent monolayer of cells is essential to get 
reproducible kinetic metabolic flux measurements in a real time basis. Since the sensors 
(i.e. proton and oxygen sensors) of the Seahorse extracellular flux analyser measure both 
glycolytic flux (i.e. proton production rate) and oxidative phosphorylation flux (i.e. 
oxygen consumption rate) in a small microenvironment, it is important that the 
microenvironment is truly representative of the whole culture and not influenced by 
regional differences in cell density. To determine the consistency of seeding in the 
microenvironment likely to be sampled in the XF microplate, representative images were 
captured and the number of cells were counted using the InCell analyser 2000 and InCell 
Developer Toolbox 1.9 (GE Healthcare). This approach is not only useful for 
normalisation of the extracellular flux assay data with the total cell count, it also 
demonstrates the consistency of cell layers in each well of the XF microplate. Figures 
3.1D, 3.1E and 3.1F show that 200,000 BMDM/well was the optimal seeding density and 
provided consistent, confluent, clumping-free cell layers in the XF24 cell plate’s 
microenvironment.  
In contrast, as shown in Figure 3.1A, 3.1B and 3.1C 500,000 BMDM/well yielded more 
variation in cell density with fluctuating cell number and clumping of cells in the 
microenvironment of the XF24 microplate. In addition, as shown in Figure 3.2A and 
3.2B, the glycolytic rate data also demonstrated that 200,000 and 300,000 cells/well 
produced similar trends in ECAR after addition of equal amounts of glucose. In contrast, 
despite the increasing cell density the ECAR was similar with 500,000 cells/well as 
compared to 200,000 or 300,000 cells/well.  Therefore, the cell density/count with the 
InCell analyser and the real time metabolic responses demonstrated that 200,000 
BMDM/well was the optimum cell density for the 24 well format extracellular flux 
analyser. 
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Figure 3.1. Mouse BMDM cell density titration with Seahorse XF24 flux plate. Different 
densities of BMDM were seeded in the XF24 cell plate, after overnight incubation and the 
SeaHorse extracellular flux measurements, CyQuant® NF dye was added and cell images (x20) 
were captured at Ex490/Em525nm wavelength (i.e. FITC channel). Figure A, B and C show the 
average cell count of each field, total cell count of each well and a representative field’s captured 
image using the InCell analyser2000 technology, respectively, for 500,000 BMDM/well in the 
XF24 cell culture microplate. Figures D, E and F demonstrate the same parameters for 200,000 
BMDM/well. Figure shows two representative experiments results with 500,000 and 200,000 
BMDM/well seeding density. Images were created by using InCell Developer Toolbox 1.9.  
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Figure 3.2. Cell density titration and measurement of the rate of extracellular acidification. 
Different densities of BMDM were seeded in the XF24 cell plate, after overnight incubation the 
ECAR was measured by XF24 flux analyser. Figure A shows the representative extracellular 
acidification rate (ECAR) as mpH/min for 100,000-500,000/well of BMDM before and after 
adding glucose (1mg/mL). Figure B shows the average increased ECAR after adding glucose 
(mean ± SD, n=3). 
 
3.3.2. Oxygen tension and pH optimisation  
The settings used will also introduce variation into measurements of changes in O2 
tension, measured in mmHg and changes in pH over time, which are recorded as the OCR 
and ECAR, respectively.  Figure 3.3 represents the change in oxygen tension with respect 
to time in each group of wells. Typically, these parameters show at the starting point of 
each measurement, therefore, the microenvironment of each well needs to have an 
adequate amount of time to allow re-equilibaration during the mixing and waiting stages. 
This allows the O2 sensor to re-equilibrate and yield reproducible OCR data with the 
ambient O2 tension in the microenvironment. Figure 3.3A and 3.3B show that before the 
injection of the compound of interest, the O2 level returned to the initial level (i.e. the 
ambient level), however, after an injection of glucose containing XFAM medium, the 
starting O2 levels decreased at each successive measurement. This indicated that the cells 
consumed oxygen at an increased rate after injection of glucose and that with the mixing 
time (2.5 minutes) and waiting time (8 minutes) were inadequate to allow the system to 
reach equilibrium again before the O2 sensors made their measurements. 
 
 
  
B. A. 
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Figure 3.3. Oxygen pressure optimisation through modification of the Seahorse execution 
protocol. Figure (A) 200,000 BMDM/well and (B) 300,000 BMDM/well were seeded in 
Seahorse XF24 microplate.  Figure A and B demonstrate that the oxygen tension (in mmHg) 
dropped from baseline after injecting XFAM+ 25mM glucose medium (XF assay medium) from 
injection port A (marked as vertical line). However, after 4 times measurement with 8 minutes 
waiting time, the oxygen tension returned to baseline level after changing the waiting time from 
8 to 12 minutes. After modifying the protocol with 3 minutes mixing, 12 minutes waiting and 3 
minutes measuring time, both (C) 200,000 BMDM/well and (D) 300,000 BMDM/well showed 
consistent oxygen tension before and after injecting the XF assay medium. The figure was created 
by the Seahorse Bioscience data analysis software Wave 2.2.0. 
 
 
 
 
 
 
 
C. 
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However, after changing the mixing and waiting times at measuring point 9 and 10 to 3 
and 12 minutes respectively, the oxygen tensions returned to the basal level removing the 
variation in measures before equilibration was reached. Figure 3.3C and 3.3D 
demonstrate that pre- and post-injection of glucose supplemented XF medium, the oxygen 
tension returned to the starting point just before each measurement. Similarly, the pH of 
each injecting compound was adjusted. This was essential to get reproducible ECAR or 
proton production rate (PPR) data through the proton or pH sensor. In the case of the pH, 
the injecting compounds pH was adjusted to that of the Seahorse running medium (XF 
assay medium at pH 7.4). 
              
3.3. Titration of oligomycin A, FCCP, 2-deoxy-D-glucose, Rotenone and 
Antimycin A for the Seahorse extracellular flux assay 
3.3.1. Oligomycin A titration  
Oligomycin is an antibiotic that inhibits ATP synthase (inhibiting complex V of the 
electron transport chain (ETC)) by blocking the proton channel (Fo subunit), which is 
essential for normal oxidative phosphorylation and the ATPase activity of F1. 
Consequently, the presence of oligomycin A increases the rate of glycolysis of cells to 
compensate for the loss of oxidative phosphorylation and to maintain cellular energy 
requirements. Hence, oligomycin A is used to measure ATP-linked oxygen consumption 
by oxidative phosphorylation. Moreover, oligomycin A induces cellular glycolytic 
capacity to the maximum level. Figure 3.4A and 3.4C show that different concentrations 
of oligomycin A (0.5 to 2.5μM) increased ECAR and decreased OCR noticeably. These 
graphs illustrated that 0.5 and 1.0μM oligomycin A increased glycolysis (measured by 
increased production of extracellular protons) and decreased oxidative phosphorylation 
(measured by decreased oxygen consumption) consistently. In addition, the bar graphs 
3.4B and 3.4D show 0.5μM oligomycin A raised ECAR to 22 mpH/min (the highest level) 
and reduced OCR by approximately 154 pmoles/min, whereas, 1.0μM increased ECAR 
to 21.75 mpH/min and decreased OCR approximately 175 pmoles/min. Therefore, 0.5-
1.0μM was identified to be the optimum concentration of oligomycin A for mouse 
BMDM in the extracellular flux assay.  
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Figure 3.4. Oligomycin A titration for the extracellular flux assay using mouse 
BMDM. 200,000 BMDM/well were seeded onto XF24 cell plates with XF assay 
medium. Figure A and B show the conversion rate of pyruvate to lactate, as recorded by 
extracellular acidification rate (ECAR) and the absolute effect of each oligomycin A 
strength on glycolytic flux. Figure C depicts the kinetics of the oxygen consumption rate 
(OCR in pmoles/minute) before and after injecting different concentrations of oligomycin 
A to respective groups and Figure D shows the OCR before and after treatment of each 
concentration of oligomycin A. The error bar indicates standard error of the mean (n=3).  
 
 
 
 
A. 
C. D. 
B. 
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3.3.2. FCCP titration 
 Electron transport chain (ETC) and oxidative phosphorylation are interrelated aspects of 
mitochondrial metabolism. Compounds which stimulate oxygen consumption without a 
concomitant increase in ATP production, are called ‘uncouplers’. It is a natural process 
in brown adipose tissue mitochondria where uncoupler protein (UCP1) disrupts the ETC 
mediated proton (H+) gradient across the inner mitochondrial membrane and generates 
heat instead of energy (i.e. ATP). However, FCCP is an ionophore and a protein-
independent mitochondrial oxidative phosphorylation uncoupler which carries protons 
across the mitochondrial inner membrane phospholipid bilayer.  
 
 
 
Figure 3.5. FCCP titration for use in the extracellular flux assay using mouse BMDM. FCCP 
was dissolved in DMSO following the supplier’s instructions. Then a range of working 
concentrations 10-25µM (10x intended final concentrations) were prepared in XF assay medium.  
Figure A and B show the kinetics and the pre- and post-FCCP treated oxygen consumption rate 
(OCR), respectively. The error bar indicates the standard error of the mean (SEM), (n=3). 
 
Consequently, the maximum amount of oxygen is consumed or converted into water by 
cytochrome oxidase, complex IV of the ETC. Figure 3.5A shows that 2.0µM FCCP 
elevated the OCR to a maximum level and levels remained consistently high over the next 
couple of measuring cycles. Figure 3.5B shows the absolute effect of oligomycin A 
(1.0µM) and FCCP on OCR. After comparing different strengths of FCCP, I determined 
A. B. 
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that 2.0µM also gives the highest increment in oxygen consumption of 404 
pmoles/minute or around 5 fold the level observed with oligomycin A treated OCR. 
 
3.3.3. 2-deoxy-D-glucose titration  
2-deoxy-D-glucose is an analogue of D-glucose and inhibits glycolysis by binding to 
glucose hexokinase and inhibiting this enzyme, which normally phosphorylates D-
glucose to 6-phospho-glucose in one of the rate limiting steps in the glycolytic pathway. 
Figure 3.6A shows that 0.5µM oligomycin A increased the rate of glycolysis to the 
maximum level from baseline, whereas, 2-deoxy-D-glucose reduced ECAR sharply 
below the baseline level of glycolysis. The difference between ECAR before and after 
oligomycin A treatment is equal to the glycolytic reserve capacity of cells. 2-DG inhibited 
the rate of glycolysis and decreased the level below baseline ECAR by ≥20 mpH/minute. 
Moreover, 2-DG insensitive ECAR is the non-glycolytic acidification which was around 
6-8mpH/minute with these settings. Figure 3.6B shows that 2-DG downregulated the rate 
of glycolysis in a concentration dependent manner up to a concentration of 100mM, 
which decreased ECAR to the greatest extent (24mpH/minute).  
 
 
 
 
 
Figure 3.6. 2-deoxy-D-glucose titration using mouse BMDM in the extracellular flux assay. 
After baseline flux measurements 10µM oligomycin A (1.0µM working concentration) was 
injected to all wells, then different concentration of 2-DG were added to respective wells except 
control wells. Figure A represents the kinetic data for a range of concentrations from a 
representative experiment. Figure B represents the mean and standard error of the mean of the 
A. B. 
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extracellular acidification rate (ECAR) values in mpH/min for each concentration pre- and post- 
addition of 2DG. The absolute reduction and fold change in ECAR is shown below for each 
concentration of 2DG. The error bar indicates the standard error of the mean (SEM), (n= 3).  
 
3.3.4. Rotenone and Antimycin A titration 
The mitochondrial electron transport chain (ETC) and oxidative phosphorylation are 
tightly linked via the five complexes that make up the ETC. Rotenone is a plant product 
which is used as an insecticide and pesticide. It blocks electron flow from complex I (i.e. 
NADH dehydrogenase) to CoQ of ETC. Consequently, rotenone inhibits NADH 
oxidation (Corbett, 1984). However, it does not affect FADH2 oxidation by complex II 
(i.e. Succinate dehydrogenase). Antimycin A is an antibiotic which blocks electron flow 
from cytochrome bH in Complex III (i.e. Cytochrome C oxidoreductase) to CoQ. 
Therefore, a combination of rotenone and antimycin A effectively limits electron flow 
through the mitochondrial ETC and disrupts OXPHOS. Moreover, the non-mitochondrial 
respiration or oxygen consumption can be measured in the presence of rotenone and 
antimycin A. From analysis of OCR data and the absolute rate of OCR in the presence of 
different concentrations of rotenone and antimycin A, 1.0µM of rotenone or antimycin A 
was found to be the optimum concentration for mouse BMDM (Figure 3.7A-D).  
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Figure 3.7. Rotenone and antimycin A titration using mouse BMDM in the extracellular flux 
assay.  Rotenone and antimycin A were dissolved in DMSO following the supplier’s instructions. 
Then a range of working concentrations 5-15µM (10 fold the final working solutions in media) 
for Rotenone and 10-50µM (10 fold the final working solutions in media) for antimycin A were 
prepared in XF assay medium.  Figure A and B show the kinetics and the pre- and post-rotenone 
treated oxygen consumption rate (OCR), respectively. Figure C and D show the kinetics and the 
pre- and post-antimycin A treated oxygen consumption rate (OCR), respectively. The error bar 
indicates the standard error of the mean (SEM), (n=3). 
 
 
A. 
B. 
D. 
C. 
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3.4. Optimising the Extracellular flux assay with human monocyte-
derived macrophages (MDM) 
As I had performed for mouse BMDM, I also analysed the optimal parameters for assays 
of human MDM, specifically adjusting cell density and oxygen tension for mitochondrial 
stress and glycolysis stress tests in the XF24 flux analyser. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Human MDM cell density, oxygen tension optimisation for the EX24 flux assay. 
Human monocyte-derived macrophages (MDM) (150,000 cells/well) were seeded in the XF24 
cell plate and incubated overnight at 37oC and 5% CO2. Following day, DNA staining dye 
CyQuant® NF dye was added for 1 hour. Subsequently, CyQuant stained cells images of each 
well’s central representative area (e.g. 9 fields of each well) were captured by the InCell Analyser 
2000, using 490nm excitation laser and 525nm emission spectrum with a 20x objective lens. Next, 
the cell number of each field was automatically counted by the InCell Developer Toolbox 1.9.  
Figure A shows the average cell count for each field and figure B shows the total cell count for 
the central representative area of each well (total 9 fields). Figure C illustrates a representative 
image of a field which was captured by the InCell Analyser 2000. In another set of experiment, 
150,000 MDM/well were seeded in the XF24 cell plate and incubated overnight at 37oC and 5% 
CO2. Following day, MDM cell culture medium was replaced with XF assay medium. 
Subsequently, the cell plate was loaded into the XF24 flux analyser and subsequently the oxygen 
tension was recorded with 3 minutes mixing, 12 minutes waiting and 3 minutes measuring 
  
A. B. 
C. D. 
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interval. Figure D shows the baseline ambient oxygen tension, oxygen tension after oligomycin 
(vertical line A), FCCP (vertical line B) and rotenone plus antimycin A (vertical line C) injection 
to XF24 cell plate with 150,000 MDM/well. Figure D was created by the Seahorse Bioscience 
data analysis software Wave 2.2.0. 
 
3.4.1. MDM glycolytic and mitochondrial stress test inhibitor 
optimisation 
As previously performed for mouse BMDM, I next optimised the doses of inhibitors used 
in the glycolytic and mitochondrial stress tests for human MDM. The optimum 
concentration of each inhibitor used for the analysis of glycolytic and mitochondrial 
respiration, as quantified by the extracellular flux analyser. The titration assay data has 
shown that 1.5 µM oligomycin, 75 mM 2-DG, 2.0 µM FCCP and 1.0 µM rotenone plus 
antimycin A were optimum concentration for the XF24 extracellular flux assay with 
human MDM. The optimum concentration of each inhibitor for the Glyco-stress and 
Mito-stress test are shown in the following tables: 
a. Glyco-stress test: 
 
 
 
 
 
 
 
 
b. Mito-stress test: 
Name of inhibitors Optimum concentration 
Oligomycin A (2 mM stock in 
DMSO) 
1.5 µM 
FCCP (10 mM stock in DMSO) 2.0 µM 
Rotenone (1 mM stock in DMSO) 1.0 µM 
Antimycin A (3 mM stock in 
DMSO) 
1.0 µM 
 
3.5. Characterisation of Streptococcus pneumoniae for macrophages 
challenge 
To observe how S. pneumoniae alters macrophage’s metabolic profile, serotype 2 (strain 
D39) were grown and characterised to confirm key microbiological features of 
Name of inhibitors Optimum concentration 
Oligomycin A  
(2 mM stock in DMSO) 
1.5 µM 
2-deoxy-D-glucose 75 mM 
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pneumococci, such as optochin sensitivity, gram positive staining and catalase negativity.  
Figure 3.9A and 3.9B show that S. pneumoniae started growing exponentially after 2 
hours lag phase growth and reached the stationary phase after 6 hours incubation. The 
mid-log phase was reached after 5 hours of culture and its optical density was 
approximately 0.4 to 0.5. Figure 3.9C shows the Gram-stained S. pneumoniae retained 
crystal violet dye (i.e. deep violet to blue) instead of counter stain dye safranin (i.e. red). 
Figure 3.9D shows a representative surface colony forming units of serotype 2 S. 
pneumoniae grown overnight in the Columbia blood agar plate after serial dilution. Figure 
3.9E shows the zone of inhibition of optochin sensitivity test with S. pneumoniae. 
  
 
 
 
Figure 3.9. Streptococcus pneumoniae D39 growth curve and microbiological characteristics. 
Figure A shows the optical density at 610 nm at different time points and figure B shows the 
viable S. pneumonie as colony forming units (cfu)/mL after overnight incubation on a Columbia 
blood agar plate (Miles-Misra serial dilution). Both curves show that after 5 hours incubation S. 
pneumoniae reached the mid-log phase and after 6 hours the stationary phase was reached. Figure 
C shows the colonies of S. pneumoniae after gram staining. Figure D shows the colonies of 
serially diluted stock S. pneumoniae using surface viability counting and figure E shows the zone 
of inhibition around the optochin disks, confirming optochin sensitivity. 
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Table 3.1. Microbiological characteristics of Streptococcus pneumoniae 
 
Name of 
experiment 
Observation Results/comments 
1. Gram 
Staining 
After staining of S. pneumoniae on microscope 
slides with crystal violet and iodine and then 
counter staining with safranin, bacteria 
retained deep violet to blue colour, whereas E. 
coli, stained for comparison, lost violet and 
showed pink to red staining. 
S. pneumoniae is a 
Gram-positive 
bacteria 
2. Catalase 
test 
No noticeable reaction was observed after 
adding a few colonies of S. pneumoniae on a 
4% H2O2 droplet on a microscopic slide, 
whereas Staphylococcus aureus generated 
bubbles.   
S. pneumoniae is 
catalase negative 
3. Pattern 
of growth on 
blood agar and 
hemolysis  
S. pneumoniae were streaked onto blood agar 
plates and after overnight incubation it 
produced greyish colonies rather than clear or 
transparent colonies with an area of hemolysis 
around the colonies which was not transparent. 
S. pneumoniae is 
α- hemolytic 
4. Optochin 
(Ethylhydrocup
reine 
hydrochloride) 
sensitivity test 
After overnight incubation of S. pneumoniae 
streaked onto blood agar plates with an 
optochin (Sigma-Aldrich) impregnated disc 
there was more than a 15mm clear area (i.e. 
zone of inhibition) observed around the disc. 
S. pneumoniae is 
sensitive to 
optochin 
 
3.6. Optimisation of extracellular flux assay with macrophages 
challenged with S. pneumoniae 
 To assess macrophages metabolic status after bacterial challenge, either heat inactivated 
S. pneumoniae exposed after baseline ECAR/OCR measurement, or heat inactivated and 
live S. pneumoniae were used to challenge macrophages for 5 hours. 
 
3.6.1. Heat-inactivated S. pneumoniae’s effect on macrophage 
metabolism  
Acutely injected heat inactivated S. pneumoniae (MOI of 10) caused a modest increase 
baseline glycolytic flux (Figure 3.10A) and reduction in OCR (Figure 3.10C) of mouse 
BMDM, but this level of bacterial challenge was not sufficient to alter the maximum 
glycolytic capacity or the glycolytic reserve of cells (Oligomycin treated ECAR, Figure 
3.10A). Therefore, the stimulation with bacteria was repeated after baseline measurement 
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using a bacterial challenge increased to an MOI of 20. It was then observed that the basal 
glycolytic rate was increased by 10 mpH/min, whereas at an MOI of 10 the ECAR 
increase was only 6.5mpH/min (Figure 3.10B). In addition, the rate of oxidative 
phosphorylation was also further reduced, compared to baseline, by addition of heat-
killed bacteria at an MOI of 20, falling by 48 pmoles/min compared to the MOI of 10 
experiments where the reduction was 33 units pmoles/min (Figure 3.10D). However, the 
maximum glycolytic capacity was comparable between mock infected cultures and those 
acutely exposed to heat inactivated S. pneumoniae, irrespective of MOI (Oligomycin A 
treated ECAR, Figure 3.10A).  
 
 
 
 
 
 
 
 
Figure 3.10. Effect of different inocula of heat inactivated S. pneumoniae on mouse BMDM’s 
metabolism. Wells were seeded with 200,000 BMDM/well in an XF24 microplate and BMDM 
mock-infected or challenged with heat inactivated S. pneumoniae (HISPN), at a multiplicity of 
infection (MOI) of 10 or 20, after the baseline extracellular flux measurements, at 36 minutes. 
Subsequently, oligomycin A (Oligo A; final concentration 1µM) was added at 126 minutes and 
2-deoxy-D-glucose (2-DG; final concentration 100mM) was added was subsequently added at 
216 minutes to measure the maximum level of glycolysis and non-glycolytic ECAR. Figure A 
shows the representative extracellular acidification rate (ECAR) from pre- to post-bacterial 
exposure, illustrating the mean and standard error of the mean, respectively. Figure B shows the 
A. B. 
C. D. 
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ECAR level before the BMDM challenge (mock infection or HISPN at an MOI of 10 or 20). 
Figure C shows a representative measure of oxygen consumption rate (OCR) kinetics under each 
condition and Figure D shows the absolute change from pre- to post-bacterial stimulation values, 
illustrating the mean and standard error of the mean of the duplicating wells. 
 
3.6.1. Metabolically active S. pneumoniae’s effect on glycolytic 
metabolism in macrophages  
I next addressed whether the impact of live bacteria might be more significant on 
macrophage metabolism and how this compared to classical activation stimuli. In 
conducting these experiments, I added both live and heat-inactivated S. pneumoniae for 
a more prolonged time (5 hours) before the metabolic measures were conducted to also 
examine if this would allow more impact on metabolism. Metabolically active and heat 
inactivated opsonised S. pneumoniae significantly altered various parameters of 
glycolytic metabolism (Figure 3.11A-D). Live, but not heat inactivated bacteria, 
decreased baseline OCR (Figure 3.11B), whereas it significantly increased basal 
glycolytic rate (Figure 3.11C). Both live and heat inactivated bacteria significantly 
increased maximum glycolytic respiration (Figure 3.11D). The effect of live bacteria was 
similar to that observed in macrophages that underwent classical activation with LPS and 
IFN-γ that also showed significant increases in basal and maximal glycolytic metabolism 
(Figure 3.11E-F). In contrast IL-4, an alternative activation stimulus, did not significantly 
alter basal or maximum ECAR (Figure 3.11E-F). 
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Figure 3.11. Metabolically active S. penumoniae upregulated macrophage glycolytic 
respiration. Mouse bone marrow-derived macrophages (BMDM), were either mock-infected 
(MI), exposed to opsonised live or heat inactivated (HI) S. pneumoniae (D39, MOI of 10) or 
treated with LPS (100ng/mL) plus IFN-γ (20ng/mL) or with IL-4 (20ng/mL) for 5 hours, then the 
basal glycolytic rate and the maximum glycolytic capacity were measured by the XF24 
extracellular flux analyser. Figure A demonstrates the representative extracellular acidification 
rate (ECAR) and figure B the mitochondrial oxygen consumption rate (OCR) rate data for S. 
pneumoniae exposed BMDM respectively. Figure C shows the normalised basal glycolytic rate 
and Figure D the maximum glycolytic capacity of mock-infected or heat inactivated or live S. 
pneumoniae exposed macrophages, respectively. Figure E shows the normalised basal ECAR and 
Figure F the maximum glycolytic capacity of LPS+ IFN-γ and IL-4 treated BMDM, respectively. 
Data were normalized by total cell count with InCell analyser 2000 and show mean and standard 
error of the mean values and were analysed by One-way ANOVA with Bonferroni multiple 
comparison test (*p≤0.05, n=4).  
 
A. B. 
C. D. 
E. 
F. 
Page | 114 
 
3.7. Macrophages over expressing Mcl-1 show enhanced rates of 
mitochondrial oxidative phosphorylation  
The mitochondrial electron transport chain (ETC) acquires electrons from reducing 
equivalents (e.g. NADH and FADH2 from the Krebs cycle). These electrons are 
transferred to cytochrome C oxidase which reduces molecular oxygen into water. During 
this process, protons are pumped out from the mitochondrial matrix to the intermembrane 
space, generating a proton gradient. This gradient drives phosphorylation of ADP to ATP 
and this process coupling a proton gradient to ATP generation is called mitochondrial 
oxidative phosphorylation (OXPHOS).  OXPHOS is the major source of cellular energy 
(i.e. ATP) production, which is in turn proportional to the mitochondrial oxygen 
consumption rate (i.e OCR). Mcl-1 is an anti-apoptotic protein, a recent study 
demonstrated that matrix Mcl-1 increases OXPHOS and maintains mitochondrial 
homeostasis (Perciavalle, 2012). Our group developed a human CD68.Mcl-1 transgenic 
mouse (manuscript in review).  
I therefore utilised these cells to and performed the metabolic profile assays described 
earlier in this chapter to test whether the Mcl-1 transgene influenced macrophage 
metabolism.  I observed that human Mcl-1 transgenic mouse BMDM significantly 
increased baseline OCR (Figure 3.12A), maximum respiration capacity (Figure 3.12C), 
ATP-linked OCR (Figure 3.12D) and proton leak (Figure 3.12F) compared to non-
transgenic littermate’s BMDM. S. pneumoniae exposure for 4 hours decreased basal OCR 
in both wild-type and Mcl-1 transgenic BMDM compared to mock-infected BMDM 
(Figure 4.12A). It also reduced ATP-linked OCR (Figure 4.12D) and proton leak (Figure 
3.12F) in the transgenic BMDM though there were also less marked and non-significant 
decreases seen in the wild-type cells. Overall; the transgene did not appear to have a major 
influence on the infection-related changes in metabolism. On the other hand, baseline 
glycolytic rate (Figure 3.13B) and maximum glycolytic capacity (Figure 3.13C) were 
comparable between wild-type and transgenic BMDM. S. pneumoniae exposure, 
however, significantly increased both basal glycolytic respiration (Figure 3.13B) and 
maximum glycolytic capacity (Figure 3.13C) of wild type and transgenic BMDM. 
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Figure 3.12. Mitochondrial oxidative phosphorylation in macrophages is modified 
by a Mcl-1 transgene. Both wild type (WT) and human Mcl-1 transgenic (TG) mouse 
bone marrow derived macrophages (BMDM) were exposed to opsonised serotype 2 S. 
pneumoniae (D39) or mock infected (MI) for 5 hours, then mitochondrial oxygen 
consumption rate (OCR) was measured using the X24 Seahorse extracellular flux 
analyser. (A) Representative normalised OCR for one experiment, summary data for, (B) 
basal OCR, (C) maximum respiration capacity, (D) ATP linked OCR, (E) respiration 
reserve and (F) proton leak calculated from the OCR data is depicted. Oligomycin A 
(1.0µM) was added to measure ATP-linked OCR, maximum respiration capacity was 
estimated by subtracting non-mitochondrial OCR with rotenone (1.0µM) plus antimycin 
A (1.0µM) from FCCP (2.0µM) OCR data (details in method-materials section). Data 
were normalized by total protein and are shown as mean ± standard error of the mean and 
A. 
B. 
C. D. 
E. F. 
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analysed by one-way ANOVA with Sidak’s multiple comparison test. (*p≤0.05, **p 
≤0.01, n=6).  
 
 
3.8. Human Mcl-1 transgenic mouse BMDM and non-transgenic 
BMDM show comparable baseline and bacterial induced glycolysis 
 
 
 
 
 
 
3.9. Discussion 
Immune cells, especially macrophages, consume energy for metabolically demanding 
functions that require ATP. Some of these functions include cell migration and 
phagocytosis, antigen processing and presentation, cell proliferation and immune effector 
Figure 3.13. Comparable glycolytic respiration is 
observed in wild type and human Mcl-1 transgenic 
mouse bone marrow-derived macrophages. Both 
non-wild type (WT) and human Mcl-1 transgenic (TG) 
mouse bone marrow-derived macrophages (BMDM) 
were exposed with opsonised serotype 2 S. pneumoniae 
(D39) or mock infected (MI) for 5 hours, then 
extracellular acidification rate (ECAR) was measured 
using the X24 seahorse extracellular flux analyser. (A) 
representative kinetic ECAR data from one experiment 
and (B) summary basal ECAR was calculated from 
ECAR kinetic data and (C) maximum glycolytic 
capacity was calculated from glycolytic stress test data. 
Data were normalized by total protein for each 
condition and shown as mean and standard error of the 
mean and analysed by one-way ANOVA with Sidak’s 
multiple comparison test. (*p≤0.05, n=6 for A and B 
and n=4 for C). 
 
A. B. 
C. 
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functions such as bacterial killing, cytokine and chemokine generation and induction of 
cell apoptosis (Buttgereit et al., 2000). Macrophages show high plasticity and they are 
highly adapted to environmental cues. Moreover, macrophages exhibit varying forms of 
activation and show variations in polarisation from the in-vitro extremes of M1 and M2 
phenotype, which show distinct metabolic profiles (Haschemi et al., 2012, Tannahill et 
al., 2013). Jacobs et al. and Rathmell et al. both demonstrated that inhibition of cell 
metabolism may lead to impaired function and apoptosis, whereas excessive metabolic 
function may also alter functional phenotype and predispose to disease conditions such 
as autoimmunity and inflammatory diseases (Jacobs et al., 2008, Rathmell et al., 2003). 
It will be important to determine in the future whether clinical conditions such as chronic 
obstructive pulmonary disease (COPD), which are associated with altered host-pathogen 
responses such as reduced phagocytosis of bacteria (Taylor et al., 2010, Bewley et al., 
2016), are also associated with altered metabolic responses whether these are 
mechanistically linked. 
 
To further investigate the metabolic profiles of macrophages and their relationship to 
susceptibility to infection, the XF24 Seahorse extracellular flux assay was thoroughly 
optimised for use with differentiated mouse BMDM and human MDM. From the titration 
experiments, 200,000 BMDM/well and 150,000 MDM/well were observed as the 
optimum cell density for the XF24 microplate. To get an optimum ambient oxygen 
tension inside the XF24 microenvironment, 3 minutes measuring time was identified as 
the best option after 3 minutes of mixing time and 12 minutes of waiting time. To assess 
the glycolytic metabolism (i.e. ECAR) of macrophages, oligomycin A and 2-deoxy-D-
glucose, and for mitochondrial OXPHOS assessment, oligomycin A, FCCP and 
rotenone/antimycin A were titrated against response in the XF24 flux analyser. These 
compounds formed the glycolytic stress test  and the mitochondrial stress tests and a range 
of concentrations was tested to get the most accurate bioenergetic profiles for 
macrophages as evidenced by the ability to produce the expected changes in key 
bioenergetics measurements (Pelletier et al., 2014).  
The titration experiments showed that 0.5-1.5µM oligomycin A, 75-100mM 2-deoxy-D-
glucose, 2.0µM FCCP and 1.0 µM rotenone/antimycin A are optimum for the 
extracellular flux assay with mouse BMDM and human MDM. Oligomycin A inhibits 
ATP synthase (complex V), hence it decreases oxygen consumption via complex IV (i.e. 
cytochrome oxidase) of the mitochondrial ETC, resulting in oxidation of molecular 
oxygen to water in the presence of protons (Hong and Pedersen, 2008). To compensate 
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for the inhibition of ATP synthesis, cellular energy production is maintained through 
increases in the rate of glycolysis, and increases in glycolysis occur to the maximum level 
in the presence of oligomycin A. Therefore, oligomycin A is not only used to determine 
the mitochondrial ATP-linked oxygen consumption and proton leakage but also to 
measure the maximum glycolytic capacity and glycolytic reserve of the cell. In contrast, 
2-deoxy-D-glucose is a glucose analogue which inhibits hexokinase (i.e. glucokinase) 
competitively, hence it is used to determine the basal glycolytic rate, and the non-
glycolytic acidification rate.  
On the other hand, FCCP is an uncoupler of mitochondrial oxidative phosphorylation 
from ETC. It upregulates oxygen consumption rate massively without ATP synthesis, 
because it disrupts the proton gradient across the mitochondrial membranes by 
transferring protons across the inner mitochondrial membrane to the matrix. Like 
uncoupling proteins (UCP1/2), FCCP breaks coupling between substrate oxidation and 
mitochondrial oxidative phosphorylation (OXPHOS) of ADP to ATP (Heytler, 1980). 
Hence it is called an ‘‘uncoupler’’ and is used to measure the maximum mitochondrial 
respiration rate. All of the inhibitors including rotenone (complex I inhibitor) and 
antimycin A (complex III inhibitor) were optimised separately to avoid artefacts. 
 
Metabolically active S. pneumoniae increased BMDM basal and maximum glycolytic 
respiration with decreased basal OXPHOS at an earlier time point (5 hours post-
infection). But at this stage, the maximum respiration capacity of mitochondria was 
unaltered, suggesting that the earlier metabolic switch to glycolysis is not due to 
mitochondrial impairment, but rather is activated to compensate for the high energy 
demand required for coping with intracellular bacteria. This metabolic shift is like a 
Warburg type-effect, as has been observed in LPS-activated macrophages (Palsson-
Mcdermott et al., 2015) or as has been mediated by various TLR stimuli (TLR 2, 4 and 
9) in dendritic cells (Krawczyk et al., 2010). Moreover, like LPS, heat inactivated or 
metabolically active S. pneumoniae increased the maximum glycolytic capacity of 
macrophages when exposure was sustained for several hours. The baseline glycolytic rate 
was comparable between mock-infected and heat inactivated bacteria exposed 
macrophages, suggesting that metabolically active bacteria could be contributory to 
increased baseline ECAR. Presumably heat inactivated Gram positive pneumococci 
provide peptidoglycan whose degradation products may signal via pattern recognition 
receptors, such as nucleotide-binding oligomerisation domain containing protein 2 (Nod 
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2), to generate similar results on metabolism to that provided by LPS-mediated TLR4 
activation (Sriskandan and Cohen, 1999).  
Moreover, it appeared that S. pneumoniae stimulate macrophages similarly to classic 
activation by LPS and IFN-γ and showed metabolic signatures similar to M1 polarised 
macrophages, in that they upregulate glycolysis. Recently Rodriguez-Prados and 
colleagues demonstrated that classical activation with LPS and IFN-γ or TLR-2,3,4 or 9-
agonists increase glycolytic fluxes through shifting the expression pattern of 
phosphofructokinase 2 (PFK2) isoforms, resulting in an increase in ubiquitous PFK2 
(uPFK2) expression and a decrease in the liver PFK2 (L-PFK2) isoform. This decreases 
phosphatase activity and causes accumulation of fructose-2,6-bisphosphate in 
macrophages, a positive regulator of one of the rate limiting enzymes of glycolysis called 
phosphofructokinase 1 (PFK1) (Rodríguez-Prados et al., 2010). On the other hand, human 
Mcl-1 transgenic mouse BMDM increased mitochondrial respiration capacity and ATP-
linked OXPHOS with unaltered glycolytic respiration, in the mock infected condition.  
This is consistent with data from Perciavalle and co-workers, concerning mitochondrial 
bioenergetics in Mcl-1 transgenic murine embryonic fibroblasts (Perciavalle, 2012). S. 
pneumoniae reduced several OCR related parameters in the transgenic BMDM though 
there were similar trends in the wild type cells, so these changes were probably not 
specifically because of the transgene but are likely to reflect a modest reduction in OCR 
in the context of bacteria.  
 
Overall, this section shows that the Seahorse XF24 extracellular flux analyser can be used 
to analyse metabolic responses of macrophages to S. pneumoniae. The data shown here 
suggests that like classical activation stimuli macrophages upregulate glycolytic 
metabolism in response to pneumococci, while my data also suggests that Mcl-1 can 
enhance oxidative phosphorylation. Further chapters in this thesis will explore potential 
alterations in macrophage metabolism following bacterial challenge with clinical disease 
states and relate these changes to other aspects of mitochondrial homeostasis. 
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Chapter 4. Evaluation of macrophages metabolic phenotype 
and their metabolites mROS or NO interactions with S. 
pneumoniae in the phagolysosomes 
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4.1. Introduction 
Metabolic reprogramming is a signature of most immune cell’s activation, and it is a 
pivotal part of immunometabolism that is linked to immune-regulation (Loftus and 
Finlay, 2016). For example, Gram-negative bacterial lipopolysaccharide (LPS) activates 
murine peritoneal macrophages, which absorb more glucose, upregulating glucose 
transporter 1 (GLUT1) (Fukuzumi et al., 1996), and LPS shifts the metabolic profile by 
increasing reliance on glycolysis, which is required to induce a proinflammatory 
macrophage phenotype (Jha et al., 2015). Moreover, the innate activation with LPS and 
interferon (IFN)-γ also upregulates inducible nitric oxide synthase (iNOS) in 
macrophages, which produces reactive nitrogen species (eg. nitric oxide radical, NO) 
(Lorsbach et al., 1993). NO inhibits mitochondrial oxidative phosphorylation (OXPHOS) 
by nitrosylating iron-sulfur rich proteins in complex I (NADH dehydrogenase) (Emilio et 
al., 1998, Drapier and Hibbs Jr, 1988) and complex IV (cytochrome oxidase) (Cleeter et 
al., 1994) of the electron transport chain (ETC) involved in mitochondrial oxidative 
phosphorylation (OXPHOS).  
Furthermore, the metabolic reprogramming induces glycolysis and disrupts the Krebs 
cycle, inducing breaks in the Krebs cycle and diverts substrates, which are involved in 
the reprogramming that leads to the generation of proinflammatory cytokines. For 
example, breaks in the Krebs cycle in LPS-stimulated macrophages (M1), result in 
accumulation of the intermediate succinate, which acts as a signalling molecule to 
upregulate HIF-1α and induces IL-1β production (Tannahill et al., 2013). Moreover, 
Krebs cycle disruption also elevates citrate levels, which is converted into itaconic acid 
that limits the growth of bacteria, such as Salmonella enterica and Mycobacterium 
tuberculosis (Jha et al., 2015, Alessandro et al., 2013). However, it is not fully understood 
how elevated succinate or itaconic acid inhibit bacterial growth. Interestingly, several 
studies have demonstrated that succinate, the substrate of complex II (in the 
mitochondrial respiration chain) induces mitochondrial superoxide (i.e. mROS) 
production by transferring electrons in a reverse manner to complex I, rather than direct 
electron transferring to ubiquinone then complex III. This succinate-driven mROS 
production is also sensitive to complex I inhibitors (e.g. rotenone or piericidin) (Lambert 
and Brand, 2004, Liu et al., 2002, Hansford et al., 1997), suggesting that this is generated 
at the complex I site rather than in complex II. Besides, the Dockrell group have recently 
demonstrated that human immunodeficiency virus (HIV-1) (Collini et al., 2018) or 
chronic obstructive pulmonary disease (COPD) alveolar macrophages show impaired 
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intracellular S. pneumoniae killing (Bewley et al., 2017), which could be causes of 
increased susceptibility to pneumococcal pneumonia in HIV-1 infection or infection-
mediated exacerbations in COPD respectively. Both of these studies also observed that 
in patients with COPD or HIV-1 infection, S. pneumoniae fails to trigger adequate 
induction of mROS over baseline and fails to activate a delayed mitochondrial pathway 
of apoptosis, which is essential for intracellular bacterial killing and inflammation 
resolution.  
Typically, 0.2-2% of cellular consumed oxygen is converted into mROS, during 
mitochondrial OXPHOS,  as a by-product due to electron leak from complex I and 
complex III of ETC (Balaban et al., 2005). But this de novo electron leak and subsequent 
mROS generation is augmented by TLR-agonists (e.g. LPS), which induce TRAF6 
signalling associated with complex I inactivation (West et al., 2011a), or  by triggering 
RIP1/RIP3 signalling pathway in macrophages, as shown following challenge with 
Mycobacterium tuberculosis (Roca and Ramakrishnan, 2013). This induction of mROS 
is also be caused by IFNγ/STAT1 signalling, as seen in macrophages challenged with 
Listeria monocytogenes (Sonoda et al., 2007).  
Moreover,  recently it has been shown that HIV envelope glycoprotein gp120 not only 
alters mitochondrial dynamics but also decreases mitochondrial respiration capacity in 
neurons (Avdoshina et al., 2016). Similarly, oxidative stress or COPD diminishes 
mitochondrial respiration capacity, respiration reserve and ATP-linked respiration in 
airway small muscle cells (Wiegman et al., 2015). Thus both COPD and HIV-1 infection 
may stimulate reduced OXPHOS and conditions that might allow increased baseline 
mROS, and potentially reduced induction of mROS during infection. Therefore, it is 
important to determine the exact metabolic phenotype - especially mitochondrial 
OXPHOS - after challenge in S. pneumoniae in COPD macrophages or macrophages 
stimulated with recombinant glycoprotein gp120, as the work of Collini and colleagues 
suggests this phenocopies the defect of mROS induction following S. pneumoniae 
challenge in HIV-1 infection (Collini et al., 2018). Overall, this complex scenario might 
aid our understanding of the mitochondrial role in innate immunity beyond energy supply, 
through its role as an effector of microbicidal responses. Therefore, in this section I will 
explore the mitochondrial bioenergetic profile of human monocyte-derived macrophages 
after challenge with S. pneumoniae. I will also investigate the metabolic phenotype of 
COPD macrophages or recombinant gp120 pre-treated macrophages challenged with or 
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without S. pneumoniae. Moreover, I will also evaluate the mitochondrial ROS and nitric 
oxide levels and investigate their interaction with bacteria in phagolysosomes.  
 
4.2. S. pneumoniae decreased mitochondrial OXPHOS of human 
monocyte-derived macrophages 
Cellular oxygen consumption is an integral part of mitochondrial OXPHOS and this 
process is the major site of ATP production. Recently it has been demonstrated that, 
unlike classical activation (i.e. M1 macrophage),  macrophages with parasitic infection 
(e.g. Leishmania infantum) diverted an early increase in aerobic glycolysis to a later 
increase in mitochondrial OXPHOS (Moreira et al., 2015), which results in an M2 
metabolic phenotype in macrophages. Whereas, LPS stimulated or Gram-positive (e.g. S. 
aureus) or Gram-negative bacteria (e.g. E. coli) exposed monocytes show increased 
glycolysis, but varied mitochondrial metabolic responses, characteristic of an M1 
metabolic phenotype (Moreira et al., 2015).  
To assess the metabolic responses in human monocytes-derived macrophages (MDM) in 
the presence of the lung pathogen S. pneumoniae, MDM were exposed to opsonised 
serotype 2 S. pneumoniae (D39) for 4 hours or 16 hours, then the mitochondrial OXPHOS 
and glycolytic responses were evaluated by the extracellular flux analyser (Seahorse, 
Bioscience).  S. pneumoniae significantly increased the basal glycolysis of human MDM 
at both time points (Basal ECAR in the Figure 4.1A and ECAR rate data in Figure 4.1H 
and Figure 4.1I). Although the baseline OXPHOS was comparable between mock 
infected MDM and pneumococcal challenged MDM at the later time point, and although 
it was significantly decreased at the earlier time point the change was of small magnitude 
suggesting that basal OCR was not altered to a large extent (OCR rate data in Figure 4.1B 
and 4.1C and basal OCR in Figure 4.1D). Other changes were more marked at the 16 hour 
time point after bacterial challenge; S. pneumoniae decreased mitochondrial respiration 
capacity by approximately two-thirds (Figure 4.1E) and ATP-linked OXPHOS by one-
third (Figure 4.1F), with increased proton leak (by approximately 3-fold) through the 
mitochondrial inner membrane at the later time (Figure 4.1G). 
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Figure 4.1. S. pneumoniae decreased mitochondrial respiration capacity and increased 
mitochondrial inner membrane proton leak in human MDM. Human monocyte-derived 
macrophages (MDM) were challenged with opsonised serotype 2 S. pneumoniae (D39) for 4 
hours or 16 hours. Subsequently, the glycolysis (i.e. extracellular acidification rate (ECAR)) and 
mitochondrial OXPHOS (i.e. oxygen consumption rate (OCR)) were measured by the XF24 
extracellular flux analyser. From the ECAR rate data (Figure H for 4 hours and figure I for 16 
hours post-infection (hpi)), the basal glycolytic rate (ECAR) was calculated (A), and from OCR 
rate data (Figure B for 4 hours and Figure C for 16 hours post-challenge), the mitochondrial basal 
respiration (D), maximum respiration capacity (E), ATP-linked OCR (F), and proton leak (G) 
were calculated. Oligomycin A (Oligo) is an ATP synthase inhibitor (Complex V) that was added 
after the baseline ECAR and OCR measurement to measure ATP-linked OCR. The maximum 
respiration capacity is calculated by subtracting non-mitochondrial OCR with rotenone (Rot) plus 
antimycin A (AntA) from the FCCP treated OCR. Data were normalized by total protein of MDM, 
and shown as mean ± SEM for ECAR (mpH/minute/µg of protein) and OCR (pmoles/minute/µg 
of protein). Statistical analysis was performed using a one-way ANOVA and Sidak’s post-hoc 
test for multiple comparison, and student paired t-test for time point comparisons. (*p≤0.05, **p 
≤0.01, n=6).  
 
A. 
B. 
C. 
D. E. F. 
G. 
H. I. 
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4.3. HIV-1 envelop glycoprotein gp120 and S. pneumoniae alter 
mitochondrial metabolism in human monocyte-derived macrophages  
Human immunodeficiency virus (HIV-1) can penetrate and replicate in macrophages like 
in its more common reservior the CD4+T-cell (Lum and Badley, 2003). HIV-1 envelop 
glycoprotein gp120 itself is sufficient to disrupt macrophage function and delay 
macrophage apoptosis,which produces a congenial milieu for viral replication (Cummins 
et al., 2010, Cicala et al., 2002). Moreover, HIV-1 patients are more susceptible to 
bacterial lung infection (Gordin et al., 2008, Yin et al., 2012).  
To observe HIV-1 effects on macrophages metabolism, recombinant gp120 was used to 
pre-treat cells, prior to stimulation with the lung pathogen S. pneumoniae. Then, 
macrophage glycolysis and mitochondrial OXPHOS were evaluated using the 
extracellular flux analyser. The glycolytic response showed an increased trend in 
pneumococcal challenged MDM at the same time point (Figure 4.2A-B), although not to 
a significant level unlike Figure 4.1, likley due to donor variation, intensity of infection 
and other experimental variables. The mitchondrial OXPHOS was comparable between 
mock-infected and gp120 treated human macrophages (i.e. MDM), whether challenged 
with or without pneumococci when studied at an earlier time point (e.g. 4 hours) (Figure 
4.2C-H).  
On the other hand, pneumococcal challenge significantly upregulated the basal glycolytic 
response in MDM, whether treated or untreated with gp120 at 16 hours (Figure 4.3A-B). 
In contrast, at this later time point, the  mitochondrial maximum respiration capacity 
(Figure 4.3E), respiration reserve (Figure 4.3F) and ATP-linked OXPHOS (Figure 4.3G) 
were significantly decreased in MDM after challenge with S. pneumoniae, irrespective of 
gp120 prior treatment. Moreover, S. pneumoniae significantly increased the proton leak 
in mitochondrial inner membrane (Figure 4.3H). Interestingly, HIV-1 gp120 decreased 
the proton leak at baseline, and significantly diminished pneumococcal induced proton 
leak (Figure 4.3H). 
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 Figure 4.2. Human Immunodeficiency virus (HIV-1) envelop glycoprotein gp120 and S. 
pneumoniae effects on human MDM’s metabolism after 4 hours. Human MDM were pre-
treated with recombinant gp120 (100ng/mL) for an hour. Then, MDM were challenged with 
opsonised S. pneumoniae (D39) with a MOI (multiplicity of infection) of 10 for 4 hours. The 
glycolytic rate (ECAR) and mitochondrial OXPHOS (OCR) were measured by the XF24 
extracellular flux analyser. From the ECAR rate data (A), the basal glycolytic rate was calculated 
(B), and from the OCR rate data (C), the mitochondrial basal respiration (D), maximum 
respiration capacity (E), respiration reserve (F), ATP-linked OCR (G), and proton leak (H) were 
calculated. ATP synthase inhibitor oligomycin A (Oligo) was added after baseline ECAR and 
OCR measurement to measure ATP-linked OCR. The maximum respiration capacity was 
calculated by subtracting non-mitochondrial OCR with rotenone (Rot) plus antimycin A (antA) 
from FCCP treated OCR. Data were normalized by total protein of respective MDM and shown 
as mean ± SEM for ECAR (mpH/minute/µg of protein) and OCR (pmoles/minute/µg of protein) 
n=2. 
A. B. 
C. 
D. 
E. F. G. H. 
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Figure 4.3. Human Immunodeficiency virus (HIV-1) envelop glycoprotein gp120 and 
pneumococcal effects on mitochondrial respiration after 16 hours. Human MDM were pre-
treated with recombinant gp120 (100ng/mL) for 24 hours. Then, MDM were challenged with 
opsonised S. pneumoniae (D39) at an MOI of 10, for 16 hours. The glycolytic (defined as ECAR) 
and mitochondrial OXPHOS (OCR) were measured by the XF24 extracellular flux analyser. 
From the ECAR baseline rate data (A), the basal glycolytic rate was calculated (B), and from the 
OCR rate data (C), the mitochondrial basal respiration (D), maximum respiration capacity (E), 
respiration reserve (F), ATP-linked OCR (G), and proton leak (H) were calculated. Oligomycin 
A (Oligo) was added after baseline ECAR and OCR measurement. The ATP-linked OCR was 
calculated by subtracting oligo treated OCR from basal OCR. The maximum respiration capacity 
was calculated by subtracting the non-mitochondrial OCR [rotenone (Rot) plus antimycin A 
(AntA) treated OCR] from FCCP treated OCR. Data were normalized by total protein and are 
shown as mean ± SEM for ECAR (mpH/minute/µg of protein) and OCR (pmoles/minute/µg of 
protein). Statistical analysis was performed with two-way ANOVA and Holm-Sidak’s post-hoc 
test for multiple comparisons, and Mann-Whitney paired test for pair-wise comparisons. 
(*p≤0.05, **p ≤0.01, n=6).  
G. 
A. B. 
C. D. E. 
F. H. 
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4.4. S. pneumoniae diminishes mitochondrial respiration capacity in 
COPD macrophages 
Cigarette smoking is the primary cause of chronic obstructive pulmonary disease 
(COPD), and S. pneumoniae, nontypeable Haemophilus influenzae and Moraxella 
caterrhalis are the common causes of infection-induced COPD exacerbations (Sapey and 
Stockley, 2006, Torres et al., 1996). COPD also causes functional impairment of 
pulmonary parenchyma resulting in damage to the airways. In the COPD MAP study 
investigators have demonstrated that in COPD airway small muscle cells (ASM) the 
mitochondrial respiration capacity and mitochondrial inner transmembrane potential are 
diminished compared to healthy ASM (Wiegman et al., 2015). These observations 
prompted me to hypothesise that COPD-MDM may also have mitochondrial impairment, 
or have altered mitochondrial metabolism after challenge with pneumococcus. 
To assess COPD-MDM mitochondrial metabolism, COPD patients and age-matched 
healthy control monocytes were differentiated into MDM. Subsequently, MDM were 
challenged with opsonised S. pneumoniae (D39) for 4 hours and then the mitochondrial 
OXPHOS and glycolytic respiration were measured by the extracellular flux analyser. 
The baseline mitochondrial respiration capacity (Figure 4.4C) and respiration reserve 
(Figure 4.4D) were significantly decreased in COPD-MDM compared to age-matched 
healthy MDM. Interestingly, S. pneumoniae further declined the mitochondrial 
respiration capacity (Figure 4.4C), respiration reserve (Figure 4.4D) and ATP-linked 
OXPHOS (Figure 4.4E). Apart from these observations, proton leak was unaltered in 
COPD-MDM with pneumococci in contrast to COPD mock-infected MDM, while it was 
an increase trend for healthy MDM challenged with pneumococci versus the mock-
infected sample. However, the baseline proton leak was significantly elevated in COPD 
MDM compared to healthy MDM (Figure 4.4F), which was consistent with a trend 
towards lower baseline mitochondrial inner transmembrane potential (ΔΨm) in COPD-
MDM compared to healthy-MDM (Figure 4.6A-B). On the other hand, the baseline 
glycolytic rate was comparable between COPD and healthy-MDM and pneumococcal 
challenge gave an increased trend in the basal glycolysis in both COPD and healthy MDM 
(Figure 4.5B), although in this small dataset this difference did not reach statistical 
significance unlike other data in this chapter, again emphasising the donor variability and 
experimental variation in the infection in MDM cultures. 
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Figure 4.4. Mitochondrial metabolic phenotype of COPD and healthy MDM. Both COPD and 
age-matched healthy control volunteers MDM (HC-MDM) were challenged with opsonised S. 
pneumoniae (D39, MOI of 10) for 4 hours, then the basal oxygen consumption rate (OCR) (B), 
maximum respiration capacity (C), respiration reserve (D), ATP-linked OCR (E) and the proton 
leak (F) were calculated from the OCR kinetic data (A). Oligomycin A (oligo), Rotenone (Rot), 
antimycin A (AntA). Data were normalized by total protein of MDM and are shown as mean ± 
SEM. Results were analysed with one-way ANOVA and Dunnett’s post-hoc test. (*p≤0.05, **p 
≤0.01, n=3). 
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Figure 4.5. Glycolytic metabolism of COPD and healthy monocyte derived macrophages. 
COPD and age-matched healthy volunteer’s MDM were challenged with opsonised S. 
pneumoniae (D39, MOI of 10) for 4 hours. Then, the baseline glycolytic rate (B) was calculated 
from the baseline extracllular acidification rate (ECAR) kinetic data (A), measured by the XF24 
extracellular flux analyser. Healthy control MDM (HC MDM) were either mock-infected (MI) or 
challenged with D39 and were labelled in the figures as HC-MDM-MI and HC-MDM-D39, 
respectively. Mock-infected and D39 challenged COPD MDM were labelled in the figures as 
COPD-MDM-MI and COPD-MDM-D39, respectively. Data are shown as mean ± SEM (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Mitochondrial inner transmembrane potential of COPD and healthy MDM. Both 
COPD and age-matched healthy control volunteers MDM (HC MDM) were exposed to opsonised 
S. pneumoniae (D39, MOI of 10) for 4 hours, loss of mitochondrial inner membrane potential 
(ΔΨm) was measured by flow cytometry after staining with 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1, 10µM). Figure A shows the representative 
FL2-H subset for the baseline JC-1 counts of healthy and COPD MDM (orange, red and blue 
histograms for unstained, healthy and COPD mock-infected (MI) MDM, respectively) and Figure 
B shows the mean fluorescence intensity (MFI) for JC-1. Loss of fluorescence (MFI) refers to 
loss of ΔΨm. Data are shown as mean ± SEM, (n=3). 
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4.5. Streptococcus pneumoniae induces mitochondrial reactive oxygen 
species 
Mitochondria produce superoxide (mROS) as a by-product, mainly due to electron 
slippage from complex I or III to the mitochondrial matrix or intermembrane space, 
during oxidative phosphorylation (Balaban et al., 2005, Lagouge and Larsson, 2013). 
Recently it has been demonstrated that mROS especially from complex I is augmented 
by Toll like receptor (TLR)-agonists or bacterial infection, and subsequently, this mROS 
is released into the phagolysosomal compartment for intracellular bacterial killing (West 
et al., 2011a).  
To observe pneumococcal effects on mROS production, mouse bone marrow derived 
macrophages (BMDM) were challenged with S. pneumoniae (D39) for 16 hours and 
stained with an mROS probe (MitoSox red). The MitoSox-stained macrophages 
demonstrate that S. pneumoniae significantly increased mROS production. Similarly, 
rotenone (an inhibitor of complex I) and antimycin A (an inhibitor of complex III) treated 
macrophages also increased mROS production (Figure 4.7A-B). Additionally, neither 
pneumococcal challenge nor treatment with inhibitors of complex I and III altered 
mitochondrial density (Figure 4.7C-D), suggesting that observed mROS production was 
not caused by changes in mitochondrial density, rather it could be linked with the 
aforementioned mitochondrial metabolic reprogramming. Moreover, co-stained images 
of mROS and the mitochondrial marker Tom20, illustrate that mROS and mitochondria 
are co-localised (Figure 4.8), which reduces the concern of non-specific ROS staining by 
MitoSox Red. 
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Figure 4.7. S. pneumoniae triggers mitochondrial ROS in macrophages. Mouse BMDM were 
challenged with S. pneumoniae (D39, MOI of 10) or mock-infected (MI) for 16 hours, then 
stained with MitoSox red (an mROS specific probe) or mitotracker green (a mitochondria specific 
probe) followed by flow cytometry. Figure A shows a representative histogram for FL2-H of 
unstained control or MitoSox red stained BMDM (grey, deep green, blue, orange and green line 
represent unstained and stained mock-infected, S. pneumoniae (Spn) exposed, rotenone and 
antimycin A treated BMDM, respectively). Figure B shows the mean fluorescence intensity (MFI) 
for MitoSox red stained mock-infected, S. pneumoniae exposed, rotenone and antimycin A treated 
BMDM. Figure C shows the representative histogram for FL1-H of unstained control and 
mitotracker green stained BMDM (red line shows unstained BMDM and blue, orange, green and 
deep green lines shows the stained BMDM that were mock-infected, S. pneumoniae exposed, 
rotenone and antimycin A treated, respectively). Figure D shows the mean fluorescence intensity 
(MFI) for mitotracker green stained BMDM with the same treatments. Data are shown as mean ± 
SEM and results were analysed with One-way ANOVA and Bonferroni multiple comparison test. 
*p<0.05, n=5). [Note: During flow cytometry acquisition, mouse BMDM were labelled as wild-
type (WT)-BMDM and S. pneumoniae exposed BMDM labelled as Spn MOI 10-WT-BMDM]. 
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Figure 4.8. Mitochondrial ROS are co-localised with mitochondria. Mouse BMDM were 
incubated with S. pneumoniae (D39, MOI of 10) or mock-infected (MI) for 16 hours. Then, 
stained with MitoSox red. Subsequently, the mitochondrial specific marker Tom20 was labelled 
by rabbit anti-Tom20 (0.4µg/mL) primary antibody and goat anti-rabbit IgG (H+L) (4µg/mL) 
conjugated with Alexa Fluor 488. Figure A (top panel) shows the representative co-stained images 
of BMDM after mock-infection (MI), mitochondria (green pixels), mROS (red) and both merged 
with nucleus (blue, stained with Draq5). Figure B (bottom panel) shows the representative co-
stained images of macrophages challenged with S. pneumoniae, mitochondria (green), mROS 
(red) and co-localised signal (yellow, merged image). The immunofluorescence images were 
captured by Zeiss LSM510 inverted confocal microscopy with 488nm excitation and 500-530nm 
emission spectrum for Alexa Fluor 488 and 543nm excitation and 565-615nm emission spectrum 
for MitoSox red, and 63x1.4 NA oil with zoom 2 objective. Images were reconstituted by imagej 
using 13x13 hat filter. Scale bar is 5µm. 
 
4.6. S. pneumoniae upregulates mitochondrial ROS, which are co-
localised with intracellular bacteria 
Mitochondria play a pivotal role in innate immunity beyond cellular metabolism. 
Recently West and colleagues have demonstrated that mROS are localised adjacent to the 
phagosome to kill intracellular bacteria (West et al., 2011a). In section 4.5, it is shown 
that S. pneumoniae upregulates mROS in macrophages, but it is not clear whether mROS 
is directly in the vicinity of the phagosome and subsequently involved in killing of 
intracellular bacteria in macrophages, when other canonical killing strategies are 
exhausted. To observe mROS interactions with S. pneumoniae and phagolysosomes, 
Alexa Fluor-647 labelled opsonised S. pneumoniae (Figure 4.9A) was used to challenge 
B. 
A. 
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macrophages for 16 hours (Figure 4.9B). The co-staining images illustrate that the mROS 
stain co-localised or was adjacent to S. pneumoniae (Figure 4.10A). Moreover, the 
quantification data from macrophages with internalised bacteria shows that around 40% 
of internalised bacteria were co-localised and 46% were adjacent to mROS in 
macrophages (Figure 4.13A). Similarly, the mROS stain was co-localised or adjacent 
with phagolysosomes in macrophages challenged with pneumococci compared to mock-
infected macrophages (Figure 4.11A-B and correlation quantification in Figure 4.13B). 
Whereas, mock-infected or S. pneumoniae exposed macrophages lysosomal compartment 
did not co-localised with the negative comparator ER (Figure 4.12). 
In contrast, neither mROS nor pneumococci were co-localised with the endoplasmic 
reticulum (Figure 4.10B and quantification in Figure 4.13B). Moreover, inhibiting mROS 
with a superoxide scavenger MitoTempo significantly decreased the MitoSox 
fluorescence intensity in macrophages after challenge with S. pneumoniae (Figure 4.14A 
(V), and quantification data in figure 4.14D), suggesting the mithochondrial ROS species 
were selectively stained. Like mouse BMDM (Figure 4.14B), MitoSox also co-localised 
with pneumococci in human MDM (Figure 4.14C). These results corroborated our 
group’s recent observations, that inhibiting mROS with MitoTempo decreases the 
delayed phase of intracellular bacterial killing and therefore that mROS play a role in the 
microbical response against S. pneumoniae (Bewley et al., 2017). I also confirmed that 
macrophages stained with cresyl violet to label lysosomes and phagolysosomes did not 
produce any background influencing the detection of mROS with MitosSox red (Figure 
4.15A) or ER with ER tracker (Figure 4.15B) and that conversely these stains did not pick 
up any signal when trying to detect phagolysosomes. The broad emission spectrum of 
MitoSox red prevented at 565-615 nm that I could not perform similar localisation 
experiments with mROS and ER due to overlapping detection spectra. 
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Figure 4.9. S. pneumoniae labelled with Alexa Fluor tagged succinimidyl ester. S. pneumoniae 
(D39) was labelled with Alexa Fluor 647-succinimidyl ester (AF647-NHS ester, 0.05mg/mL) for 
an hour. Figure A illustrates the representative confocal fluorescence image of AF647-NHS ester 
labelled D39 (green pixel). Figure B shows the representative image of intracellular AF647-NHS 
ester labelled D39 in mouse BMDM. Images were captured by Zeiss LSM510 inverted confocal 
microscopy with 633nm excitation and 650-704nm emission spectrum and 63x1.4 NA oil with 
zoom 2 objective lens. Scale bar is 5µm. 
 
 
Figure 4.10. S. pneumoniae and mitochondrial ROS are co-localised in macrophages. Mouse 
BMDM were challenged with Alexa Fluor-647 (AF-647) labelled opsonised S. pneumoniae (D39) 
and incubated for 16 hours. Then, mitochondrial ROS (mROS) and endoplasmic reticulum (ER) 
were stained with MitoSox-red and ER-tracker red (BODIPY TR Glibenclamide), respectively. 
Figure A (top panel) shows the representative images of AF-647 labelled D39 (green), mROS 
(red) and the co-localised signal (yellow, merged image) in mouse BMDM. Figure B (bottom 
panel) shows the representative control images of D39 (green), ER (pink) in mouse BMDM. 
Images were captured by Zeiss LSM510 inverted confocal microscopy with 633nm excitation 
and 650-704nm emission spectrum for AF-647, 488nm excitation and 565-615nm emission 
spectrum for MitoSox red and 543nm excitation and 560nm emission for ER-tracker. The 
representative images were created from the maximum projected Z-stack images (Size scaling: 
0.07X0.07X0.48µm, 63x1.4 NA oil, Scan zoom 2 and the average line 4) using a 17x17 hat filter 
with intermodes black and white threshold correction by ImageJ. Scale bar is 5µm.  
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Figure 4.11. Lysosome/phagolysosome are co-localised with mitochondrial ROS in 
macrophages. Mouse BMDM were mock-infected or challenged with opsonised S. pneumoniae 
(D39) for 16 hours. Then lysosomal/phagolysosomal compartment and mitochondrial ROS 
(mROS) were co-stained with cresyl violet and MitoSox-red, respectively. Figure A (top panel) 
shows the representative images of lysosomes/phagolysosomes (green pixels), mROS (red) and 
merged image in mock-infected mouse BMDM. Figure B (bottom panel) shows the representative 
images of lysosomes/phagolysosomes (green), mROS (red) and co-localised signal (yellow, 
merged image) in mouse BMDM after challenge with D39. Images were captured by Zeiss 
LSM510 inverted confocal microscopy with 633nm excitation and 650-704nm emission spectrum 
for cresyl violet, 488nm excitation and 565-615nm emission spectrum for mitosox red. 63x1.4 
NA oil with zoom 2 objective, images were reconstituted by ImageJ using a 17x17 hat filter with 
intermodes black and white threshold correction by ImageJ. The scale bar is 5µm. 
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Figure 4.12.  Lysosomes and endoplasmic reticulum are not co-localised. Mouse BMDM were 
mock-infected or challenged with opsonised S. pneumoniae (D39) for 16 hours. Then the 
lysosomal compartment and endoplasmic reticulum (ER) were co-stained with cresyl violet and 
ER-tracker red, respectively. Figure A (upper panel) shows the representative images of 
lysosomal compartments (green pixels), ER (pink) and the merged image in mock-infected mouse 
BMDM. Figure B (bottom panel) shows the representative images of lysosomal compartments 
(green), ER (pink) and merged image in mouse BMDM exposed to D39. Images were captured 
by Zeiss LSM510 inverted confocal microscopy with 633nm excitation and 650-704nm emission 
spectrum for cresyl violet, 543nm excitation and 560nm emission spectrum for ER-tracker red. 
63x1.4 oil with zoom 2 objective lens. Images were reconstituted by ImageJ using 17x17 hat 
filter. The scale bar is 5µm. 
 
 
Figure 4.13. Mitochondrial ROS and internalised S. pneumoniae are co-localised with 
phagolysosome in macrophages. Mouse BMDM were mock-infected or challenged with 
opsonised S. pneumoniae (D39) for 16 hours. Figure A shows the percentage of S. pneumoniae 
(D39), from the data represented in Figure 4.10 that were co-localised or adjacent to mROS was 
calculated. In these experiments internalised bacteria were observed in 15.46 ± 3.50 % of BMDM. 
Figure A shows the percentage of bacteria showing a co-localised signal or proximal signal with 
Merge Lysosome 
MI 
D39 
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mROS was evaluated by a co-localisation test and digital distance measurement algorithms in 
ImageJ were used with adjacent bacteria defined as the average R value (Pearson’s correlation 
coefficient) close to zero, and co-localised as average R value is ≥0.5. Figure B shows the 
Pearson’s correlation coefficient for mROS with D39, D39 with ER, mROS with 
lysosomes/phagolysosomes, and lysosomes/phagolysosomes with ER co-staining images.  Data 
was derived from experimental data from which Figures 4.10 to 4.12 are representative images 
and was quantified by the co-localisation test with ImageJ as described above. Data are depicted 
as mean ± SEM, n=3.  
 
 
Figure 4.14.  Mitochondrial ROS are co-localised with S. pneumoniae in macrophages. 
Mouse BMDM or human MDM were mock-infected (MI) or challenged with Alexa Fluor 647 
labelled opsonised S. pneumoniae (D39) or unlabelled D39 and incubated for 16 hours. Then, 
mitochondrial ROS (mROS) were stained with MitoSox red.  Figure A (top panel) shows mROS 
(red pixels) with or without labelled D39 in mouse BMDM. BMDM were (i) mock-infected (MI) 
or (ii) challenged with unlabelled D39, or (iii) exposed with Alexa Fluor 647 labelled D39 (in 
BMDM not stained for mROS), or (iv) exposed with labelled D39 (green) in cells stained with 
MitoSox (red) or (v) challenged with labelled D39 and stained with MitoSox (red) in MitoTempo 
pre-treated cells. Figure B and C show the orthogonal view of mouse BMDM and human MDM, 
respectively, with the Alexa fluor 647 labelled D39 (green) either co-localised with mROS 
(yellow pixel) or proximal to mROS (red). Images were captured by a Zeiss LSM510 confocal 
microscopy with zoom 2 and 63x1.4 oil objective lens and 488nm excitation and 565-615nm 
emission spectrum for MitoSox red, and 633nm excitation and 650-704nm emission for Alexa 
Fluor 647 labelled D39. Figure D shows the corrected total cell fluorescence for MitoSox red 
stained BMDM. Data are shown as mean ± SEM with one-way ANOVA and Sidak’s post-hoc 
test (n=3, *p<0.05). The scale bar is 5µm. 
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Figure 4.15. Lysosome/phagolysosome specific cresyl violet staining does not influence 
mROS or endoplasmic reticulum detection. Mouse BMDM were challenged with S. 
pneumoniae and incubated for 16 hours. Then, BMDM were stained with cresyl violet to stain 
lysosomes/phagolysosomes and separately alone with either MitoSox red to detect mitochondrial 
ROS (mROS) or ER-Tracker™ Red to detect endoplasmic reticulum (ER) for 15 minutes. Panel 
A shows no mROS signal in lysosome/phagolysosome cresyl violet (green) single stained B 
MDM. Panel B shows no lysosome/phagolysosome signal in mROS (red) MitoSox red single 
stained cells. Panel C shows no ER signal in lysosome (green) cresyl violet single stained cells. 
Panel D shows no lysosome/phagolysosome signal from ER (pink) c ER-tracker single stained 
cells. Panel A and B images were captured with 488nm and 633nm excitation lasers and 565-
615nm and 650-704nm emission spectrums. Panel C and D images were captured with 543nm 
and 633nm excitation lasers and 560 and 650-704nm emission spectrums. Images were 
reconstituted by Imagej using 17x17 hat filter. Images are representative of three independent 
experiments. The scale bar is 5µm. 
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4.7. S. pneumoniae induces nitric oxide and mROS that co-localise with 
bacteria in the phagolysosomal compartment 
Macrophages initiate bacterial internalisation via phagocytosis through forming a 
phagosome at the plasma membrane. Subsequently the phagosome fuses with the early 
endosome, then late endosomes and finally with lysosomes to form a phagolysosome 
(Aderem and Underhill, 1999). The phagosome plasma membrane contains NADPH 
oxidase (NOX2) which generate an oxidative burst, producing reactive oxygen species 
(ROS) and inducible nitrogen oxide synthase (iNOS), generating the nitric oxide (NO) 
radical. Moreover, ROS and NO radicals are able to interact and generate reactive 
nitrogen species (RNS), such as peroxynitrite (ONOO-), which is a more potent 
intracellular bactericidal mediator (Fang, 2004). The NADPH oxidase generates a more 
vigorous oxidative burst in neutrophils compared to macrophages.  
In contrast macrophages generate more vigorous NO responses, particularly rodent 
macrophages (Nathan and Shiloh, 2000), and have more mitochondria that produce 
mROS, which have an antimicrobial role in macrophages (West et al., 2011a).  Although 
in the earlier sections of this chapter, I have shown that macrophage mROS are co-
localised with bacteria in the phagolysosome, it was important to show whether mROS 
interacts with NO in the phagolysosome to form more potent RNS like peroxinitrite, since 
macrophages fail to generate the more potent halogenated ROS species as they usually 
lack myeloperoxidase and many bacteria like S. pneumoniae have well developed 
antioxidant defences against ROS (Aberdein et al., 2013). Thus it was important to 
establish if mROS was being generated in the vicinity of NO, with which it could react 
to form RNS, and whether both of these were adjacent to bacteria.  
To observe mROS and NO co-localisation with S. pneumoniae or with the 
phagolysosome, Alexa Fluor-647 labelled opsonised S. pneumoniae was used to 
challenge mouse BMDM for 16 hours. mROS and NO were co-stained with Alexa Fluor 
labelled pneumococci and images illustrate that most of the NO signal was co-localised 
with mROS (yellow pixel), and some of this signal either co-localised or was located 
proximally to S. pneumoniae (blue) (Figure 4.16A-B). Similarly, the mROS, NO and 
phagolysosome co-stained images demonstrate that mROS and NO were frequently co-
localised (yellow pixels) and these microbicidals were co-localised or juxtaposed with 
the phagolysosome in macrophages challenged with S. pneumoniae, while mock-infected 
macrophages had very little staining for mROS or NO (Figure 4.17A-B). Quantification 
of this data also showed that S. pneumoniae significantly increased the fluorescence 
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intensity of DAF-FM diacetate-labelled NO in macrophages challenged with S. 
pneumoniae compared with mock-infected macrophages (Figure 4.17C). Moreover, the 
co-localisation quantification data also demonstrated that most of the mROS colocalised 
with NO (Figure 4.17D), while approximately 20% of macrophages with mROS and NO 
were either co-localised or proximally stained with S. pneumoniae and 40% were co-
localised or proximal to phagolysosomes (Figure 4.17D). I also confirmed that 
macrophages stained with cresyl violet to label lysosomes and phagolysosomes did not 
produce any background influencing the detection of mROS with MitosSox red (Figure 
4.18A) or NO with DAF-FM diacetate (Figure 4.18B) and that conversely these stains 
did not pick up any signal when trying to detect phagolysosomes (Figure 4.18C). 
 
 
 
Figure 4.16. Mitochondrial ROS and nitric oxide are co-localised with S. pneumoniae in 
macrophages. Mouse BMDM were challenged with Alexa Fluor 647 labelled opsonised S. 
pneumoniae (D39) and incubated for 16 hours. Then mitochondrial ROS (mROS) and nitric oxide 
(NO) were stained with MitoSox-red and DAF-FM diacetate, respectively. Panel A (top panel) 
shows the representative fluorescence images of mROS (red) and NO (green) in mock-infected 
BMDM. Panel B (bottom panel) shows the representative fluorescence images of mROS (red), 
NO (green) and alexa fluor 647 labelled D39 (blue) in BMDM challenged with D39. Images were 
captured by Zeiss LSM510 inverted confocal microscopy with 488nm excitation and 565-615nm 
emission spectrum for MitoSox red, and 633nm excitation and 650-704nm emission spectrum for 
Alexa Fluor 647 labelled D39. 63x1.4 oil with zoom 2 objective images were reconstituted by 
ImageJ using 17x17 hat filter. In the merged image the arrow shows mROS and NO are adjacent 
to bacterial clumps. The scale bar is 5µm. 
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Figure 4.17. Mitochondrial ROS and NO are co-localised with phagolysosomes. Mouse 
BMDM were challenged with opsonised S. pneumoniae (D39) for 16 hours followed by staining 
with nitric oxide (NO) using DAF-FM diacetate, mitochondrial ROS (mROS) using MitoSox-red 
and lysosome/phagolysosome using cresyl violet. Panel A (top panel) shows the representative 
fluorescence images of mROS (red), NO (green) and lysosome/phagolysosome (pink) in mock-
infected (MI) BMDM. Panel B (bottom panel) shows the representative fluorescence images of 
mROS (red), NO (green) and lysosome/phagolysosome (pink) in BMDM after challenge with 
D39. Images were captured by Zeiss LSM510 inverted confocal microscopy with 543nm 
excitation and 565-615nm emission spectrum for MitoSox red, 488nm excitation and 500-530nm 
emission spectrum for DAF-FM diacetate, and 633nm excitation and 650-704nm emission 
spectrum for cresyl violet. 63x1.4 NA oil with zoom 2 objective images were reconstituted by 
ImageJ using 17x17 hat filter. The scale bar is 5µm. Figure C shows the corrected total cell 
fluorescence for NO, measured by ImageJ from DAF-FM diacetate stained mock-infected (MI) 
and D39 exposed mouse BMDM. Figure D shows the percentage of macrophages with co-
localisaed signal or proximal signal in mROS with either NO or D39, and mROS with either NO 
or lysosome/phagolysosome, and D39 or phagolysosome with ER as negative comparators. Data 
are shown as mean ± SEM and statistical analysis was performed with student paired t-test (n=3, 
*p<0.05). 
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Figure 4.18. Mitochondrial ROS signal does not influence NO or lysosome/phagolysosome 
detection in macrophages. Mouse BMDM were challenged with opsonised S. pneumoniae 
(D39) for 16 hours. Then BMDM were co-stained with MitoSox red to stain mitochondrial ROS 
(mROS) and either with DAF-FM diacetate to detect nitric oxide (NO) or cresyl violet to detect 
lysosomes/phagolysosomes. Panel A (top row) shows no detectable NO or lysosomal signal in 
mROS MitoSox red (red) single stained BMDM. Panel B (middle row) shows no detectable 
mROS or lysosomal signal in the NO (green) DAF-FM diacetate single stained macrophages. 
Panel C (bottom row) shows no detectable mROS or NO signal in the lysosome/phagolysosome 
(pink) cresyl violet single stained cell. All representative images were taken from three 
independent experiments and these were captured with 488nm excitation laser and 500-530nm 
(for NO), 543nm excitation and 565-615nm (for mROS), and 633nm excitation laser with 650-
704nm emission spectrum (for lysosomes/phagolysosome). Representative images were 
reconstituted by Imagej using a 17x17 hat filter. The scale bar is 5µm. 
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4.8. Inhibiting mitochondrial ROS restores mitochondrial respiration 
capacity 
Reactive oxygen species (ROS) act as a redox signalling molecule. This signalling is 
essential for cellular homeostasis, which is maintained with low levels of ROS. But 
excessive ROS is detrimental for cell physiological function. This causes oxidative 
damage of macromolecules such as DNA and protein, which ultimately promotes cell 
death (Circu and Aw, 2010). I next investigated whether mROS generated in 
macrophages in response to S. pneumoniae modulates mitochondrial metabolism beyond 
its earlier reported bactericidal effect.  
To observe mROS effect on mitochondrial metabolism, especially on mitochondrial 
OXPHOS, mouse BMDM were pre-treated with MitoTempo, which abrogates production 
of mitochondrial matrix-specific superoxide and alkyl radicals. Subsequently, BMDM 
were challenged with opsonised S. pneumoniae for 12 hours, and then the mitochondrial 
metabolic outputs were observed by the extracellular flux analyser. MitoTempo failed to 
alter the significant increase in glycolysis associated with S. pneumoniae in macrophages 
(Figure 4.19A-B) and did not alter the increase in non-mitochondrial OCR associated 
with S. pneumoniae (Figure 4.19C). Mitochondrial ROS abrogation with MitoTempo had 
no effect on basal oxygen consumption rate (Figure 4.20B) but significantly increased 
maximal mitochondrial respiration capacity in pneumococcal challenged mouse BMDM 
compared to mock-infected BMDM (Figure 4.20C and 4.20D), although this only 
represented partial restoration. However, inhibiting mROS production neither 
ameliorated ATP-linked OXPHOS (Figure 4.20E) nor altered proton leak (Figure 4.20F) 
in pneumococcal challenged macrophages.  
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Figure 4.19. MitoTempo does not alter S. 
pneumoniae induces glycolytic metabolism and 
non-mitochondrial oxygen consumption. Mouse 
BMDM were pre-treated with MitoTempo (MT) or 
vehicle control, then mock-infected or challenged 
with opsonised S. pneumoniae (D39) for 12 hours. 
Then, the glycolysis rate was calculated by 
determining the extracellular acidification rate 
(ECAR) and the mitochondrial oxygen consumption 
rate (OCR) was also measured by the extracellular 
flux analyser. From the normalised ECAR rate over 
the first 40 minutes (A) the basal ECAR (B) was 
determined and from rotenone and antimycin A 
treated OCR the non-mitochondrial OCR (C) was 
calculated. Data are shown as mean ± SEM, and 
analysed by one-way ANOVA with Sidak’s post-
hoc test. (*p≤0.05, **p ≤0.01, n=4). 
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Figure 4.20. Inhibiting mROS partially restores mitochondrial maximal respiration capacity 
after pneumococcal challenge. Mouse BMDM were pre-treated with MitoTempo (MT) or 
vehicle control, then mock-infected (MI) exposed to opsonised S. pneumoniae (D39) for 12 hours. 
Subsequently, the mitochondrial oxygen consumption rate (OCR) was measured by extracellular 
flux analyser. From OCR rate data (A) the mitochondrial basal respiration (B), maximum 
respiration capacity (MRC) (C), % of mitochondrial MRC in macrophages challenged with D39 
or D39 with MT treatment was compared to MRC in mock-infected macrophages in the same 
experiments, (D), ATP-linked OCR (E), and proton leakage (F) were calculated.  The ATP 
synthase inhibitor oligomycin A (oligo) was added after baseline OCR acquisition, to measure 
ATP-linked OCR. The maximum respiration capacity was measured by subtracting non-
mitochondrial OCR with rotenone (Rot) plus antimycin A (AntA) from FCCP treated OCR. Data 
were normalized by total protein of BMDM and shown as mean ± SEM. Statistical analysis was 
performed with one-way ANOVA with Sidak’s post-hoc test for multiple comparisons and 
student paired t-test for pair-wise comparisons. (*p≤0.05, **p ≤0.01, n=4).   
A. 
B. 
C. D. 
E. F. 
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4.9. Discussion 
In this chapter, I have observed that S. pneumoniae diminishes a variety of parameters 
associated with mitochondrial respiration capacity in human MDM and murine BMDM 
after a sustained period of bacterial exposure (16 hours). This include reductions in 
maximal respiration capacity and ATP-linked OCR while enhancing proton leakage. 
Challenge with S. pneumoniae also induced a switch to glycolytic metabolism and this 
was apparent from 4 hours after bacterial exposure. While some of the changes in 
mitochondrial metabolism were apparent either with statistical significance or with a non-
significant trend at 4 hours the proton leakage was really only noted at the later 16 hour 
time point. I have also observed that mitochondrial maximal respiration capacity and 
ATP-linked oxygen consumption rate is downregulated in COPD MDM and proton 
leakage is higher. The maximal respiration capacity and respiratory reserve fell further 
after challenge with S. pneumoniae in COPD MDM. Moreover, I have also assessed the 
metabolic phenotype of human MDM pre-treated with a physiologically relevant 
concentration of recombinant HIV-1 envelop glycoprotein gp120 (100ng/mL), which is 
observed in HIV-1 seropositive bronchoalveolar lavage (BAL) specimens (Collini et al., 
2018).  
In addition, I have also observed that S. pneumoniae triggers mROS and NO, which were 
concentrated in the vicinity of the phagolysosomes and co-localised with intracellular 
bacteria. The latter observation support a role for mROS and NO in the delayed-phase of 
bacterial killing in the phagolysosome, when other initial canonical killing strategies such 
as phagosomal oxidative burst are exhausted. A recent study by West et al. has also 
demonstrated that TLR-agonists induce a TRAF6 signalling pathway which upregulates 
the post-translational modification involving ubiquitination of ECSIT which is involved 
in the assembly of the mitochondrial OXPHOS component complex I (NADH ubiquinone 
oxidoreductase), that augments mROS production. mROS are subsequently produced 
adjacent to  the phagosome, where it participates in intracellular bacterial killing (West et 
al., 2011a).  Presumably, the mitochondrial electron transfer complexes especially 
complex I and III (cytochrome c reductase) are the major sites of mROS production, 
which are upregulated with aging and pathological stress conditions (Raha and Robinson, 
2000). In addition, a previous study also demonstrated that during apoptosis 
mitochondrial outer membrane permeabilisation (MOMP) causes caspase 9, and 
subsequently 3 activation, which induces mROS production when caspase 3 inhibits  
complex I and complex II (succinate dehydrogenase) of mitochondrial OXPHOS (Ricci 
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et al., 2003), suggesting that mROS production in macrophages challenged with S. 
pneumoniae could be a downstream process of apoptosis. This provides potential 
evidence that mROS may function both as a microbicidal and may be induced by 
apoptosis thus linking the observation of mROS production and apoptosis-associated 
bacterial killing in macrophages with intracellular pneumococci.  
In contrast, a previous observation has shown that S. pneumoniae also augments NO and 
reactive nitrogen species (RNS) production, and their accumulation initiates MOMP and 
loss of mitochondrial membrane potential in macrophages (Marriott et al., 2004a), which 
implies that RNS is probably involved as an upstream stimulus for apoptosis. NADPH 
oxidase (NOX2) generates the oxidative burst which is an early microbicidal response 
but as discussed this is a less well developed response in macrophages as compared to 
neutrophils or even monocytes (Aberdein et al., 2013). Macrophages also utilise other 
reactive microbicidals such as NO and RNS (Flannagan et al., 2009), but these can be 
produced with slower kinetics than the initial oxidative burst, especially in response to 
bacteria such as S. pneumoniae (Marriott et al., 2004a). Thus, canonical intracellular 
bacterial killing via NOX2 may not adequately explain the later generation of RNS. 
However, mROS and NO peaks have been observed at the same time point (i.e. 16 hours 
post-bacterial challenge) in macrophages after challenge with S. pneumoniae (Preston and 
Bewley et al., in revision). Their accumulation or co-localisation with the phagolysosome 
suggests they could either form potent RNS (e.g. peroxynitrite) to kill intracellular 
bacteria or could lead to indirect effects since mROS, NO and RNS can act as signalling 
molecules and might indirectly activate alternative microbicidal strategies, such as 
generation of proteases or transcription of antimicrobial peptides for example.  
This microbicidal response involving mROS generation is linked with the metabolic 
reprogramming of macrophages in the presence of S. pneumoniae, which alters 
macrophages metabolic phenotype from OXPHOS to glycolysis with a decreased 
mitochondrial oxygen consumption and increased non-mitochondrial oxygen 
consumption. It is well established that the mitochondrial respiration chain and OXPHOS 
component cytochrome oxidase (Complex IV) reduces molecular oxygen (i.e. 
mitochondrial consumed oxygen) into water by addition of two pairs of electrons. The 
origin of these electrons is NADH and FADH2 reducing equivalents, which gained 
electrons from substrate oxidation, particularly during the Krebs cycle. Subsequently, the 
electrons pass through the electron carriers of the mitochondrial electron transport chain 
(ETC), which is coupled with pumping out protons from the mitochondrial matrix to the 
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intermembrane space, creating a proton gradient or proton motive force (Δp). This force 
drives protons back into the matrix by a nanomachine called ATP synthase (complex v), 
which generates energy (i.e. ATP from ADP and Pi) like a hydroelectric pump (Mitchell, 
1961). On the other hand, non-mitochondrial consumed oxygen also has lots of 
physiological roles apart from the oxidation of non-respirational derived substrates. For 
example, non-mitochondrial consumed oxygen can be utilised by NADPH oxidase and 
iNOS to generate reactive oxygen and nitrogen species, respectively. These species are 
well recognised immune components in the first line of microbicidal defence. In addition, 
macrophage consumed non-mitochondrial oxygen can be either reduced to oxygen anion 
(e.g. superoxide, mROS) by single electron leakage from the mitochondrial respiration 
chain, or used to produce NO by the inducible nitric oxide synthase (iNOS) at later points 
of infection. Presumably, NO has a negative effect on mitochondrial OXPHOS by 
nitrosylating iron-sulfur rich proteins in complex I of ETC (Emilio et al., 1998, Drapier 
and Hibbs Jr, 1988). 
 Interesting, I have also observed that S. pneumoniae induces proton leak through the 
mitochondrial inner membrane, which could be a plausible reason of our group’s previous 
observation, regarding the loss of mitochondrial inner transmembrane potential (ΔΨm) 
and subsequent induction of mitochondrial apoptosis (Marriott et al., 2004a). However, 
it is not clearly established how intracellular bacteria induce proton leak and electron leak 
from the mitochondrial ETC. The basal proton leak is a natural process and it is 
indispensable for heat generation and acclimatisation (Brand et al., 2005). The basal 
proton leak contributes significantly to the maintenance of basal metabolic rate (BMR) 
and involves mitochondrial anion carrier proteins such as the adenine nucleotide 
translocase (ANT) uncoupling protein I (UCP1), especially in brown adipose tissue 
(Brand et al., 2005, Parker et al., 2009). The basal proton leak is induced by fatty acids 
and reactive alkenals (e.g. hydroxynonenal), which upregulate ANT and UCPs (Parker et 
al., 2008). The proton leak causes loss of proton motive force (Δp), which is essential for 
mitochondrial ATP generation.  
Moreover, mROS production is highly sensitive to the decreased Δp and is reduced by 
proton leak (Papa and Skulachev, 1997). These observations led me to hypothesise that 
S. pneumoniae enhanced mROS and NO generation, and induced proton leak (i.e. 
mitochondrial uncoupling). NO could do this by stimulating loss of ΔΨm while proton 
leak could limit excessive mROS generation. A consequence of this increased proton leak 
would, however, be to shift metabolism away from OXPHOS would be result in 
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mitochondrial metabolic reprogramming. To reconstitute the disrupted mitochondrial 
respiration, I have applied MitoTempo, a superoxide dismutase mimetic and observed 
that it restored approximately 25% of mitochondrial respiration capacity in pneumococcal 
challenged macrophages. However, MitoTempo neither rescued the loss of ATP-linked 
OCR nor reversed the proton leak across the mitochondrial inner membrane in 
pneumococcal challenged macrophages. However, since NO can drive loss of ΔΨm, 
(Belén et al., 2000) a role for NO in inducing proton leak it might be that both 
microbicidals need to be inhibited to more effectively restore mitochondrial metabolism. 
This suggests a paradigm in which infection not only activates glycolytic metabolism but 
that the mitochondrial metabolic reprogramming also results in mitochondria becoming 
key effectors of microbicidal responses. But that mitochondrial responses to these 
changes ultimately result in further adaptions OXPHOS, such as increased proton leak 
and loss of ΔΨm, which ultimately leads to apoptosis. Mitochondrial homeostasis is not 
only regulated by metabolism, but also by active changes in mitochondrial dynamics 
(Mishra and Chan, 2016), which will be focused on in the next chapter. 
A recent study has demonstrated that oxidative stress with HIV-1 glycoprotein gp120 not 
only diminishes mitochondrial respiration capacity but also alters mitochondrial 
dynamics in neurons (Avdoshina et al., 2016), suggesting that changes in mitochondrial 
dynamics may also be a feature of the conditions I studied. Moreover, HIV-1 seropositive 
patients are more susceptible to lung infection and bacterial colonisation (Gordin et al., 
2008, Yin et al., 2012), so these mitochondrial changes may have functional changes of 
physiological relevance to host defence. Recently, our group has observed that 
recombinant gp120 increases mROS at baseline, but S. pneumoniae fails to induce further 
increases of mROS production in human MDM pre-treated with gp120 (Collini et al., 
2018), as seen for COPD alveolar macrophages responses following pneumococcal 
challenge (Bewley et al., 2017). Thus it appears an increased level of production is not 
sufficient for acute responses to bacteria and what is required in acute induction. It may 
be that chronic increases in HIV or COPD result in compensatory increases in aspects of 
the antioxidant defence that limit the capacity for acute induction of mROS. Interestingly, 
I have observed that recombinant gp120 not only decreases basal proton leak but also 
diminishes the upregulation of proton leak in pneumococcal challenged macrophages 
(Figure 4.3H). This modification is predicted to be linked with a limited mROS 
production from complex I and downregulation of MOMP and caspase 3 activation in 
macrophages (Ricci et al., 2003). 
Page | 151 
 
Apart from other comorbidities, S. pneumoniae is a major cause of community-acquired 
pneumonia in COPD and lung pathogens especially Haemophilus influenzae, S. 
pneumoniae and Moroxella catarrhalis are involved in infection-associated 
exacerbations in COPD (Sapey and Stockley, 2006, Torres et al., 1996). Furthermore, 
recently we have demonstrated that COPD alveolar macrophages (AM) have increased 
mROS at baseline, but pneumococcal challenge does not induce mROS production, in 
contrast to the mROS induction in healthy AM (Bewley et al., 2017). Besides, this 
observation with COPD AM another contemporary observation in the COPD MAP 
consortium study with COPD airway small muscle cells (ASM) was that ASM also were 
to have increased mROS at baseline. The latter study has also observed mitochondrial 
metabolic impairments. In particular the investigators observed a diminished 
mitochondrial respiration capacity, an increased proton leak and loss of inner 
mitochondrial transmembrane potential (ΔΨm) in COPD ASM (Wiegman et al., 2015). 
Interestingly, my findings have also shown mitochondrial metabolic impairments in 
COPD MDM. For instance, I observed that COPD MDM have a decreased mitochondrial 
respiration capacity and ATP-linked OCR, and an increased proton leak, suggesting that 
circulatory MDM in COPD also carry the signature of metabolic impairment, similar to 
that seen for lung structural cells in COPD, such as ASM.  
However, most of my COPD MDM metabolic data did not reach statistical significance 
because the metabolic response was quite variable between donors and the sample size 
was small. It would have been desirable to obtain access to more samples but this was not 
possible before the end of that consortium. In addition, I also acknowledge a caveat to my 
study, which was that my observations were limited only to human circulatory MDM or 
mouse BMDM rather than tissue macrophages (e.g. alveolar macrophages). Besides, I 
was unable to check the metabolic phenotype of AM either in COPD or HIV-1 
seropositive patients, since investigating the metabolic phenotype with the XF24 flux 
analyser needs approximately 3 million macrophages from each donor. Practically these 
numbers weren’t readily available in BAL specimens due to limited yields particularly in 
COPD and competing demands for samples as part of the COPD MAP consortium. 
However, every technique has some pros and cons, and other techniques such as NMR or 
mass spectrometry could be applied to confirm my observed metabolic phenotype with 
tissue macrophages.  
Overall, this section shows that S. pneumoniae not only impairs mitochondrial respiration 
capacity but also stimulates increased mROS production in human MDM as well mouse 
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BMDM. The confocal images and respective quantitative data suggest that mROS along 
with NO accumulate proximal to the phagolysosome and co-localise with intracellular 
pneumococci. Moreover, this chapter has emphasised a role for alterations in macrophage 
mitochondrial metabolism in COPD and HIV-1 glycoprotein gp120 pre-treated 
macrophages, which implies that these diseases not only impair macrophage 
mitochondrial oxidative phosphorylation but also impinges mitochondrial innate immune 
responses to S. pneumoniae. Finally, regulation of mitochondrial bioenergetics responses 
appears a necessary component of arming the mitochondria to become more effective at 
becoming effectors of the microbicidal response to pneumococci. Since mitochondrial 
bioenergetics is only one aspect of mitochondrial homeostasis, which is also influenced 
by mitochondrial dynamics, I next addressed the latter process in a later chapter of my 
thesis.  
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5.1. Introduction  
Mitochondria play a pivotal role in cellular homeostasis mainly by maintaining cellular 
metabolism, proliferation and apoptosis. These functions are regulated by mitochondrial 
dynamics including division (i.e. fission) or integration (i.e. fusion) (Benedikt, 2010). In 
addition, morphologically mitochondria are extended throughout the cytosol and mostly 
are interconnected to maintain dynamic behaviour through constant fission and fusion  
(Prashant and David, 2014). Recently, it has been shown that Dynamin-related protein 1 
(Drp1) and endoplasmic reticulum (ER)-mitochondrial tethering is essential to trigger 
mitochondrial fission (Sesaki et al., 2014, Kornmann et al., 2009). In addition to 
homeostatic roles, Stavru et al. have demonstrated that bacterial pore-forming toxins (e.g. 
listeriolysin O, a cholesterol dependent cytolysin) induce mitochondrial fission by a Drp1 
independent non-canonical manner. They have also shown that this non-canonical fission 
is rather dependent on calcium efflux from ER, which is regulated at points of ER-
mitochondrial tethering by F-actin polymerisation (Stavru et al., 2013).  
Moreover, oxidative stress also triggers uncontrolled mitochondrial fission or 
fragmentation, which accentuates excessive mitochondrial ROS (mROS) production and 
results in subsequent loss of inner mitochondrial transmembrane potential. The loss of 
inner transmembrane potential in turn can induce either apoptosis or aberrant autophagy 
(Qi et al., 2013). LPS upregulates mROS production and induces mitochondrial fission 
via a Drp1-dependent mechanism (e.g. phosphorylation of Drp1 at serine 616), which is 
inhibited by the ROS scavenger N-acetyl cysteine (Katoh et al., 2017), suggesting that 
ROS is mechanistically linked to mitochondrial fission and may be triggered by bacterial 
components. On the other hand, inhibition of mitochondrial fission inhibits ROS 
overproduction in hyperglycaemia-associated disorder (Yu et al., 2006).  Collectively, 
this indicates that excessive fission and ROS production can produce a vicious cycle and 
that ROS is not only a factor that triggers fission but also a result of increased fission. 
Mitochondrial fission is also associated with metabolic reprogramming from 
mitochondrial OXPHOS to glycolysis in activated T cells (e.g. effector T cells) (Buck et 
al., 2016).  
Mitochondrial fission/fusion plays a critical role in determining cell fate since it is 
associated with apoptosis induction. For example, inhibition of Fission 1 protein (Fis1) – 
which binds activated Drp1 to initiate mitochondrial fission - inhibits apoptosis (Lee et 
al., 2004) whilst overexpression of Fis1 upregulates apoptosis (James et al., 2003). 
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Inhibition of mitochondrial fission also inhibits cytochrome c release from the 
mitochondrial intermembrane space to the cytosol (Richard and Mariusz, 2005). 
Cytosolic cytochrome c activates caspase-9, which activates apoptosis executioners 
caspase-3 and caspase-7 (Stephen and Douglas, 2010), suggesting that mitochondrial 
fission is an upstream process of apoptosis.  
Furthermore, it has been demonstrated that depolarised mitochondria recruit Parkin (an 
E3 ubiquitin ligase), which acts in concert with Phosphatase and tensin homolog (PTEN)-
induced kinase 1 (PINK1) upregulates apoptosis through switching on the degradation of 
anti-apoptotic protein Mcl-1 by polyubiquitination (Carroll et al., 2014). In contrast, 
Parkin and PINK1 accumulation on depolarised mitochondria also plays a role in 
mitophagy and triggers mitochondrial disintegration and elimination by mitophagy 
through recruiting microtubule-associated protein 1- light chain 3 (LC3)-binding adaptor 
protein p62 and neighbour of breast cancer 1 (BRCA1) protein (NBR1). These then form 
a double membrane around the fragmented mitochondria (i.e. an autophagosome) and 
subsequently fuse with lysosomes. This is called selective autophagy or 
macroautophagy/mitophagy  (Narendra et al., 2008). The extent to which the cells 
complement of mitochondria are depolarised and decorated with parkin appears to 
influence whether the cell activates apoptosis and dies or mitophagy as a survival strategy 
(Carroll et al., 2014). Overall, this implies that eukaryotic cells mitochondria not only 
supply energy but also act as a molecular check point for cell death.  
Aside from these concepts, recent research has revealed a role for mitochondria in innate 
immunity, separate from energy production (Manan et al., 2017). However, to the best of 
my knowledge, little research has examined mitochondrial dynamics during innate 
immune responses, during host-pathogen interactions. Hence, I observed mitochondrial 
morphology after challenge with bacteria (S. pneumoniae) and related these to key steps 
during the host-pathogen interaction such as metabolic reprogramming, mROS 
production in macrophages and its role in intracellular bacterial killing.  
 5.2. S. pneumoniae upregulated Drp1-independent mitochondrial 
fission in macrophages 
Constitutive mitochondrial division (i.e. fission) and fusion processes are not only 
essential to preserve mitochondria function but also regulate cellular life-death decisions 
(Chan, 2012). Normal mitochondrial homeostasis is perturbed by excessive fission due 
to oxidative cues (Qi et al., 2013) or bacterial pore-forming toxins (Stavru et al., 2011). 
Our group previously has shown that fully differentiated macrophages have greater 
Page | 156 
 
mitochondrial volume compared to undifferentiated monocytes or less differentiated 
macrophages (Daigneault et al., 2010).  
To assess mitochondrial morphological features of differentiated macrophages, mouse 
bone marrow-derived macrophages were challenged with S. pneumoniae for 12 hours, 
subsequently the mitochondrial outer membrane protein, Tom20, was labelled using 
immunofluorescence. Confocal microscopy images and ImageJ-processed skeletonised 
images illustrated that morphologically mitochondria are mostly tubular, maintain an 
inter-connected network and extend throughout the cytoplasm in mock-infected 
macrophages (Figure 5.1A and C). Whereas, mitochondria of pneumococci exposed 
macrophages are mostly fragmented and dispersed throughout the cytosol (Figure 5.1B 
and D). Moreover, pneumococci significantly decreased mitochondrial network 
complexity whether prior treated with or without Drp1 assembly inhibitor, Mdivi-1 
(Figure 5.1E for the individual macrophages mitochondrial population and 5.1F of 
average network complexity), suggesting that pneumococci induced mitochondrial 
fission occurs in a Drp-1 independent manner. The time course fission frequency data 
demonstrate that pneumococci triggers mitochondrial fission from 12 hours onwards 
(Figure 5.1G). As a control, Mdivi-1 alone had no effect on mitochondrial complexity.   
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Figure 5.1. S. pneumoniae induces mitochondrial fission in a Drp1 independent manner. 
Mouse BMDM were exposed to serotype 2 S. pneumoniae (D39, MOI of 10) for 8, 12 and 14 
hours. Then, cells were fixed, permeablised and blocked with 4% paraformaldehyde, 0.1% triton-
x-100 and 0.2% gelatin in PBS, respectively. Subsequently, the mitochondria specific marker 
Tom20 was labelled with rabbit anti-Tom20 primary antibody (0.4µg/mL) and goat anti-rabbit 
IgG (H+L) (4µg/mL) conjugated with Alexa Fluor 488. Images were captured by Zeiss LSM510 
confocal microscopy using 488nm excitation and 500-530nm emission spectrum. Figure A shows 
the representative mitochondrial images of mock-infected and B shows the mitochondrial image 
of D39 exposed BMDMs after 12 hours. Figure C and D illustrate the representative skeletonised 
mitochondrial images rebuilt by ImageJ from the corresponding images in figures A and B. Figure 
E shows the mitochondrial network complexity, with each dot representing the ratio of total 
branch points and end points of the total mitochondrial population of each macrophage. Figure F 
shows the average network complexity of total mitochondrial population of each donor mouse 
BMDM-MI BMDM-Spn A. B. 
C. 
D. 
 
E. F. G. 
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BMDM. The network complexity was quantified by ImageJ from the mitochondrial images of 
mock-infected or D39 exposed BMDM after 12 hours, with or without pre-treatment with the 
Drp1 assembly inhibitor Mdivi-1. Figure G shows the percentage of macrophages with 
fragmented mitochondria at 8, 12 and 14 hours post-bacterial challenge. Mitochondrial network 
complexity and percentage of macrophages with fragmented mitochondria were calculated from 
three independent experiments. Data are shown as mean ± SD. Statistical analysis was performed 
with One-way ANOVA and Bonferroni post-hoc test, *p<0.05). Scale bars = 5µm.  
 
5.3. Activated Drp1 is not recruited on fragmented mitochondria after 
pneumococcal challenge 
Mitochondrial fission is positively regulated by Drp1.  Drp1 phosphorylated at serine 616 
is essential for mitochondrial division/fission (Mishra and Chan, 2016). This activated 
Drp1 (Ser616 phosphorylated-Drp1) binds with Fis1 on mitochondrial outer membranes 
and oligomerises, to constrict the mitochondrial membranes and trigger fission or 
division. This process is inhibited by Mdivi-1, a Drp1 assembly inhibitor (Cassidy-Stone 
et al., 2008). In the previous section, I showed that macrophages pre-treated with Mdivi-
1 did not have a reduction in mitochondrial fission (Fig 1E-F). To further confirm Drp-1 
independent fission, human MDM were challenged with S. pneumoniae. Subsequently 
mitochondria and serine-616 phosphorylated-Drp1 were co-stained using 
immunofluorescence method. Mitochondria and P-Drp1 co-staining images illustrated 
that there is no association of phosphorylated Drp1 with mock-infected macrophages 
mitochondria or mitochondria from pneumococcal challenged macrophages (Fig 5.2A-
B). Whereas MDM treated with FCCP, a known activator for mitochondrial fission, show 
phosphorylated Drp1 associated with fragmented mitochondria (Fig 5.2C).  
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Figure 5.2. S. pneumoniae induces p-Drp-1 independent mitochondrial fission. Human MDM 
were exposed to S. pneumoniae (D39, MOI of 10) for 16 hours. Then the mitochondria specific 
marker Tom20 and serine-616 phosphorylation (p-Drp1) specific dynamin related protein-1 (p-
Drp1) were labelled by mouse anti-Tom20 and rabbit anti-p-Drp1 primary antibodies. The 
following respective secondary antibodies were also used: goat anti-mouse IgG conjugated with 
Alexa Fluor 488 and goat anti-rabbit IgG conjugated with Alexa Fluor 568. The figure shows the 
representative images of mitochondria and p-Drp1 in macrophages with mock-infected (A, top 
panel) and macrophages challenged with D39 for 16 hours (B, middle panel). Panel C illustrates 
the representative images of mitochondria and p-Drp1 in macrophages treated with the 
mitochondrial OXPHOS uncoupler Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone 
(FCCP, 20µM). Images were captured by Zeiss LSM510 confocal microscopy using 488nm and 
543nm excitation with 500-530nm and 565-615nm emission spectrum, respectively. White 
arrows in the panel C merge image show the mitochondrial and p-Drp1 co-localised pixels 
(yellow). Images are representative of images from three independent experiments. Scale bars = 
5µm.  
 
 
 
 
 
B. 
A. 
C. 
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5.4. Pneumolysin is not essential for mitochondrial fission but 
metabolically active S. pneumoniae is 
Pneumolysin is a critical virulence factor for pneumococci and it belongs to the family of 
cholesterol-dependent cytolysins. Prior reports suggested that this family of pore-forming 
toxins, for example listeriolysin O from Listeria monocytogenes, triggers mitochondria 
fission in a Drp1-independent manner (Stavru, 2011 and Stavru, 2013). To assess the 
microbiological requirements for mitochondrial fission particularly pneumolysin’s role 
in mitochondrial fission, mouse BMDM were challenged with heat inactivated 
pneumococci or a pneumolysin deficient pneumococcal (pneumolysin stop S. 
pneumoniae) strain (Bewley et al., 2014), at a comparable MOI to the wild-type. 
Mitochondrial morphological images demonstrated that live bacteria are essential to 
trigger mitochondrial fission (Figure 5.3B-C), and the pneumolysin deficient mutant 
could also trigger mitochondrial fission/fragmentation when a higher multiplicity of 
infection (MOI) of 40 or more was used, as compared to the MOI=10 used for wild-type 
pneumococci (Figure 5.3A-G). Moreover, exogenous pneumolysin also induced 
mitochondrial fission but only with a higher concentration (2.0µg/mL or more) (Figure 
5.3H). Together, these data suggest that pneumolysin could enhance mitochondrial 
fission but it is not essential to trigger mitochondrial fission with metabolically active 
intracellular bacteria. However, it is warranted to validate the pneumolysin’s effect on 
mitochondrial fission with exogenous pneumolysin a comparable cfu fo S. pneumonaie. 
Presumably, the sandwich ELISA is more applicable method to check the concentration 
of extracted pneumolysin and the hemolytic assay with rabbit red blood cell would be the 
best option to check the lytic concentration of  exogenous pneumolysin and pneumolysin 
from the comparable cfu of pneumocococci (Sanders et al., 2008). Moreover, it is also 
essential to check the purity of E. coli source exogenous pneumolysin. Although I used 
apparently pure exogenous pneumolysin which was produced from the His tagged E. coli 
followed by HPLC purification (Timothy J. Mitchell lab, Birmingham university) 
(Bewley et al., 2014), I would not check its comparable level produced by pneumococci 
(e.g. MOI of 10) which I was exposed to mouse BMDM. 
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Figure 5.3. Pore-forming toxin pneumolysin is not essential to trigger mitochondrial fission. 
Metabolically active S. pneumoniae (D39), heat inactivated D39, pneumolysin deficient D39 
(ΔPLY D39) or exogenous pneumolysin (0.5µg/mL-5µg/mL) were used to challenge mouse 
BMDM for 12 hours. The mitochondria specific marker Tom20 was labelled with rabbit anti-
Tom20 primary antibody and goat anti-rabbit IgG conjugated with Alexa Fluor 488, and nuclei 
were stained with Draq5. Images were captured by Zeiss LSM510 confocal microscopy using 
488nm excitation and 500-530nm emission spectrum. Panel A shows the representative 
mitochondrial images of mock-infected and metabolically active D39 (MOI of 10) exposed 
macrophages. Panel B shows the representative mitochondrial images of heat inactivated D39 
(MOI of 20 and 50) exposed macrophages. Panel C shows the representative mitochondrial 
images of pneumolysin deficient mutant D39 (MOI of 20 and 50) exposed BMDM. Figure D 
shows the mitochondrial representative images of exogenous pneumolysin (2.0 and 5µg/mL) 
treated macrophages. Scale bars = 5µm. Figure E shows the percentage of macrophages with 
fragmented mitochondria after mock-infection or challenge with metabolically active wild type 
E. F. 
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D39 (MOI of 10) or heat inactivated D39 (MOI of 10 to 50) or pneumolysin mutant D39 (MOI 
of 10 to 50). Figure F shows the percentage of macrophages with fragmented mitochondria after 
treatment with 0.5µg/mL-5µg/mL of exogenous pneumolysin for 12 hours.  Data were analysed 
with One-way ANOVA and Sidak’s post-hoc test and are shown as mean ± SD, n=3. ***p<0.001, 
**p<0.01, ns- non-significant p>0.05. 
 
 
5.5. S. pneumoniae exposure upregulates E3 ligase Parkin expression on 
fragmented mitochondria in macrophages 
Parkin is a cytosolic E3 ligase protein and mostly responsible for ubiquitination of 
misfolded or damaged proteins expressed on the outer mitochondrial membrane, which 
are subsequently removed via the 26S proteasome system (Trempe et al., 2013). It is well 
established that during mitochondrial stress conditions, Parkin is recruited to damaged 
mitochondria and triggers selective autophagy or mitophagy, to minimise cellular toxicity 
(Narendra et al., 2008). Genetic defects or mutations in Parkin causes mitochondrial 
dysfunction and leads to development of juvenile Parkinson disease (Tohru et al., 1998). 
Moreover, a few studies have also demonstrated roles for Parkin in innate immunity. For 
example, single nucleotide polymorphisms (SNPs) in the Parkin (PARK2) regulatory 
regions have been associated with increased susceptibility to intracellular bacteria, such 
as typhoid and leprosy in humans (Ali et al., 2006, Mira et al., 2004). Recently, it has also 
been shown that Parkin interacts with the mitochondrial TSPO-VDAC1 (translocator 
protein and voltage-dependent anion channel 1) protein complex to mediate innate 
defence against bacterial infection in Drosophila (Cho et al., 2015).  
Therefore, next I tested whether Parkin is involved with mitochondrial fission in 
macrophages in response to pneumococci. To assess this association, macrophages were 
challenged with pneumococci and then co-stained with anti-Parkin and anti-Tom20 
antibodies, and were assessed by immunofluorescence microscopy. Mitochondria and 
Parkin co-staining showed that pneumococci upregulated Parkin expression in 
macrophages compared to mock-infected cells (Figure 5.4A-B and 5.5A-B), and Parkin 
was mostly co-localised with fragmented mitochondria (Figure 5.5C). Moreover, the 
Drp1 assembly inhibitor, Mdivi-1 did not modulate Parkin expression after bacterial 
challenge (Figure 5.4C and 5.5A-B). In contrast, 3-methyladenine, a type I/III 
phosphatidyl-inositol-3 kinase (PI-3K) inhibitor reversed Parkin activation in response to 
pneumococci (Figure 5.4D and 5.5A-B). This observation is also corroborated by 
immunoblotting with subcellular fractions. Mouse BMDM challenge with pneumococci 
has shown a trend towards increased Parkin expression in both cytosolic and 
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mitochondrial fractions compared to mock-infected macrophage fractions (Figure 5.5D-
F). Moreover, 3-MA shows a trend towards decreased Parkin activation in the 
mitochondrial compartment of pneumococci exposed macrophages, compared to mock-
infected macrophages (Figure 5.5D-F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Macrophage exposure to S. pneumoniae induces mitochondrial E3 ligase parkin 
expression in association with fragmentation. Mouse BMDM were treated with Mdivi-1 or 3-
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MA for an hour, then exposed to S. pneumoniae (D39, MOI of 10) for 12 hours. Then, 
mitochondria and parkin were co-stained using rabbit anti-Tom20 (tagged with Alexa Fluor 568 
labelled-red) and mouse anti-Parkin antibody (tagged with Alexa Fluor 488-green). Each panel 
figure shows the representative images of mitochondria and Parkin in mock-infected (A), or 
pneumococci exposed macrophages (B), or in Mdivi-1 treated (C), or 3-MA treated 
pneumococcal exposed BMDM (D). Images were taken as the representative images from three 
independent experiments.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. Macrophages exposure to S. pneumoniae induces E3 ligase Parkin expression 
which translocate to mitochondria. Mouse BMDM were treated with 3-MA or Mdivi-1 for an 
hour, then exposed to S. pneumoniae (D39, MOI of 10) for 12 hours. Figure A shows the 
quantitative data obtained from figure 5.4, and shows the corrected total cell fluorescence (CTCF) 
for Parkin in each macrophages after pre-treatment with or without Mdivi-1 or 3MA, followed by 
mock infection or D39 exposure. Figure B shows the average CTCF for Parkin. Figure C shows 
the co-localisation quantification data as the Pearson’s correlation coefficient for mitochondrial 
outer membrane protein Tom20 and Parkin in mock-infected and D39 exposed BMDM from the 
same experiments. Immunoblotting was also performed after SDS-PAGE with the extracted 
cytosolic and mitochondrial fractions (n=2). Figure D shows the representative Immunoblots’ of 
the cytosolic fraction where it shows the bands for Parkin (50kD) and alpha-actin (40kD), and the 
mitochondrial fraction shows the bands for Parkin and voltage-dependent anion-selective channel 
1 (VDAC1; 32kD), used as a mitochondrial fraction loading control. Figure E and F show the 
ratio of Parkin/Actin and Parkin/VDAC1 for cytosolic and mitochondria fractions, respectively. 
Data are shown as mean ± SEM. Statistical analysis (for figure A-C, n=3) was performed with 
one-way ANOVA and Sidak’s post-hoc test and paired t-test (for figure B). *p<0.05, **p<0.01. 
E. F. 
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5.6. Fragmented mitochondria during S. pneumoniae challenge do not 
associate with the autophagy marker LC3B 
Autophagy is an evolutionarily conserved selective or non-selective intracellular 
lysosomal degradation process, which is essential to maintain cellular homeostasis 
(Klionsky and Codogno, 2013). This autophagosomal process is initiated by forming a 
double-membrane containing vacuole which is regulated by different sets of autophagy-
related core proteins (Atg). Among them, Atg8/MAP1LC3 or microtubule associated 
protein 1 light-chain 3 (i.e. LC3) – particularly in its form conjugated with phosphatidyl-
ethanolamine (a membrane bound LC3 also referred to as LC-II or LC3B) - is essential 
for autophagosome elongation and maturation, and its level is also correlated with the 
number of autophagosomes (Lee and Lee, 2016). Moreover, recently it has been 
demonstrated that Parkin ubiquitin ligase is harnessed to mediate autophagy/xenophagy 
associated intracellular killing of Mycobacterium tuberculosis, Listeria monocytogenes 
and Salmonella Typhimurium in macrophages (Manzanillo et al., 2013).  
Therefore, I hypothesised that macrophages might also recruit autophagy machinery to 
fragmented mitochondria generated in response to pneumococci, and subsequently clear 
them by mitophagy. To assess this hypothesis, mitochondria and LC3B were co-stained 
in macrophages after challenge with pneumococci. Immunofluorescence images, 
however, demonstrated that there was no-association of LC3B in fragmented 
mitochondria in response to bacterial internalisation (Figure 5.6A-B). Whereas, 
macrophages treated with a known mitochondria fission/fragmentation inducer Carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) upregulated LC3B and most of 
the LC3B was recruited to fragmented mitochondria (Figure 5.6C).  
Moreover, the topographical images with transmission electron microscopy (TEM) 
allowed observation of the ultrastructure of mitochondria. The TEM images demonstrated 
that there was no evidence of double membrane vacuoles around the fragmented 
mitochondria in macrophages, after challenged with pneumococci (Figure 5.7). In 
addition, the TEM images also depicted that mock-infected macrophage mitochondria are 
mostly tubular and maintain the distinctive cristae compartments, compared to 
pneumococci exposed macrophage mitochondria (figure 5.7A-B). Furthermore, the 
number of cristae per mitochondrion were significantly decreased in fragmented 
mitochondria after bacterial internalisation, compared to mock-infected macrophage 
mitochondria (figure 5.7C).   
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Figure 5.6. S. pneumoniae does not modulate the autophagy marker LC3B. Human MDM 
were exposed to S. pneumoniae (D39, MOI of 10) for 16 hours. Then the mitochondria specific 
marker Tom20 and LC3B were labelled by mouse anti-Tom20 and rabbit anti- LC3B primary 
antibodies, then respective secondary antibodies, goat anti-mouse IgG conjugated with Alexa 
Fluor 488 and goat anti-rabbit IgG conjugated with Alexa Fluor 568, were added. The figure 
shows the representative images of mitochondria and LC3B in macrophages after mock-infection 
(A, top panel) or D39 challenge (B, middle panel). Panel C illustrates the representative images 
of mitochondria and LC3B in macrophages treated with the mitochondrial OXPHOS uncoupler 
Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 20µM). Images were captured 
by Zeiss LSM510 confocal microscopy using 488nm and 543nm excitation with 500-530nm and 
565-615nm emission spectrums, respectively. White arrows in panel C merged image show the 
LC3B and mitochondrial co-localised pixels (yellow). Images shown are representative images 
from three independent experiments. Scale bars = 5µm.  
A. 
B. 
C. 
Mitochondria LC3B Merged with nucleus  
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Figure 5.7. Fragmented mitochondria following S. pneumoniae challenge do not engage with 
mitophagy. Mouse BMDM were exposed to S. pneumoniae for 12 hours. Then, cells were fixed 
using glutaraldehyde and osmium tetroxide followed by dehydration with 75-100% ethanol. 
Subsequently, macrophages pellets were embedded in Araldite Resin followed by sectioning into 
ultra-thin (90nm) sections using a diamond knife in a Ultramicrotome. Next, images of each 
section were captured following Transmission Electron Microscopy using an attached Gatan 
digital camera after staining with uranyl acetate and lead acetate. Figure A shows the 
representative TEM image of mock-infected macrophages. Figure B shows the representative 
TEM image of macrophages after exposure to pneumococci. Figure C shows the average number 
of cristae per mitochondrion in mock-infected and pneumococci exposed macrophages. Cristae 
number was counted from the ultrastructural images of mitochondria, from two independent TEM 
experiments. Data are shown as mean ± SD and statistical analysis was performed with paired t-
test. **p=0.0016. Scale bars = 500nm/0.5µm. 
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5.7. Fragmented mitochondria stay proximal to the 
lysosome/phagolysosome  
In the previous chapter, I have shown that mitochondrial ROS are generated close to the 
phagosome/phagolysosome and engage in intracellular bacterial killing. Recently West 
et al. have demonstrated that mitochondria also translocate to the phagosome and trigger 
mROS production, participating in intracellular bacterial killing. They  have also shown 
that mROS is generated via TLR-mediated signally involving tumour necrosis factor 
receptor-associated factor 6 (TRAF6), which in turn activates evolutionarily conserved 
signalling intermediate in Toll pathways (ECSIT) a protein contributing to mitochondrial 
respiratory chain assembly to enable intracellular killing in the 
phagosome/phagolysosome (West et al., 2011a).  
To investigate whether the fragmented mitochondria following bacterial challenge were 
associated with the phagolysosomes, mitochondrial (e.g. Tom20) and 
lysosomal/phagolysosomal (e.g. LAMP1- lysosome-associated membrane protein 1) 
markers were co-stained and immunofluorescence carried out. Co-stained fluorescence 
images of macrophages after bacterial internalisation demonstrated that Tom20 on 
fragmented mitochondria co-localises or is proximal with LAMP1, whereas in mock-
infected macrophages co-localisation was not apparent (Figure 5.8A-B). This observation 
suggests that fragmented mitochondria in macrophages, following interaction with 
bacteria, and the associated production of mROS, are associated with phagolysosomes, 
to maximise mitochondrial-mediated innate immune responses against intracellular 
bacteria. For example, the orthogonal view of a representative z-stack fluorescence image 
illustrated that mitochondria, mROS and intracellular pneumococci are proximally 
associated in macrophages (Figure 5.8C). 
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Figure 5.8. Fragmented-mitochondria in response to pneumococci are associated with 
lysosomes/phagolysosomes.  Human MDM were exposed to S. pneumoniae (D39, MOI of 10) 
for 16 hours, and mitochondria and lysosomes/phagolysosomes were co-stained using rabbit anti-
Tom20 (tagged with Alexa Fluor 568 labelled-red) and mouse anti-LAMP1 antibody (tagged with 
Alexa Fluor 488-green). Each panel shows the representative images of mitochondria and 
lysosomes/phagolysosomes in mock-infected (A), or pneumococci exposed macrophages (B). 
The white arrows in the panel B merged image shows the co-localised pixels (yellow) of Tom20 
and LAMP1. Representative images were taken from three independent experiments. Figure C 
shows the orthogonal view of mitochondrial ROS probe MitoSox red (red), Tom20 (green) and 
D39 (blue) in the same compartment. The white arrows (in figure C) shows the mROS (red) blobs 
on D39 (blue) and red arrow shows the mitochondrial area which is overlapped with D39. 
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5.8. Inhibiting mitochondrial fission by 3-methyladenine decreases 
mROS production 
Balanced mitochondrial dynamics (e.g. fission/fusion) are critical to maintain cellular 
homeostasis. In contrast, oxidative stress causes excessive mitochondrial 
fission/fragmentation, which is associated with mROS production and apoptosis in 
neuronal cells (Qi et al., 2013). In the literature, it has been shown that apart from 
Drp1/Fis1, mitochondrial protein MTP18 is also an important regulator of mitochondrial 
fission in mammalian cells (Tondera et al., 2005). Previously, this same group has also 
shown that MTP18 works as the downstream target of phosphatidyl-inositol-3 kinase (PI-
3K) signalling. They have shown that PI-3K inhibition, by the pan-PI-3K inhibitor 
Ly294002 or anti-sense RNA, not only blocks mitochondrial membrane protein MTP18 
expression at mRNA and protein levels, but also prevents fission-associated 
mitochondrial morphological alteration in HaCat/Cos-7 cells, which causes induction of 
apoptosis (Tondera et al., 2004). However, the latter observation is controversial because 
most of the literature suggests that mitochondrial fission rather than fusion occur as an 
upstream process of apoptosis (Suen et al., 2008). I hypothesised that PI-3K could also 
play a role in mitochondrial fission/fragmentation; following pneumococcal challenge. 
Therefore, mouse BMDM were pre-treated with the type I/III PI-3K inhibitor 3-
methyladenine and challenged with pneumococci for 12 hours, then mitochondrial outer 
membrane specific Tom20 was labelled and immunofluorescence measured as before. 
Pneumococci challenge induced mitochondrial fission, diminishing mitochondrial 
network complexity/mitochondrial connectivity, however, this effect was reversed with 
3-methyladenine treatment (Figure 5.9A-C). Moreover, 3-methyladenine also decreased 
mROS production from 12 hours onwards after pneumococcal challenge (Figure 5.9D).  
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Figure 5.9. The PI-3K inhibitor 3-methyladenine inhibits mitochondrial fission and mROS 
production in macrophages. Mouse BMDM were pre-treated with 3-methyladenine (3MA) or 
Pan-PI-3K inhibitor (Ly294002) for 1 hour. Next, BMDM were exposed to S. pneumoniae (D39, 
MOI of 10) for 12 hours. The mitochondrial outer membrane specific marker Tom20 was labelled 
using rabbit anti-Tom20 primary antibody and a secondary goat anti-rabbit IgG conjugated with 
Alexa Fluor 568. Images were captured by Zeiss LSM510 confocal microscopy using 543nm 
excitation and 565-615nm emission spectrums. Figure A shows the representative mitochondrial 
images of BMDM after mock-infection (MI) or challenge with D39 in the untreated or 3MA pre-
treated conditions, respectively. Figure B shows the mitochondrial network complexity of 
individual cell and figure C shows the average network complexity of each donor’s macrophages, 
which was quantified by the ImageJ from the mitochondrial images of BMDM with mock-
infected or D39 exposed for 12 hours, with or without 3MA pre-treatment condition (n=3). Figure 
D shows the mean fluorescence intensity for the mROS staining probe Mitosox red, from mouse 
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BMDM under the above mentioned conditions at 12, 14 and 16 hours time points. Data are shown 
as mean ± SD and statistical analysis was performed with one-way ANOVA and Bonferroni post-
hoc test. *p<0.05, **p<0.01, ***p<0.001, *ns- non-significant, n=5.   
 
 
 
5.9. Inhibition of PI-3K by 3MA restores mitochondrial inner 
transmembrane potential and decreases caspase activation  
Mitochondrial fission/fragmentation downregulates mitochondrial oxidative 
phosphorylation, ATP production, permeabilises the mitochondrial outer membrane, 
causing membrane blebbing and induces loss of mitochondrial inner transmembrane 
potential. Moreover, it has been shown that cytochrome c, an apoptosis initiator is 
released in to the cytosol from mitochondria, during mitochondrial fission/fragmentation 
in Hela cells (Suen et al., 2008).  Subsequently, cytochrome c activates caspases, to trigger 
apoptosis or programme cell death.  
To assess macrophages mitochondrial inner transmembrane potential and caspase activity 
after challenge with pneumococci, macrophages were stained with the mitochondrial 
inner transmembrane potential sensitive and live cell dyes, JC-1 and NucView 530, 
respectively. JC-1 is aggregated in intact mitochondria with polarised inner 
transmembrane potential, and loss of JC-1 aggregates implies loss of mitochondrial inner 
transmembrane potential (m). NucView 530 carries a caspase 3/7 substrate-tagged with 
DNA intercalating fluorescence dye, which is detached in the presence of caspases and 
binds with nuclear DNA. JC-1 stained macrophages were measured by flow cytometry. 
NucView 530 positive macrophages were counted via fluorescence microscopy. 
Pneumococci noticeably induced loss of m in macrophages 16 hours post-challenge, 
and the PI-3K inhibitor 3-methyladenine restored the loss of m (Figure 5.10 A-B). 
Moreover, pneumococci also upregulated the activity of intrinsic apoptosis mediators, 
caspases 3 and 7, in macrophages, particularly after 16 hours bacterial exposure (Figure 
5.10C), indicating that macrophage apoptosis occurs after mitochondrial fission. 
However, to further confirm this speculation, it would be important observe 
mitochondrial fission and apoptosis in the presence of caspase inhibitors (e.g the pan-
caspase inhibitor z-VAD-fmk) and show that this block apoptosis but not fission. 
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Figure 5.10.  The PI-3K inhibitor 3-methyladenine restores mitochondrial inner 
transmembrane potential and decreases macrophage apoptosis. Mouse BMDM were pre-
treated with 3-methyladenine (3MA) for 1 hour. Then, BMDM were exposed to S. pneumoniae 
(D39, MOI of 10) for 12, 14 or 16 hours. Figure A shows the percentage of macrophages showing 
loss of mitochondrial inner transmembrane potential (ΔΨm) or loss of JC-1 (5,5′,6,6′-tetrachloro-
1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide) aggregates from the mitochondrial inner 
transmembrane, after 16 hours of bacterial exposure (n=3). Figure B shows the mean fluorescence 
intensity of mitochondrial inner membrane, calculated from the data shown in Figure A. Figure 
C shows the percentage of macrophages with caspase 3/7 activity after 12, 14 and 16 hours of 
bacterial challenge. Caspase 3/7 activity was numerically counted by fluorescence microscopy 
after live cell staining with NucView 530, a caspase 3/7 substrate tagged with a fluorogenic DNA-
intercalating dye. Data are shown as mean ± SEM and statistical analysis (for figure A and B) 
was performed with one-way ANOVA and Bonferroni’s post-hoc test. Figure C data were 
analysed with one-way ANOVA and Sidak’s post-hoc test. *p<0.05, **p<0.01, ***p<0.001.    
B. A. 
C. 
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9.10. The PI-3K inhibitor, 3-methyladenine decreases intracellular 
bacterial killing 
Previous research suggests that induction of autophagy in lung epithelial cells works as a 
host-protective mechanism against intracellular bacteria such as Mycobacterium 
tuberculosis (Guo et al., 2013)  and S. pneumoniae (Li et al., 2015). Moreover, recently 
it has been shown that virulent Mycobacterium tuberculosis (H37Rv) evades autophagy-
associated intracellular killing or xenophagy by modulating autophagosomal maturation 
in macrophages (Pallavi et al., 2015). However, I have not found an association of 
autophagy or mitophagy in a nutrient-rich cell culture model after pneumococcal 
challenge (Figure 5.6 and 5.7). Rather, my data (Figure 5.9) indicates that PI-3K 
signalling is a positive mediator of pneumococci induced mitochondrial fission and 
mROS production. Therefore, I hypothesised that PI-3K inhibition could also alter 
mROS-associated intracellular bacterial killing in macrophages.  
To assess intracellular S. pneumoniae killing in macrophages, mouse BMDM were pre-
treated with either the PI-3K inhibitor 3-methyladenine, the Drp1 assembly inhibitor 
Mdivi-1 or lysosomal fusion (with phagosomes) blocker bafilomycin A1. Macrophages 
were then challenged with pneumococci for 8, 12 and 16 hours, and a gentamycin 
protection assay carried out. The intracellular bacterial survival data suggest that 3MA, 
Mdivi-1 and bafilomycin A1 did not alter intracellular killing at 8 hours post-bacterial 
killing (Fig 5.11A). But 3-MA significantly decreased intracellular bacterial killing at 12 
hours (circa 4-fold decrease) and 16 hours (circa 9-fold decrease) compared to untreated 
(vehicle) macrophages. Whereas, the Drp1 inhibitor Mdivi-1 did not noticeably alter 
killing at 8, 12 or 16 hours (Figure 5.11 B and C). Moreover, the lysosomal fusion 
inhibitor bafilomycin A1 did not alter intracellular killing at 8 or12 hours, but 
significantly decreased at 16 hours post-bacterial challenge (circa 7.5 fold decrease) 
(Figure 5.11B and C).  
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Figure 5.11. Bafilomycin A1 and PI-3K inhibitor 3-methyladenine decreases intracellular 
bacterial killing. Mouse BMDM were exposed to S. pneumoniae (D39, MOI of 10) for 8 hours, 
or 12 and 16 hours and a gentamycin protection assay was carried out. Briefly, for an 8 hour 
intracellular killing assay, cells were washed 3 times with PBS after 4 hours, then incubated 4 
hours more with normal cell culture media, then cells were treated with gentamycin (20µg/mL) 
and penicillin (40megaU/mL) for 30 minutes to kill extracellular bacteria, before cell lysis (with 
0.02% saponin) to assess intracellular pneumococci. In another set of experiment, for 12 hour 
time point, at 12 hours cells were treated with gentamycin plus penicillin for half an hour before 
cell lysis and estimation of colony forming units by Miles-Mirsa assay. For the 16 hour time point, 
after 12 hours incubation, cells were treated with gentamycin plus penicillin for half an hour, then 
incubated 4 hours more with vancomycin (0.75mg/mL), then lysed with 0.02% saponin and 
performed Miles-Mirsa serial dilution assay. Figure A shows the fold change in survival of 
intracellular pneumococci in macrophages after 8 hours and figures B shows 12 to 16 hours of 
bacterial challenge. Figure C shows the intracellular pneumococci growth curve (cfu/mL in a 
log10 scale) of 3-MA, bafilomycin A1 and Mdivi-1 pre-treated macrophages, after 12 and 16 
hours post-bacterial challenge. Data are shown as mean ± SEM. Statistical analysis was performed 
with one-way ANOVA and Bonferroni’s multiple comparison test, and paired t-test for pair-wise 
comparison between two-time points. *p<0.05, **p=0.005, n=6.     
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5.11. Discussion  
In this chapter, I have observed that macrophages ingesting S. pneumoniae demonstrate 
altered mitochondrial dynamics, with increased mitochondrial fission or network 
fragmentation in human MDM and in mouse BMDM. Mitochondrial fission after 
pneumococcal phagocytosis occurs in a Drp1 independent non-canonical manner, like the 
fission previously described as triggered by the bacterial pore-forming toxin listeriolysin 
O in Hela cells (Stavru et al., 2011, Stavru et al., 2013). Moreover, the macrophage 
response to S. pneumoniae also upregulates Parkin (an E3 ubiquitin ligase) and induces 
Parkin translocation to fragmented mitochondria. In addition, I have also assessed the 
association of selective autophagy or mitophagy with fragmented mitochondria following 
bacterial challenge, and both my Immunostaining and Transmission electron microscopy 
findings demonstrate that fission in response to bacterial ingestion does not trigger 
mitophagy/autophagy. Moreover, in this chapter I have shown that mitochondrial fission 
following pneumococcal ingestion has a role in innate immunity, particularly mROS 
production and intracellular bacterial killing. These observations suggest that the 
mitochondrial dynamics of macrophages, especially fission, could represent a host-
protective mechanism against intracellular bacteria.   
In healthy cells, mitochondrial dynamics (e.g. fission/fusion) is a constant process, and is 
essential to maintain an interconnecting network and cellular homeostasis (Suen et al., 
2008). For example,  interruption of mitochondrial fusion causes the loss of mitochondrial 
inner transmembrane potential (Δm), as well as hampering of embryonic development 
(Chen et al., 2003). Whereas, defective mitochondrial fission is associated with increased 
inflammation in macrophages (Sangjun et al., 2015). In addition, mitochondria fission is 
universally linked with programmed cell death (i.e. apoptosis) (Suen et al., 2008). 
However, excessive fission can occur without triggering apoptosis. For example, FCCP-
induced mitochondrial fission is reversible upon drug removal and it does not induce 
apoptosis (Richard and Mariusz, 2005). Rather FCCP-mediated excessive mitochondrial 
fission triggers autophagy or mitophagy (Narendra et al., 2008). Moreover, viral 
infection, for instance with cytomegalovirus (CMV), also induces mitochondrial 
fission/fragmentation which also does not induce apoptosis, as CMV viral proteins 
interact with pro-apoptotic Bcl-2 family members and blocks mitochondrial-associated 
apoptosis (Damien et al., 2004, Poncet et al., 2004). However, viral protein R of HIV-1 
and hepatitis B virus protein HBx respectively interact with mitochondrial outer 
membrane protein VDAC and VDAC3, resulting in the opening of mPTP, loss of ΔΨm 
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and leading to massive mitochondrial fragmentation, and rapid programmed cell death 
(Jacotot et al., 2000, Rahmani et al., 2000).   
On the other hand, the pathogenic bacteria, for example Listeria monocytogenes, induces 
Drp1 independent mitochondrial fragmentation and loss of Δm through its pore-forming 
toxin listeriolysin O (LLO), which decreases respiration associated ATP production in 
Hela cells (Stavru et al., 2011, Stavru et al., 2013). I have observed that macrophages 
generating a host response to pneumococci demonstrate mitochondrial fission or 
fragmentation in primary macrophages. Moreover, the pharmacological fission inhibitor 
Mdivi-1, an assembly blocker of Drp1 with Fis1 (Cassidy-Stone et al., 2008), does not 
inhibit fission during the macrophage response to pneumococci, which implies that 
fission occurs in a non-canonical fashion. Since pneumolysin deficient pneumococci also 
trigger mitochondrial fragmentation in macrophages with a high bacterial dose (MOI of 
>40), my findings suggest pneumolysin related cholesterol dependent cytolysin is not 
essential for fission. Rather it appears pneumolysin may enhance the frequency of fission, 
but is dispensable for mitochondrial fission in macrophages after challenge with 
metabolically active pneumococci (figure 5.2). Previously my laboratory group has 
demonstrated that pneumolysin’s pore-forming activity is not essential for apoptosis 
induction in macrophages although in this case there was very little apoptosis in the 
absence of pneumolysin (Bewley et al., 2014),whereas in my model fission still occur in 
the absence of apoptosis if the inoculum is high enough.  
ER-mitochondria tethering is indispensable for mitochondrial fission (Friedman et al., 
2011). F-actin filaments are required to regulate mitochondrial network fragmentation in 
DRP-1 dependent models of fission (De Vos et al., 2005). Inhibition of F-actin 
polymerisation with cytochalasin D inhibits LLO mediated non-canonical mitochondrial 
network fragmentation (Stavru et al., 2013). The latter observation implies that F-actin 
polymerisation could also be essential for pneumococci induced fission. However, I 
would not able to assess mitochondrial morphological network features in the presence 
intracellular pneumococci and cytochalasin D, because cytochalasin D inhibits >90% of 
pneumococcal internalisation (Ribes et al., 2010), as actin polymerisation is essential for 
phagocytosis and subsequent phagosome formation (Coppolino et al., 2001). 
On the other hand, apart from Drp1/Fis1, the mitochondrial protein MTP18 is also an 
important regulator for mitochondrial fission in mammalian cells (Tondera et al., 2005). 
Moreover, MTP18 is a downstream target of PI-3K signalling, and genetic or chemical 
inhibition of PI-3K  both downregulates MTP18 expression at transcriptional and 
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translational levels, but also decreases mitochondrial fission (Tondera et al., 2004). These 
observations align with my findings, where I have shown that pneumococci challenged 
macrophages, following pre-treatment with 3-methyladenine (3MA), a type I/III inhibitor 
of PI-3K, demonstrate decreased mitochondrial fission/fragmentation. Moreover, the 
macrophage response to pneumococci induces Parkin upregulation and translocation to 
fragmented mitochondria in macrophages. Admittedly, since 3MA pre-treatment 
appeared to reverse the increased Parkin recruitment to mitochondria following bacterial 
challenge, this observation further corroborated the suggestion that PI-3K played a role 
in fission regulation. It is well established Parkin is recruited to damaged mitochondria, 
and ubiquitinates the damaged mitochondrial proteins to activate their degradation in the 
26S proteasome system (Yoshii et al., 2011). 
In addition, Parkin activation and recruitment at extensively damaged mitochondria are 
essential to trigger selective autophagy or mitophagy and to minimise cellular toxicity 
(Narendra et al., 2008). I found no evidence of mitophagy or selective autophagy in 
macrophages after pneumococcal challenge. However, the mitochondrial oxidative 
phosphorylation uncoupler FCCP induced the autophagy marker LC3B and its 
recruitment to fragmented mitochondria, allowing FCCP to function as a positive control 
for mitophagy (Narendra et al., 2008). Apart from these roles, Parkin also has a role in 
innate immunity. For example, point mutations in Parkin’s regulatory regions cause 
increased susceptibility to infectious diseases such as typhoid and leprosy, infections 
associated with intracellular pathogens (Ali et al., 2006, Mira et al., 2004). In addition, 
Parkin interacts with the mitochondrial TSPO-VDAC1 protein complex to aid innate 
immunity against bacterial infection in Drosophila (Cho et al., 2015). Interestingly, TSPO 
blocks mitophagy, allowing accumulation of dysfunctional mitochondria, and TSPO 
interaction with VDAC1 diminishes mitochondrial coupling and triggers ROS production 
in fibroblasts (Gatliff et al., 2014). I have also observed that the macrophage response to 
pneumococci induces mROS production along with fragmented mitochondria, instead of 
recruiting autophagy or mitophagy pro-survival machinery in macrophages. Presumably, 
mitochondrial fission-associated fragmentation augments mROS production (Yu et al., 
2006).  
Although I have not found an association between the macrophage host response to 
pneumococci-associated mitochondrial fission and autophagy/mitophagy in 
macrophages, I do observe fragmented mitochondria producing mROS are proximal to 
lysosomes/phagolysosomes, inferring the signature of a mitochondrial innate immune 
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response to intracellular bacterial cues. Interestingly, the interaction of mitochondria and 
mROS with bacteria-containing phagolysosomes are considered a new avenue of 
mitochondria mediated innate immunity against intracellular bacteria (West et al., 
2011b). Moreover, recent publications by my host group and others also suggested that 
mROS is essential for intracellular bacterial killing (Bewley et al., 2017, West et al., 
2011a).   
In addition, PI-3K inhibition by 3-MA decreases mROS production in macrophages 
challenged with pneumococci, however, it is not clear how PI-3K decreased mROS 
production. Perhaps, it could be a direct result of the downregulation of mitochondrial 
fission/fragmentation by 3-MA. Besides, recently it has been shown that Akt1, a 
downstream target of PI-3K signalling, increases mROS production in alveolar 
macrophages during pulmonary fibrosis (Larson-Casey et al., 2016), suggesting that 3-
MA inhibition of mROS production may involve PI-3K mediated Akt1 activation. 
Interpretation of PI-3K inhibition could be confounded by differential effects on 
phagocytosis since PI-3K signalling is involved in phagocytosis of larger opsonised 
objects (Daniel et al., 2015) and PI-3K blocks phagocytosis of a broad-spectrum of IgG 
and complement opsonised particles or of unopsonised zymosan and bacteria (Aderem, 
2003).  
Recent data, however, suggests PI-3K is dispensable for the ingestion of IgG opsonised 
particles ≤5 m which would be the size range of opsonised pneumococci (Daniel et al., 
2015) My host group has recently demonstrated that PI-3K-specific inhibitors do not alter 
uptake of unopsonised S. pneumoniae or earlier intracellular killing in macrophages 
(Martin et al.). Although my bacteria were opsonised I have also observed that 3MA does 
not alter intracellular bacterial numbers at 8 hours before fission occurred, and in fact I 
found increased numbers of bacteria from 12 hours onwards, so the reduction in fission 
does not appear to be a consequence of reduced phagocytosis and intracellular bacterial 
burden following use of the PI-3K inhibitor. Macrophage responses result in gradual 
increases in mROS production over time with highest levels being observed after caspase 
induction when mROS plays its main role in the late phase of apoptosis-associated killing 
(Bewley et al., 2017).  Thus, the 3-MA  mediated reduction  in killing at 16 hours could 
reflect a reduction in mROS associated with apoptosis induction and be a consequence of 
PI-3K inhibition of apoptosis induction or the mitochondrial fission that precedes 
apoptosis and therefore may be necessary to maximise mROS release during apoptosis 
(Karbowski, 2010). At earlier times (e.g. 12 hours) the 3-MA mediated decrease in killing 
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could be linked to a decrease in mROS production from mitochondria undergoing fission 
before apoptosis induction, although further experiments would be needed to block this 
phase of killing with an mROS inhibitor such as MitoTEMPO and to increase the number 
of experiments measuring mROS to determine if the apparent reduction by 3-MA was 
significant.  
Finally, mitochondrial fission is associated with apoptosis.  I have also observed that 
inhibition of fission by 3-MA also decreases activity of caspase 3/7 (apoptosis 
executioners), especially at a late time point (e.g. 16 hour) when apoptosis occurs in this 
infection model (Marriott et al., 2005). In addition, 3-MA also reduced loss of min 
macrophages exposed to pneumococci. My host groups previous publications 
demonstrated that apoptosis triggers more mROS and re-engages intracellular killing 
when it has become exhausted via the mechanism of apoptosis-associated intracellular 
killing (Bewley et al., 2017, Jubrail et al., 2016). These suggest that 3-MA not only down-
regulates fission-associated mROS production, but also limits apoptosis-associated 
intracellular killing. A potential link could be via Parkin which as Carroll et al., have 
shown can induce ubiquitination and downregulation of Mcl-1, which is a key regulator 
of apoptosis in this infection model in macrophages (Carroll et al., 2014, Marriott et al., 
2005). 
Overall, this section shows that macrophages engaging in innate responses to S. 
pneumoniae not only modulate mitochondrial dynamics but also recruits Parkin to 
mitochondria which are likely to becoming dysfunctional with loss of m. Conversely, 
the confocal and electron microscopy data suggest that these fragmented mitochondria in 
macrophages responding to pneumococci do not activate macroautophagy/mitophagy. 
Rather the fragmented mitochondria produce mROS and engage with phagolysosomes to 
kill intracellular bacteria. Ultimately the fragmented mitochondria, which preceded 
caspase activation appear to facilitate downstream apoptosis activation which results in 
caspase activation and further increases in mROS to enhance intracellular bacterial 
killing. 
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Chapter 6. General Discussion 
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6.1. Background discussion 
S. pneumoniae is one of the major causative agents of community-acquired pneumonia. 
Macrophages are a critical cellular effector of innate immune responses against S. 
pneumoniae. In this thesis I have focused on host-pathogen interactions at the cellular 
level, particularly focusing on macrophage compartments involving mitochondria and 
phagolysosomes and their relationship to critical microbicidals, mROS and NO and 
internalised pneumococci. I have also focused on the pneumococcal effect on the human 
monocyte-derived macrophages metabolic phenotype and examined the impact of the 
HIV-1 glycoprotein gp120 and of COPD on metabolic phenotype. Macrophages sense 
bacteria rapidly via cell membrane and cytoplasmic pattern recognition receptors and 
demonstrate plasticity in morphology, functional phenotype and metabolism. Moreover, 
macrophages adapt these responses to recruit appropriate antimicrobial responses 
following phagocytosis. These responses include mitochondria-mediated responses such 
as generation of mROS and apoptosis, to eradicate intracellular bacteria. This thesis has 
explored novel mitochondrial dynamics relating to anti-microbial strategies against 
intracellular bacteria. Mitochondria are considered the metabolic hub of eukaryotic cells 
and the major supplier of cellular energy, which is essential for immune cells 
physiological functions such as migration and phagocytosis (Buttgereit et al., 2000). 
Furthermore, mitochondrial immunometabolism and dynamics are essential components 
for cellular homeostasis. 
 
6.2. Key findings in the study 
I have assessed macrophage metabolic phenotypes and carried out functional experiments 
with mouse bone marrow-derived macrophages and human monocyte-derived 
macrophages (MDM). I report that S. pneumoniae rewires macrophages metabolism from 
oxidative phosphorylation (OXPHOS) to glycolysis, and that overexpression of the 
human Mcl-1 protein in mouse BMDMs modulates baseline mitochondrial respiration 
capacity. Moreover, pneumococci also increase proton and electron leak from the 
mitochondrial inner membrane during mitochondrial OXPHOS. As a result, S. 
pneumoniae diminishes inner mitochondrial transmembrane potential (ΔΨm), ATP-linked 
OXPHOS and augments mROS production. Apart from this, this thesis also reported that 
macrophage mROS and NO are engaged with intracellular pneumococci in 
phagolysosomes (Bewley et al., 2017).  
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In addition, I have also reported that macrophage mitochondrial respiration is further 
decreased in MDMs following pneumococcal challenge in MDM derived from a COPD 
cohort, when compared to age-matched health volunteers. This thesis reported that the 
HIV-1 glycoprotein gp120 diminishes both baseline and pneumococcal induced proton 
leak, which upheld Collini and colleagues recent observation on preservation of intact 
mitochondrial inner transmembrane potential in gp120 pre-treated MDM in the same 
infection model. These findings bring a plausible explanation as to why alveolar 
macrophages from HIV-1 seropositive cohorts cannot enhance mROS generation after 
challenge with pneumococci (Collini et al., 2018). Although proton uncoupling can limit 
mROS generation (Jastroch et al., 2010) presumably, excessive proton leak can enhance 
mROS production due to loss of inner mitochondrial transmembrane potential, activation 
of caspases and inhibition of Complex I, -a major mROS production site (Ricci et al., 
2003).  
In addition, this thesis also showed that metabolically active pneumococci induce 
noncanonical mitochondrial fission which has a positive role in facilitating intracellular 
bacterial killing. Instead of autophagy or selective mitophagy, fragmented mitochondria 
recruit the E3 ubiquitin Parkin, a determinant of mitochondrial quality. Moreover, 3-
methyladenine a type I/III inhibitor of PI-3K not only inhibits pneumococcal induced 
mitochondrial fission but also protects ΔΨm and decreases mROS production, apoptosis 
and intracellular bacterial killing in macrophages.  All the above mentioned key findings 
are summarised as a table below. 
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Table 6.1. Summary of key findings of all models 
 
Cell model 
Challenge with S. 
pneumonaie/stimuli 
Host Responses 
Metabolic 
phenotype/response 
Mitochondrial 
fission/fragmentation 
 
 
 
 
 
 
 
 
 
 
 
 
i.Mouse 
BMDM 
Heat inactivated S. 
pneumoniae 
-Increases the maximum 
glycolytic capacity. 
-No effect on mitochondrial 
fission 
 
 
 
 
Metabolically active 
wild type S. 
pneumoniae 
-Increases basal and 
maximum glycolytic 
metabolism, 
-Decreases 
mitochondrial 
respiration capacity and 
ATP-linked OCR, 
-Increases proton leak 
and mROS production.  
-Induces Drp1 independent 
mitochondrial 
fragmentation, 
-Upregulates Parkin 
expression and recruits 
them to mitochondria, 
-Does not recruit mitophagy 
or double membrane 
vacuole to fragmented 
mitochondria. 
-Mitochondrial fission 
occurs prior to apoptosis. 
 
 
LPS and INFγ 
-Increases both basal 
and maximum 
glycolytic capacity. 
 
Did not investigate yet. 
IL-4 -No effect on glycolytic 
metabolism. 
Did not investigate yet. 
 
Pneumolysin mutant or 
deficient S. pneumoniae 
 
 
Did not investigate yet. 
-Insignificant effect with 
low burden of bacteria (e.g. 
MOI of 10), 
-Induces mitochondrial 
fragmentation with a higher 
MOI (e.g. MOI ≥40). 
Exogenous 
pneumolysin 
 
Did not investigate yet. 
-Induces mitochondrial 
fragmentation with a higher 
titre (e.g. ≥2µg/mL).  
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ii.Human 
MDM 
 
 
Challenge with 
metabolically active 
wild type S. 
pneumoniae 
-Increases basal and 
maximum glycolytic 
metabolism, 
-Decreases 
mitochondrial 
respiration capacity and 
ATP-linked OCR, 
-Increases proton leak. 
 
 
 
Did not investigate yet. 
 
 
 
iii. HIV 
infection 
model 
 
Human MDM pre-
treated with HIV-1 
recombinant gp120 and 
challenge with S. 
pneumoniae 
-Increases basal and 
maximum glycolytic 
metabolism, 
-Decreases 
mitochondrial 
respiration capacity and 
ATP-linked OCR, 
-Increases proton leak 
but gp120 decreases the 
baseline proton leak. 
 
 
 
 
Did not investigate yet. 
 
 
 
iv. COPD 
infection 
model 
 
 
 
COPD MDM Challenge 
with S. pneumoniae 
-Decreases both baseline 
and pneumococci induce 
mitochondrial 
respiration capacity and 
respiration reserve. 
 -Decreases baseline 
ATP-linked OCR, 
-Increases baseline 
proton leak.  
 
 
 
Did not investigate yet. 
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6.3. Macrophages metabolic phenotype and its role in controlling 
internalised bacteria  
Immunometabolism is considered a fast evolving research area which investigates how 
the metabolic phenotype of immune cells achieves effective function in response to 
distinct microenvironmental cues (Geeraerts et al., 2017).  From the literature it has been 
shown that M1 macrophages are mostly dependent on glycolysis rather than OXPHOS, 
whereas M2 macrophages rely on mitochondrial metabolism for their physiological 
function (Haschemi et al., 2012). Moreover, LPS or IFNγ stimulated M1 macrophages 
produce pro-inflammatory cytokines and microbicidal reactive nitrogen and oxygen 
species, whereas IL-4/13 stimulated M2 macrophages produce anti-inflammatory 
cytokines and anti-parasitic mediators (e.g. polyamines) (Galvan-Pena and O'Neill, 
2014). Recently, it has been shown that bacterial endotoxin LPS and IFNγ activated 
macrophages accumulate TCA cycle intermediates succinate and citrate (reviewed by 
(Geeraerts et al., 2017). Subsequently the accumulated citrate acts as a precursor of 
itaconic acid – a macrophage-specific metabolite which has an anti-microbial role against 
intracellular bacteria (Alessandro et al., 2013). LPS/IFNγ (classical activation) 
upregulates the immune-responsive gene 1 (irg1) which encodes the itaconic acid 
producing enzyme cis-aconitate decarboxylase (Jha et al., 2015).  
Like classical activation, pneumococci stimulate macrophages to develop M1-like 
characteristics, such as generation of pro-inflammatory cytokines (Bewley mBIO) and 
indicible nitric oxide synthase (Marriott FasebJ). Therefore, activation of macrophages 
towards an M1 metabolic phenotype, is not unexpected and since studies suggest these 
metabolic function may drive immune effector functions further driving this phenotype 
could help macrophages handle pneumococci more effectively, particularly in conditions 
like COPD where activation may not show the required classical polarisation (Shaykhiev 
et al., 2009a), as a potential way to cope with intracellular bacteria. 
 
6.4. Importance of mitochondrial dynamics in innate responses against 
ingested extracellular bacteria 
Mitochondrial dynamics (fission and fusion) represent a continuous process which 
maintains cellular homeostasis. Although mitochondrial fission is an upstream process in 
mitophagy (Narendra et al., 2008), I observed that pneumococcal challenge induced 
fragmented mitochondria that do not recruit the autophagy or mitophagy marker LC3B, 
and do not form double membrane vacuoles around fragmented mitochondria. Rather the 
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fragmented mitochondria produce mROS in close proximity to 
lysosomes/phagolysosomes, implying that fission might have an anti-microbial role. 3-
MA not only inhibits mitochondrial fission and protects mitochondrial inner 
transmembrane potential, but also decreases mROS production as well as intracellular 
pneumococcal killing.  Thus I have postulated that fission is an upstream process of 
apoptosis as reviewed in (Suen et al., 2008).  Besides I have also observed that Parkin, a 
ubiquitin E3 ligase, is recruited to fragmented mitochondria following pneumococcal 
challenge which, as Carroll et al., have shown, can induce ubiquitination and 
downregulation of the anti-apoptotic protein Mcl-1, a key regulator of apoptosis-
associated killing of ingested extracellular bacteria in macrophages (Carroll et al., 2014, 
Marriott et al., 2005).  
Moreover,  previous research also demonstrated that mitochondrial fission augments 
mROS production (Yu et al., 2006). Apart from this, macrophage apoptosis is essential 
to resolve lung inflammation during chronic diseases (e.g. COPD) (Robb et al., 2016). 
Therefore, mitochondrial fission and subsequent apoptotic pathways in macrophages 
might be a potential therapeutic target to eradicate internalised extracellular bacteria as 
well as control chronic tissue inflammation.   
  
6.5. Limitations 
Although I have discussed possible caveats in each results chapter, biological techniques 
and research with in vitro or ex vivo cell models always have some limitations. For 
example, the metabolic phenotype of macrophages was assessed by the Extracellular flux 
analyser (e.g. XF24), which can only measure the major metabolic outputs such as 
glycolytic rate and mitochondrial OXPHOS rate in a real time basis. However, individual 
metabolites or other metabolic pathways, such as fatty acid oxidation (β-oxidation) or the 
pentose phosphate pathway would not be measurable with the XF24 flux analyser. 
Whereas NMR or Mass spectrometry could measure total cellular metabolites, which 
more directly implies the metabolic phenotype of cells. Moreover, this research was 
conducted with either human circulatory MDM or mouse BMDM which do not represent 
exact lung tissue macrophages (e.g. alveolar macrophages). Therefore, it is needed to 
further confirm these findings with alveolar macrophages.  
In addition, mitochondrial fission is reported as a non-canonical fission which occurs in 
a Drp-1 independent manner. However, possible mediators causing the non-canonical 
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fission, are yet to be identified. However, the mitochondrial co-staining with 
phosphorylated Drp1 or LC3B could not able to check with mouse cell model because 
available matching species of mitochondrial Tom20 antibody (mouse anti-Tom20) did 
not bind with mouse macrophages mitochondrial Tom20. Although I had rabbit anti-
Tom20 antibody which binds with mouse macrophages mitochondrial Tom20, the species 
overlaps with available species raised p-Drp1 or LC3B primary antibodies species (i.e. 
Rabbit).  In addition, the mitochondrial fission-associated intracellular bacterial killing 
needs further confirmation, using genetic manipulation or with more specific 
pharmacological inhibitors of PI-3K (e.g. PI-3K γ or δ-inhibitors) rather than the 
relatively non-specific inhibition provided by 3-methyladenine. All findings in this thesis 
are based on in vitro or ex vivo infection cell models, and therefore a relevant in vivo 
mouse or zebrafish model is warranted to elucidate mitochondrial dynamics and its role 
to internalised bacteria. Besides, all infection related experiments in this thesis are carried 
out with opsonised type 2 serotype of S. pneumoniae (D39), and therefore the in vivo 
infection study should be conducted with more relevant clinical serotypes (e.g. S14) and 
with other extracellular bacteria.     
 
6.6. Hypothetical model 
Some major findings of this thesis are linked with other bacterial infection related mouse 
models in the literature described by other key papers on this topic (West et al., 2011b, 
Roca and Ramakrishnan, 2013, Sonoda et al., 2007). The major sites of electron leak and 
mROS production are Complex I and III in the mitochondrial inner membrane, and 
mROS are produced adjacent to phagolysosomes to kill internalised pneumococci 
(Bewley et al., 2017). Similarly West and colleagues demonstrated that TLR1/2 and 4-
agonists allow the TLR adaptor protein tumour necrosis factor receptor-associated factor 
6 (TRAF6) to translocate to the mitochondria where it interacts with evolutionary 
conserved signalling intermediate in Toll pathways (ECSIT), allowing its ubiquitination. 
ECSIT plays a role enabling  assembly of Complex I of the electron transport chain, and 
triggering mROS production in proximity to the phagolysosome (West et al., 2011a).  
Moreover, like other classical stimuli, S. pneumoniae switches the macrophage metabolic 
phenotype from OXPHOS to glycolysis. This metabolic reprogramming and modification 
of Complex I assembly modifies proton and electron leakage, reorientates mitochondrial 
electron transfer away from ATP generation and instead promotes mROS production in 
pneumococci challenged macrophages. I hypothesise that intracellular oxidative stress 
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and mitochondrial protein modification induce irreversible mitochondrial fission that 
further increases mROS production. Subsequently, S. pneumoniae challenged 
macrophages with fragmented mitochondria lose their inner mitochondrial 
transmembrane potential and further diminish their ATP-linked OXPHOS. Consequently 
macrophages rely on glycolysis for energy production as the role of mitochondria shifts 
away from effective ATP generation and rather mROS production. Parkin is also recruited 
to these fragmented and depolarised mitochondria. But instead of autophagy marker 
recruitment - a pro-survival process - fragmented mitochondria develop mitochondrial 
outer membrane permeabilisation, potentially due to the extent of the mitochondrial 
changes and release cytochrome c which activates the apoptososme and caspase 9 
activation upstream of caspase 3/7 to execute programmed cell death via apoptosis. 
Previously my host group has demonstrated that mROS production also increases with 
apoptosis, which kills internalised bacteria as an apoptosis-associated bacterial killing 
mechanism (Bewley et al., 2017).   My model shows how metabolism and mitochondrial 
dynamics upstream of this also promote mROS and lead to conditions which make the 
cell susceptible to apoptosis. 
 
 
Figure 6.1. Schematic diagram of my hypothetical model. Opsonised pneumococci are 
internalised and like the Salmonella infection model could also activate TRAF6 signalling 
pathway and ubiquitinate ECSIT leading to assembly of complex I of the mitochondrial electron 
transport chain and induce mROS production, described in (West et al., 2011a). On the other 
hand, pneumococci stimulate metabolic reprogramming and trigger mitochondrial fission in 
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macrophages. Fragmented mitochondria develop loss of inner mitochondrial transmembrane 
potential ( m) and ultimately accumulate Parkin, but activate the intrinsic programmed cell 
death pathway rather than engage mitophagy as a pro-survival effect. In addition, mROS or 
apoptosis-associated mROS are produced adjacent to internalised pneumococci in 
phagolysosomes. MitoTempo inhibits intracellular bacterial killing by scavenging mROS. ECSIT 
–Evolutionary conserved signalling intermediate in Toll pathways, C-I –Complex I, TLR –Toll-
like receptor, TRAF6 –Tumour necrosis factor receptor-associated factor 6, Mt –Mitochondria, 
Ub –ubiquitination, mROS –Mitochondrial reactive oxygen species, LC3 –Microtubule 
associated protein light chain 3. 
 
 
6.7. Future work directions 
i. It is essential to further confirm the link between immuno-metabolism and 
mitochondrial dynamics in in vivo infection models. 
ii. It would be important to observe macrophages mitochondrial metabolism after 
challenge with pneumolysin mutant S. pneumoniae. 
iii. It would be important to perform live cell imaging with a transfected fluorochrome 
marker of mitochondria is essential for bone-fide evidence of mitochondrial fission 
and its downstream consequences in macrophages. 
iv.  I would like to develop a Parkin knock out or overexpression macrophage cell 
model, to characterise its relationship to fission and its consequences for apoptosis 
and intracellular bacterial killing. 
v.  It would be important to identify the molecular pathway associated with non-
canonical fission. 
vi. I would need to further confirm that mitochondrial apoptosis acts as a downstream 
process of fission by applying appropriate caspase inhibitors (e.g. pan-caspase 
inhibitor z-VAD-fmk) and showing these do not alter fission only apoptosis, in order 
to confirm fission is not an artefact of apoptosis (even though my time course 
experiments argue against this since fission precedes apoptosis). 
 
6.8. Conclusions 
This thesis demonstrates that S. pneumoniae modulates macrophage metabolic phenotype 
and manipulates mitochondrial morphology. Like classical activation, pneumococci 
stimulate macrophages into a pro-inflammatory phenotype, which turns on aerobic 
glycolysis and augments mROS and NO production. The latter are engaged with 
intracellular pneumococci in the phagolysosome. Moreover, mitochondrial fission allows 
development of a host-protective mechanism to kill internalised pneumococci in 
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macrophages and shifts the mitochondrial function away from OXPHOS-linked ATP 
generation to mROS generation. This provides a potent but time-limited microbicidal 
response which ultimately ends in programmed cell death. 
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Chapter 7: Appendices 
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7.1 XF assay medium for Glycol-stress test (200 mL) 
 
Reagents Amount 
XF assay media 196 mL 
L-glutamine (200mM) 2 mL 
Penicillin/Streptomycin 2 mL 
D-glucose (anhydrous) 0.90 g (4.5 g/L) 
Adjust pH 7.4 with 1.0 M NaOH and passed through 0.22 µm filter 
 
7.2 XF assay medium for Mito-stress test (200 mL) 
 
Reagents Amount 
XF assay media 194 mL 
L-glutamine (200mM) 2 mL 
Sodium-pyruvate (100mM) 2 mL 
Penicillin/Streptomycin 2 mL 
D-glucose (anhydrous) 0.90 g (4.5 g/L) 
Adjust pH 7.4 with 1.0 M NaOH and passed through 0.22 µm filter 
 
7.3 Brain hear infusion broth (BHI broth) preparation (200 mL)  
 
Reagents Amount 
BHI powder (Oxoid, CM1135) 7.4 g 
Distilled water  200 mL 
Autoclaved at 121oC  for 15 minutes 
 
7.4 Quenching solution for Immunofluorescence assay (500 mL) 
 
Reagents Amount 
PBS (1x) 500 mL 
Triton-x-100 500 µL (0.1 %) 
Ammonium chloride (NH4Cl)   1.34 g 
 
7.5 Blocking/PGAT solution for Immunofluorescence assay 
 
Reagents Amount 
PBS (1x) 500 mL 
Gelatine 1.0 g (0.2 %) 
Triton-x-100 50 µL (0.01 %) 
Sodium-Azide 0.1 g (0.02 %) 
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7.6 Reagents used in Western blotting 
 
i. Lysis buffer for cytosolic and mitochondrial fractions (10 mL)  
 
Reagents Amount 
PBS (1x) 7.5 mL 
0.1 M NaH2PO4 200 µL 
0.2 M Na2HPO4 800 µL 
1.0 M NaCl 1.5 mL 
Add 3.75 µL digitonin (5% stock) in 1 mL lysis buffer [or add 9.38 µg digitonin per 
million cells); Add 1:25 complete protease inhibitor (Roche) [Stock: Add 1 tablet to 2 
mL distilled water].  
 
ii. 2x Sample buffer (for 25 mL) 
 
Reagents Amount 
20% SDS 5 mL 
Glycerol 5 mL 
Bromophenol Blue 0.5 mL 
2-Mercaptoethanol 2.5 mL 
Tris HCl pH 6.8 6.25 mL 
Water 5.75 mL 
 
iii. Stacking gel preparation (5% for 2 gels) 
 
Reagents Amount 
Distilled water 6 mL 
40% Acrylamide 1240 µL 
0.5M Tris buffer pH 6.8 2520 µL 
20% sodium dodecyl sulphate (SDS) 50 µL 
20% Ammonium persulphate (APS) 100 µL 
Tetramethyl ethylene diamine (TEMED) 10 µL 
 
iv. Resolving gel preparation (12% for 2 gels) 
 
Reagents Amount 
Distilled water 9.9 mL 
40% Acrylamide 6.8 mL 
1.5M Tris buffer pH 8 5.8 mL 
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20% sodium dodecyl sulphate (SDS) 112.5 µL 
20% Ammonium persulphate (APS) 225 µL 
Tetramethyl ethylene diamine (TEMED) 9 µL 
 
v. 10x Running buffer 
 
Reagents Amount 
Glycine (Fisher Scientific) 190 g 
Tris Base (Fisher Scientific) 30.3 g 
20% SDS solution 50 mL 
Distilled water Up to 1000 mL 
 
 
vi. 1x Running buffer 
 
Reagents Amount 
10x Running buffer 100 mL 
Distilled water 900 mL 
 
vii. 1x Transfer buffer 
 
Reagents Amount 
Glycine (Fisher Scientific) 2.9 g 
Tris Base (Fisher Scientific) 1.45 g 
20% SDS solution 925 µL  
Methanol 100 mL 
Distilled water 500 mL 
 
viii. 10x TBS 
 
Reagents Amount 
Tris-HCl 1.0 M pH 8.0 (Bio-Rad Lab) 100 mL 
NaCl (Fisher Scientific) 97.3 g 
 Distilled water  Up to 1000 mL 
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iX. 10x TBS-Tween 
 
Reagents Amount 
Tris-HCl 1.0 M pH 8.0 (Bio-Rad Lab) 100 mL 
NaCl (Fisher Scientific) 97.3 g 
Tween-20 (Fisher Scientific) 5 mL 
Distilled water Up to 1000 mL 
 
X. Blocking solution (5% skimmed milk) (40 mL) 
 
Reagents Amount 
Skim milk powder (Sigma-aldrich) 2 g 
1x TBS-tween 40 mL 
 
7.7 Araldite resin preparation (20 mL) (for TEM assay) 
 
Reagents Amount 
CY212 resin 10 mL 
DDSA hardener 10 mL 
BDMA accelerator 1 drop per 1 mL of resin mixture 
 
7.8 Growth of S. pneumoniae in cell culture media with mitochondrial 
fission inhibitors 
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Figure 7.1. S. pneumoniae culture in DMEM cell media. 8-10 colonies of S. 
pneumoniae (D39) inoculated in vehicle (DMSO) or Bafilomycin A1 (100nM) or Mdivi-
1 (25µM) or 3-Methyladenine (3MA, 10mM) and incubated at 37oC and 5% CO2 for 6 
hours. Then 1 mL bacterial suspension was serial diluted and plated in the Columbia 
blood agar plates (Miles-Mirsa method). Bacterial colonies were counted after 16 hours 
incubation at 37oC and 5% CO2. (n=1). 
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